Testhyperlink123: Difference between revisions

From GlyGen Wiki
Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 1: Line 1:


===Monosialylated===
===T antigen===
  '''term (main_entry)''' : Monosialylated <br>
[[File:G00031MO.png|thumb|G00031MO]]
  '''glycan_dictionary_accession''' : GSD000123 <br>
'''term (main_entry)''' : T antigen <br>
'''glycan_dictionary_accession''' : GSD000163 <br>
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00031MO G00031MO] <br>
'''term_in_sentence''' : Tn, sTn, and T antigen neo- or over-expression occurs in many types of cancer including gastric, colon, breast, lung, esophageal, prostate, and endometrial cancer.[PMID:27679419] <br>
'''publication''' : 723127|[https://pubmed.ncbi.nlm.nih.gov/19505650 19505650]|[https://pubmed.ncbi.nlm.nih.gov/31527246 31527246]|[https://pubmed.ncbi.nlm.nih.gov/28113048 28113048]|[https://pubmed.ncbi.nlm.nih.gov/25868857 25868857]|[https://pubmed.ncbi.nlm.nih.gov/26731525 26731525]|[https://pubmed.ncbi.nlm.nih.gov/22994493 22994493]|[https://pubmed.ncbi.nlm.nih.gov/3849428 3849428]|[https://pubmed.ncbi.nlm.nih.gov/25589241 25589241]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/12709866 12709866] [https://pubmed.ncbi.nlm.nih.gov/12709866 12709866]]|[https://pubmed.ncbi.nlm.nih.gov/26615524 26615524]|[https://pubmed.ncbi.nlm.nih.gov/26136575 26136575]|[https://pubmed.ncbi.nlm.nih.gov/19671663 19671663]|[https://pubmed.ncbi.nlm.nih.gov/18551603 18551603]|[https://pubmed.ncbi.nlm.nih.gov/11160729 11160729]|[https://pubmed.ncbi.nlm.nih.gov/22261839 22261839]|[https://pubmed.ncbi.nlm.nih.gov/30758913 30758913]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/25681708 25681708] [https://pubmed.ncbi.nlm.nih.gov/25681708 25681708]]|[https://pubmed.ncbi.nlm.nih.gov/29113555 29113555]|[https://pubmed.ncbi.nlm.nih.gov/24998850 24998850]|[https://pubmed.ncbi.nlm.nih.gov/1654819 1654819]|[https://pubmed.ncbi.nlm.nih.gov/28039910 28039910]|[https://pubmed.ncbi.nlm.nih.gov/29206210 29206210]|[https://pubmed.ncbi.nlm.nih.gov/32404521 32404521]|[https://pubmed.ncbi.nlm.nih.gov/10555041 10555041]|[https://pubmed.ncbi.nlm.nih.gov/26517398 26517398]|[https://pubmed.ncbi.nlm.nih.gov/2446015 2446015]|[https://pubmed.ncbi.nlm.nih.gov/2998768 2998768]|[https://pubmed.ncbi.nlm.nih.gov/3026642 3026642]|[https://pubmed.ncbi.nlm.nih.gov/18812503 18812503]|[https://pubmed.ncbi.nlm.nih.gov/6092664 6092664]|[https://pubmed.ncbi.nlm.nih.gov/2153691 2153691]|[https://pubmed.ncbi.nlm.nih.gov/8709258 8709258]|[https://pubmed.ncbi.nlm.nih.gov/3009889 3009889]|[https://pubmed.ncbi.nlm.nih.gov/15109748 15109748]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/12709866 12709866] [https://pubmed.ncbi.nlm.nih.gov/12709866 12709866]]|[https://pubmed.ncbi.nlm.nih.gov/31787742 31787742]|[https://pubmed.ncbi.nlm.nih.gov/27433780 27433780]|[https://pubmed.ncbi.nlm.nih.gov/26017382 26017382]|[https://pubmed.ncbi.nlm.nih.gov/24048785 24048785]|[https://pubmed.ncbi.nlm.nih.gov/26735515 26735515]|[https://pubmed.ncbi.nlm.nih.gov/9224657 9224657]|[https://pubmed.ncbi.nlm.nih.gov/26061652 26061652]|[https://pubmed.ncbi.nlm.nih.gov/29343574 29343574]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/25681708 25681708] [https://pubmed.ncbi.nlm.nih.gov/25681708 25681708]]|[https://pubmed.ncbi.nlm.nih.gov/23805194 23805194]|[https://pubmed.ncbi.nlm.nih.gov/26751495 26751495]|[https://pubmed.ncbi.nlm.nih.gov/22023388 22023388]|[https://pubmed.ncbi.nlm.nih.gov/15381338 15381338]|[https://pubmed.ncbi.nlm.nih.gov/8249277 8249277]|[https://pubmed.ncbi.nlm.nih.gov/3023660 3023660]|[https://pubmed.ncbi.nlm.nih.gov/25866902 25866902] <br>
'''definition''' : An amino disaccharide composed of D-galactose and N-acetyl-α-D-galactosaminyl residues in β-(1→3) linkage.[CHEBI:61820] <br>
'''term_xref''' : GTC:G00031MO|GlycoEpitope:EP0020|CID:[https://pubmed.ncbi.nlm.nih.gov/5288347 5288347]|CHEBI:61820|GlycoMotif:GGM.000009<br>
'''synonyms''' : TF antigen <br>
'''function''' : accumulation Lipoprotein(a) or LDL within arterial walls in atherogenesis [GlycoEpitope:EP0020]|cancer progression (increase interaction/communication of the cells)[GlycoEpitope:EP0020]|T antigen expression in RMA lymphoma cells leads to a reduced growth of the tumor[GlycoEpitope:EP0020]|correlation with elevated Golgi pH in cancer cell (breast, colorectal cancer cells)[GlycoEpitope:EP0020]|T antigen on apical surfaces of corneal epithelial cells provide protection against rose bengal penetrance.[GlycoEpitope:EP0020]|reduction of a flexibility of the glycosidic bond and thereby favour certain glycan conformation[GlycoEpitope:EP0020]|T antigen is a target for NK cell-mediated lysis[GlycoEpitope:EP0020]|inverse relationship between T antigen expression and VWF plasma levels[GlycoEpitope:EP0020] <br>
'''disease_associations''' : anaplastic meningioma[GlycoEpitope:EP0020]|breast cancer[GlycoEpitope:EP0020]|colorectal cancer[GlycoEpitope:EP0020]|colon cancer[GlycoEpitope:EP0020]|esophageal cancer|gastric cancer[GlycoEpitope:EP0020]|liver cancer[GlycoEpitope:EP0020]|ovarian cancer[GlycoEpitope:EP0020]|prostate cancer[GlycoEpitope:EP0020]|bladder tumor[GlycoEpitope:EP0020]|invasive pneumococcal infection (hemolytic uremic syndrome, hemolytic anemia)[GlycoEpitope:EP0020] <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453023/ Chapter 47]<br>
 
 
===Tetraantennary===
  '''term (main_entry)''' : Tetraantennary <br>
  '''glycan_dictionary_accession''' : GSD000164 <br>
  '''glytoucan_accession ''' :  <br>
  '''glytoucan_accession ''' :  <br>
  '''term_in_sentence''' : The structures of the asparagine-linked sugar chains of U- CD59 were biantennary complex type , only 4.2% of which are monosialylated.[PMID:[https://pubmed.ncbi.nlm.nih.gov/7514386 7514386]] <br>
  '''term_in_sentence''' : In contrast, myeloma IgE showed a higher abundance of triantennary and tetraantennary glycan structures and a low abundance of species with a bisecting N-acetylglucosamine.[PMID:[https://pubmed.ncbi.nlm.nih.gov/24308486 24308486]] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/7514386 7514386]|[https://pubmed.ncbi.nlm.nih.gov/8477709 8477709]|[https://pubmed.ncbi.nlm.nih.gov/8942648 8942648]|[https://pubmed.ncbi.nlm.nih.gov/29752599 29752599]|[https://pubmed.ncbi.nlm.nih.gov/31669586 31669586]|[https://pubmed.ncbi.nlm.nih.gov/29747818 29747818]|[https://pubmed.ncbi.nlm.nih.gov/16425369 16425369]|[https://pubmed.ncbi.nlm.nih.gov/12089170 12089170]|[https://pubmed.ncbi.nlm.nih.gov/31390883 31390883]|[https://pubmed.ncbi.nlm.nih.gov/1632647 1632647]|[https://pubmed.ncbi.nlm.nih.gov/29733234 29733234]|[https://pubmed.ncbi.nlm.nih.gov/31110965 31110965]|[https://pubmed.ncbi.nlm.nih.gov/31566965 31566965]|[https://pubmed.ncbi.nlm.nih.gov/30555678 30555678]|[https://pubmed.ncbi.nlm.nih.gov/28263871 28263871]|[https://pubmed.ncbi.nlm.nih.gov/29652662 29652662]|[https://pubmed.ncbi.nlm.nih.gov/25915761 25915761]|[https://pubmed.ncbi.nlm.nih.gov/16381065 16381065]|[https://pubmed.ncbi.nlm.nih.gov/29247593 29247593]|[https://pubmed.ncbi.nlm.nih.gov/28370937 28370937]|[https://pubmed.ncbi.nlm.nih.gov/23896595 23896595]|[https://pubmed.ncbi.nlm.nih.gov/26633899 26633899]|[https://pubmed.ncbi.nlm.nih.gov/32155999 32155999]|[https://pubmed.ncbi.nlm.nih.gov/25261856 25261856]|[https://pubmed.ncbi.nlm.nih.gov/2737211 2737211]|[https://pubmed.ncbi.nlm.nih.gov/26945091 26945091]|[https://pubmed.ncbi.nlm.nih.gov/27065039 27065039]|[https://pubmed.ncbi.nlm.nih.gov/26784838 26784838]|[https://pubmed.ncbi.nlm.nih.gov/26582205 26582205] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/24308486 24308486]|[https://pubmed.ncbi.nlm.nih.gov/17951374 17951374]|[https://pubmed.ncbi.nlm.nih.gov/28880909 28880909]|[https://pubmed.ncbi.nlm.nih.gov/9177699 9177699]|[https://pubmed.ncbi.nlm.nih.gov/9760189 9760189]|[https://pubmed.ncbi.nlm.nih.gov/12322961 12322961]|[https://pubmed.ncbi.nlm.nih.gov/20129637 20129637]|[https://pubmed.ncbi.nlm.nih.gov/2492275 2492275]|[https://pubmed.ncbi.nlm.nih.gov/3402460 3402460]|[https://pubmed.ncbi.nlm.nih.gov/2361735 2361735]|[https://pubmed.ncbi.nlm.nih.gov/6525453 6525453]|[https://pubmed.ncbi.nlm.nih.gov/27730440 27730440]|[https://pubmed.ncbi.nlm.nih.gov/2551687 2551687]|[https://pubmed.ncbi.nlm.nih.gov/25365149 25365149]|[https://pubmed.ncbi.nlm.nih.gov/9751793 9751793]|[https://pubmed.ncbi.nlm.nih.gov/29875690 29875690]|[https://pubmed.ncbi.nlm.nih.gov/29479898 29479898]|[https://pubmed.ncbi.nlm.nih.gov/9134426 9134426]|[https://pubmed.ncbi.nlm.nih.gov/30943309 30943309]|[https://pubmed.ncbi.nlm.nih.gov/3546284 3546284]|[https://pubmed.ncbi.nlm.nih.gov/29888905 29888905]|[https://pubmed.ncbi.nlm.nih.gov/30624066 30624066]|[https://pubmed.ncbi.nlm.nih.gov/30537828 30537828]|[https://pubmed.ncbi.nlm.nih.gov/31110965 31110965]|[https://pubmed.ncbi.nlm.nih.gov/29311294 29311294]|[https://pubmed.ncbi.nlm.nih.gov/12852965 12852965]|[https://pubmed.ncbi.nlm.nih.gov/3015940 3015940]|[https://pubmed.ncbi.nlm.nih.gov/1907570 1907570]|[https://pubmed.ncbi.nlm.nih.gov/29137999 29137999]|[https://pubmed.ncbi.nlm.nih.gov/29359131 29359131]|[https://pubmed.ncbi.nlm.nih.gov/29858715 29858715]|[https://pubmed.ncbi.nlm.nih.gov/30295034 30295034]|[https://pubmed.ncbi.nlm.nih.gov/31829566 31829566]|[https://pubmed.ncbi.nlm.nih.gov/8381405 8381405]|[https://pubmed.ncbi.nlm.nih.gov/26929217 26929217]|[https://pubmed.ncbi.nlm.nih.gov/20662591 20662591]|[https://pubmed.ncbi.nlm.nih.gov/30612270 30612270]|[https://pubmed.ncbi.nlm.nih.gov/3089784 3089784]|[https://pubmed.ncbi.nlm.nih.gov/28186213 28186213]|[https://pubmed.ncbi.nlm.nih.gov/3427034 3427034]|[https://pubmed.ncbi.nlm.nih.gov/26763099 26763099]|[https://pubmed.ncbi.nlm.nih.gov/27354006 27354006]|[https://pubmed.ncbi.nlm.nih.gov/24991291 24991291]|[https://pubmed.ncbi.nlm.nih.gov/7496138 7496138]|[https://pubmed.ncbi.nlm.nih.gov/1940447 1940447]|[https://pubmed.ncbi.nlm.nih.gov/11114588 11114588]|[https://pubmed.ncbi.nlm.nih.gov/29031301 29031301]|[https://pubmed.ncbi.nlm.nih.gov/9448855 9448855]|[https://pubmed.ncbi.nlm.nih.gov/3979385 3979385]|[https://pubmed.ncbi.nlm.nih.gov/27722599 27722599]|[https://pubmed.ncbi.nlm.nih.gov/31126011 31126011]|[https://pubmed.ncbi.nlm.nih.gov/28002670 28002670]|[https://pubmed.ncbi.nlm.nih.gov/28991403 28991403]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/24032650 24032650] [https://pubmed.ncbi.nlm.nih.gov/24032650 24032650]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/15316281 15316281] [https://pubmed.ncbi.nlm.nih.gov/15316281 15316281]]|[https://pubmed.ncbi.nlm.nih.gov/25154914 25154914]|[https://pubmed.ncbi.nlm.nih.gov/22490318 22490318]|[https://pubmed.ncbi.nlm.nih.gov/22430811 22430811]|[https://pubmed.ncbi.nlm.nih.gov/1463783 1463783]|[https://pubmed.ncbi.nlm.nih.gov/18803208 18803208]|[https://pubmed.ncbi.nlm.nih.gov/7881173 7881173]|[https://pubmed.ncbi.nlm.nih.gov/7697655 7697655]|[https://pubmed.ncbi.nlm.nih.gov/7240157 7240157]|[https://pubmed.ncbi.nlm.nih.gov/1768292 1768292] <br>
  '''definition''' : A glycan that have the addition of one sialic acid residues. <br>
  '''definition''' : Type of N-linked glycan in which four antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The four antennae are initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 2 GlcNAcs to the _6 Man (at the 2 and 6 positions) of the trimannosyl core. Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453019/ Glossary]] <br>
  '''term_xref''' :  <br>
  '''term_xref''' :  <br>
  '''synonyms''' :  <br>
  '''synonyms''' :  <br>
  '''function''' : appears in bovine brain gangliosides.[PMID: [https://pubmed.ncbi.nlm.nih.gov/29752599 29752599]] <br>
  '''function''' : <br>
'''disease_associations''' :  <br>
'''wikipedia''' : https://www.wikidata.org/wiki/Q[https://pubmed.ncbi.nlm.nih.gov/27104888 27104888] <br>
'''essentials_of_glycobiology''' :  <br>
 
 
===Tetraantennary complex-type===
'''term (main_entry)''' : Tetraantennary complex-type <br>
'''glycan_dictionary_accession''' : GSD000165 <br>
'''glytoucan_accession ''' :  <br>
'''term_in_sentence''' : A variety of high-mannose structures , as well as bi-, tri-, and tetraantennary complex-type carbohydrate , has been found, in relative amounts of 1-25% of the total oligosaccharides.[PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/1899031 1899031] [https://pubmed.ncbi.nlm.nih.gov/1899031 1899031]]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/1899031 1899031] [https://pubmed.ncbi.nlm.nih.gov/1899031 1899031]]|[https://pubmed.ncbi.nlm.nih.gov/8251489 8251489]|[https://pubmed.ncbi.nlm.nih.gov/8274017 8274017]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/1899031 1899031] [https://pubmed.ncbi.nlm.nih.gov/1899031 1899031]]| [https://pubmed.ncbi.nlm.nih.gov/6317691 6317691]|[https://pubmed.ncbi.nlm.nih.gov/23668542 23668542]| [https://pubmed.ncbi.nlm.nih.gov/6088518 6088518]|[https://pubmed.ncbi.nlm.nih.gov/21495009 21495009]|[https://pubmed.ncbi.nlm.nih.gov/1457971 1457971]|[https://pubmed.ncbi.nlm.nih.gov/1783599 1783599]|[https://pubmed.ncbi.nlm.nih.gov/10988252 10988252]|[https://pubmed.ncbi.nlm.nih.gov/11425798 11425798]|[https://pubmed.ncbi.nlm.nih.gov/7522229 7522229]|[https://pubmed.ncbi.nlm.nih.gov/2574992 2574992]|[https://pubmed.ncbi.nlm.nih.gov/3730425 3730425]|[https://pubmed.ncbi.nlm.nih.gov/10200178 10200178]|[https://pubmed.ncbi.nlm.nih.gov/2939068 2939068]|[https://pubmed.ncbi.nlm.nih.gov/21584695 21584695]| [https://pubmed.ncbi.nlm.nih.gov/7524670 7524670]|[https://pubmed.ncbi.nlm.nih.gov/7682847 7682847]|[https://pubmed.ncbi.nlm.nih.gov/2930192 2930192]|[https://pubmed.ncbi.nlm.nih.gov/1726466 1726466]|[https://pubmed.ncbi.nlm.nih.gov/9881746 9881746]|[https://pubmed.ncbi.nlm.nih.gov/11068879 11068879]|[https://pubmed.ncbi.nlm.nih.gov/6704968 6704968]|[https://pubmed.ncbi.nlm.nih.gov/2302846 2302846]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/24032650 24032650] [https://pubmed.ncbi.nlm.nih.gov/24032650 24032650]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/15316281 15316281] [https://pubmed.ncbi.nlm.nih.gov/15316281 15316281]]|[https://pubmed.ncbi.nlm.nih.gov/11051207 11051207]|[https://pubmed.ncbi.nlm.nih.gov/10220588 10220588]|[https://pubmed.ncbi.nlm.nih.gov/2813359 2813359]|[https://pubmed.ncbi.nlm.nih.gov/2174368 2174368]|[https://pubmed.ncbi.nlm.nih.gov/21755550 21755550]|[https://pubmed.ncbi.nlm.nih.gov/3571208 3571208]|[https://pubmed.ncbi.nlm.nih.gov/1929437 1929437]|[https://pubmed.ncbi.nlm.nih.gov/3681300 3681300]|[https://pubmed.ncbi.nlm.nih.gov/6581225 6581225]|[https://pubmed.ncbi.nlm.nih.gov/3364983 3364983]|[https://pubmed.ncbi.nlm.nih.gov/2902877 2902877]|[https://pubmed.ncbi.nlm.nih.gov/2297756 2297756]|[https://pubmed.ncbi.nlm.nih.gov/1315684 1315684]|[https://pubmed.ncbi.nlm.nih.gov/6830758 6830758]|[https://pubmed.ncbi.nlm.nih.gov/1998670 1998670] <br>
'''definition''' : Type of N-linked glycan in which four antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The four antennae are initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 2 GlcNAcs to the _6 Man (at the 2 and 6 positions) of the trimannosyl core. Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453019/ Glossary]]  <br>
'''term_xref''' : https://www.sigmaaldrich.com/technical-documents/articles/biology/glycobiology/n-glycans.html<br>
'''synonyms''' :  <br>
'''function''' :  <br>
  '''disease_associations''' :  <br>
  '''disease_associations''' :  <br>
  '''wikipedia''' :  <br>
  '''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' : <br>
  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453030/ Chapter 10]<br>




===Monosialyl-biantennary===
===Tetrasialylated diantennary===
  '''term (main_entry)''' : Monosialyl-biantennary <br>
  '''term (main_entry)''' : Tetrasialylated diantennary <br>
  '''glycan_dictionary_accession''' : GSD000124 <br>
  '''glycan_dictionary_accession''' : GSD000166 <br>
  '''glytoucan_accession ''' :  <br>
  '''glytoucan_accession ''' :  <br>
  '''term_in_sentence''' : In contrast, the sugar chain structure of HCC highly specific AFP isoform was found to comprise a monosialyl-biantennary sugar chain with additional fucosylation of the proximal N-acetylglucosamine.[PMID:[https://pubmed.ncbi.nlm.nih.gov/7686446 7686446]] <br>
  '''term_in_sentence''' : A further preparation, obtained from the most anionic DEAE-cellulose fraction (peak V) or rTf contained several tetrasialylated diantennary glycans whose precise structures remain to be established in future studies.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1997323 1997323]] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/7686446 7686446]|[https://pubmed.ncbi.nlm.nih.gov/1374031 1374031]|[https://pubmed.ncbi.nlm.nih.gov/9648261 9648261]|[https://pubmed.ncbi.nlm.nih.gov/10460833 10460833]|[https://pubmed.ncbi.nlm.nih.gov/19524219 19524219]|[https://pubmed.ncbi.nlm.nih.gov/10207016 10207016]|[https://pubmed.ncbi.nlm.nih.gov/15797573 15797573]|[https://pubmed.ncbi.nlm.nih.gov/15218190 15218190] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1997323 1997323] <br>
  '''definition''' : A biantennary glycan with two GlcNAc branches linked to the core and the addition of one sialic acid residues. <br>
  '''definition''' : A biantennary glycan with two GlcNAc branches linked to the core and the addition of four sialic acid residues. <br>
  '''term_xref''' :  <br>
  '''term_xref''' :  <br>
  '''synonyms''' : monosialyl biantennary|sialylated diantennary|sialylated biantennary <br>
  '''synonyms''' : <br>
  '''function''' :  <br>
  '''function''' :  <br>
  '''disease_associations''' :  <br>
  '''disease_associations''' :  <br>
Line 30: Line 61:




===Monosialyl-Gb5===
===Tn antigen===
[[File:G32254QI.png|thumb|G32254QI]]
[[File:G57321FI.png|thumb|G57321FI]]
  '''term (main_entry)''' : Monosialyl-Gb5 <br>
  '''term (main_entry)''' : Tn antigen <br>
  '''glycan_dictionary_accession''' : GSD000125 <br>
  '''glycan_dictionary_accession''' : GSD000167 <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G32254QI G32254QI] <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G57321FI G57321FI] <br>
  '''term_in_sentence''' : Thus, malignancy of MCF-7 is highly dependent on monosialyl-Gb5, and its activation of cSrc and FAK in GEM.[PMID:[https://pubmed.ncbi.nlm.nih.gov/12401210 12401210]] <br>
  '''term_in_sentence''' : Furthermore, we confirmed that LS174T cells (Tn-positive) transfected with wild-type Cosmc, thus expressing no Tn antigen, had down-regulation of H-Ras expression and subsequent inhibition of EMT process.[PMID:30637914] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12401210 12401210]|[https://pubmed.ncbi.nlm.nih.gov/16995838 16995838]|[https://pubmed.ncbi.nlm.nih.gov/27318475 27318475] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27679419 27679419]|[https://pubmed.ncbi.nlm.nih.gov/31938254 31938254]|[https://pubmed.ncbi.nlm.nih.gov/30637914 30637914]|[https://pubmed.ncbi.nlm.nih.gov/24643043 24643043]|[https://pubmed.ncbi.nlm.nih.gov/31225574 31225574]|[https://pubmed.ncbi.nlm.nih.gov/21259410 21259410]|[https://pubmed.ncbi.nlm.nih.gov/31742337 31742337]|[https://pubmed.ncbi.nlm.nih.gov/28514044 28514044]|[https://pubmed.ncbi.nlm.nih.gov/33014816 33014816]|[https://pubmed.ncbi.nlm.nih.gov/28708980 28708980]|[https://pubmed.ncbi.nlm.nih.gov/27432485 27432485]|[https://pubmed.ncbi.nlm.nih.gov/33050853 33050853]|[https://pubmed.ncbi.nlm.nih.gov/26045765 26045765]|[https://pubmed.ncbi.nlm.nih.gov/27542280 27542280]|[https://pubmed.ncbi.nlm.nih.gov/24411673 24411673]|[https://pubmed.ncbi.nlm.nih.gov/27760846 27760846]|[https://pubmed.ncbi.nlm.nih.gov/30115016 30115016]|[https://pubmed.ncbi.nlm.nih.gov/1410473 1410473]|[https://pubmed.ncbi.nlm.nih.gov/29802864 29802864]|[https://pubmed.ncbi.nlm.nih.gov/29669308 29669308]|[https://pubmed.ncbi.nlm.nih.gov/29251002 29251002]|[https://pubmed.ncbi.nlm.nih.gov/32541028 32541028]|[https://pubmed.ncbi.nlm.nih.gov/31019509 31019509]|[https://pubmed.ncbi.nlm.nih.gov/1582597 1582597]|[https://pubmed.ncbi.nlm.nih.gov/2981150 2981150]|[https://pubmed.ncbi.nlm.nih.gov/10842187 10842187]|[https://pubmed.ncbi.nlm.nih.gov/29638123 29638123]|[https://pubmed.ncbi.nlm.nih.gov/22367369 22367369]|[https://pubmed.ncbi.nlm.nih.gov/10778170 10778170]|[https://pubmed.ncbi.nlm.nih.gov/1510031 1510031]|[https://pubmed.ncbi.nlm.nih.gov/19372570 19372570]|[https://pubmed.ncbi.nlm.nih.gov/20641477 20641477]|[https://pubmed.ncbi.nlm.nih.gov/16149605 16149605]|[https://pubmed.ncbi.nlm.nih.gov/15770530 15770530]|[https://pubmed.ncbi.nlm.nih.gov/27856425 27856425]|[https://pubmed.ncbi.nlm.nih.gov/23814067 23814067]|[https://pubmed.ncbi.nlm.nih.gov/28068458 28068458]|[https://pubmed.ncbi.nlm.nih.gov/32134186 32134186]|[https://pubmed.ncbi.nlm.nih.gov/8174100 8174100]|[https://pubmed.ncbi.nlm.nih.gov/10571017 10571017]|[https://pubmed.ncbi.nlm.nih.gov/27453399 27453399]|[https://pubmed.ncbi.nlm.nih.gov/1727666 1727666]|[https://pubmed.ncbi.nlm.nih.gov/23740330 23740330] <br>
  '''definition''' : alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->3)-alpha-D-Galp-(1->4)-beta-D-Galp-(1->4)-beta-D-Glcp is a linear amino hexasaccharide comprising β-D-glucose at the reducing end with at the 4-position a β-D-galactosyl-(1→3)-N-acetyl-β-D-glucosaminyl-(1→3)-α-D-galactosyl-(1→4)-β-D-galactosyl moiety, α(2→3)-sialylated at the terminal galactosyl residue.[CHEBI:62313] <br>
  '''definition''' : Tn anitigen or alpha-galnac or N-Acetylgalactosamine is an N-acetyl-D-galactosamine having alpha-configuration at the anomeric centre. It has a role as an epitope. It derives from an alpha-D-galactosamine.[CHEBI:40356,HMDB[https://pubmed.ncbi.nlm.nih.gov/0000212 0000212]] <br>
  '''term_xref''' : GTC:G32254QI|GlycoEpitope:EP0099|GlycoMotif:GGM.000080|CID:73427363|CHEBI:62313 <br>
  '''term_xref''' : GTC:G57321FI|GlycoEpitope:EP0021|CID:84265|CHEBI:40356|HMDB[https://pubmed.ncbi.nlm.nih.gov/0000212 0000212]|GlycoMotif:GGM.000008 <br>
  '''synonyms''' : GL-7 globoseries ganglioside (SSEA-4)|Monosialyl Gb5|Sialosyl galactosyl globoside|GL-7 globoseries ganglioside|SSEA-4 <br>
  '''synonyms''' : <br>
  '''function''' : <br>
  '''function''' : lymphatic metastasis[GlycoEpitope:EP0021]|tube formation in Drosophila development[GlycoEpitope:EP0021]|modulation of malignant phenotype (gastric carcinoma cell)[GlycoEpitope:EP0021]|correlation with tumor stage, lymphatic invasion and lymph node matastasis[GlycoEpitope:EP0021] <br>
  '''disease_associations''' : renal cell carcinoma/RCC[GlycoEpitope:EP0099] <br>
  '''disease_associations''' : breast cancer[GlycoEpitope:EP0021]|cervical cancer[GlycoEpitope:EP0021]|colon cancer[GlycoEpitope:EP0021]|colorectal cancer[GlycoEpitope:EP0021]|fibrosarcoma[GlycoEpitope:EP0021]|gastric cancer[GlycoEpitope:EP0021]|liver cancer[GlycoEpitope:EP0021]|ovarian cancer[GlycoEpitope:EP0021]|pancreas cancer[GlycoEpitope:EP0021]|prostate cancer[GlycoEpitope:EP0021]|Tn syndorome[GlycoEpitope:EP0021]|Barrett'sesophagus[GlycoEpitope:EP0021]|Schindler/Kanzaki desease (alpha-N acetylgalactosaminidase deficiency)[GlycoEpitope:EP0021]. <br>
  '''wikipedia''' :  <br>
  '''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' :  <br>
  '''essentials_of_glycobiology''' :  <br>




===Mono-sulfated globopentaosylceramide===
===Triantennary===
[[File:G80193TN.png|thumb|G80193TN]]
  '''term (main_entry)''' : Triantennary <br>
  '''term (main_entry)''' : Mono-sulfated globopentaosylceramide <br>
  '''glycan_dictionary_accession''' : GSD000168 <br>
  '''glycan_dictionary_accession''' : GSD000126 <br>
  '''glytoucan_accession ''' : <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G80193TN G80193TN] <br>
'''term_in_sentence''' : Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.[PMID:24992960] <br>
  '''term_in_sentence''' : Mono-sulfated globopentaosylceramide from human kidney.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2777788 2777788]] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/24992960 24992960]|[https://pubmed.ncbi.nlm.nih.gov/27025342 27025342]|[https://pubmed.ncbi.nlm.nih.gov/29642865 29642865]|[https://pubmed.ncbi.nlm.nih.gov/29456020 29456020]|[https://pubmed.ncbi.nlm.nih.gov/26914862 26914862]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/26926155 26926155] [https://pubmed.ncbi.nlm.nih.gov/26926155 26926155]]|[https://pubmed.ncbi.nlm.nih.gov/26299345 26299345]|[https://pubmed.ncbi.nlm.nih.gov/28981809 28981809]|[https://pubmed.ncbi.nlm.nih.gov/18395704 18395704]|[https://pubmed.ncbi.nlm.nih.gov/2211710 2211710]|[https://pubmed.ncbi.nlm.nih.gov/23461434 23461434]|[https://pubmed.ncbi.nlm.nih.gov/18327885 18327885]|[https://pubmed.ncbi.nlm.nih.gov/15264862 15264862]|[https://pubmed.ncbi.nlm.nih.gov/22954207 22954207]|[https://pubmed.ncbi.nlm.nih.gov/9061362 9061362]|[https://pubmed.ncbi.nlm.nih.gov/16581187 16581187]|[https://pubmed.ncbi.nlm.nih.gov/26537865 26537865]|[https://pubmed.ncbi.nlm.nih.gov/3979568 3979568]|[https://pubmed.ncbi.nlm.nih.gov/28129130 28129130]|[https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]|[https://pubmed.ncbi.nlm.nih.gov/8068017 8068017]|[https://pubmed.ncbi.nlm.nih.gov/7783116 7783116]|[https://pubmed.ncbi.nlm.nih.gov/3857231 3857231]|[https://pubmed.ncbi.nlm.nih.gov/20540518 20540518]|[https://pubmed.ncbi.nlm.nih.gov/1706936 1706936]|[https://pubmed.ncbi.nlm.nih.gov/2430615 2430615]|[https://pubmed.ncbi.nlm.nih.gov/8078981 8078981]|[https://pubmed.ncbi.nlm.nih.gov/2211711 2211711]|[https://pubmed.ncbi.nlm.nih.gov/6767476 6767476]|[https://pubmed.ncbi.nlm.nih.gov/3814128 3814128]|[https://pubmed.ncbi.nlm.nih.gov/2597120 2597120]|[https://pubmed.ncbi.nlm.nih.gov/7451505 7451505]|[https://pubmed.ncbi.nlm.nih.gov/8204583 8204583]|[https://pubmed.ncbi.nlm.nih.gov/20619452 20619452]|[https://pubmed.ncbi.nlm.nih.gov/10460831 10460831]|[https://pubmed.ncbi.nlm.nih.gov/1924399 1924399]|[https://pubmed.ncbi.nlm.nih.gov/6643471 6643471]|[https://pubmed.ncbi.nlm.nih.gov/31809011 31809011]|[https://pubmed.ncbi.nlm.nih.gov/30042045 30042045]|[https://pubmed.ncbi.nlm.nih.gov/2477056 2477056]|[https://pubmed.ncbi.nlm.nih.gov/7882496 7882496]|[https://pubmed.ncbi.nlm.nih.gov/2430614 2430614]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2551687 2551687] [https://pubmed.ncbi.nlm.nih.gov/2551687 2551687]]|[https://pubmed.ncbi.nlm.nih.gov/2426141 2426141]|[https://pubmed.ncbi.nlm.nih.gov/2065052 2065052]|[https://pubmed.ncbi.nlm.nih.gov/28988716 28988716]|[https://pubmed.ncbi.nlm.nih.gov/31144994 31144994]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/26966183 26966183] [https://pubmed.ncbi.nlm.nih.gov/26966183 26966183]]|[https://pubmed.ncbi.nlm.nih.gov/29809215 29809215] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2777788 2777788] <br>
  '''definition''' : Type of N-linked glycan in which three antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The three antennae can be be initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 1 GlcNAc to the _6 Man (at the 2 position) of the trimannosyl core or 1 on the _3 and 2 on the _6 Man (at the 2 and 6 positions). Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453019/ Glossary]] <br>
  '''definition''' : <br>
  '''term_xref''' : <br>
  '''term_xref''' : GlycoMotif:GGM.000072|GTC:G80193TN <br>
  '''synonyms''' : <br>
  '''synonyms''' : Monosulfated globopentaosylceramide <br>
  '''function''' :  <br>
  '''function''' :  <br>
  '''disease_associations''' :  <br>
  '''disease_associations''' :  <br>
Line 62: Line 92:




===Mono-sulfated globotetraosylceramide===
===Triantennary complex===
[[File:G05297EK.png|thumb|G05297EK]]
  '''term (main_entry)''' : Triantennary complex <br>
  '''term (main_entry)''' : Mono-sulfated globotetraosylceramide <br>
  '''glycan_dictionary_accession''' : GSD000169 <br>
  '''glycan_dictionary_accession''' : GSD000127 <br>
  '''glytoucan_accession ''' : <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G05297EK G05297EK] <br>
'''term_in_sentence''' : Fucosylated biantennary complex-type and small amounts (less than 5%) of triantennary complex-type structures were identified on the glycosylated asparagine residues using sequential exoglycosidase and endoglycosidase digestions combined with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS).[PMID:9118998] <br>
  '''term_in_sentence''' : Mono-sulfated globotetraosylceramide from human kidney.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2559078 2559078]] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9118998 9118998]|[https://pubmed.ncbi.nlm.nih.gov/9061362 9061362]|[https://pubmed.ncbi.nlm.nih.gov/18395704 18395704]|[https://pubmed.ncbi.nlm.nih.gov/3814128 3814128]|[https://pubmed.ncbi.nlm.nih.gov/7451505 7451505]|[https://pubmed.ncbi.nlm.nih.gov/10460831 10460831]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/26926155 26926155] [https://pubmed.ncbi.nlm.nih.gov/26926155 26926155]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/26966183 26966183] [https://pubmed.ncbi.nlm.nih.gov/26966183 26966183]]|[https://pubmed.ncbi.nlm.nih.gov/16581187 16581187]|[https://pubmed.ncbi.nlm.nih.gov/16973123 16973123]|[https://pubmed.ncbi.nlm.nih.gov/8204583 8204583]|[https://pubmed.ncbi.nlm.nih.gov/29809215 29809215]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/11114588 11114588] [https://pubmed.ncbi.nlm.nih.gov/11114588 11114588]]|[https://pubmed.ncbi.nlm.nih.gov/31322324 31322324]|[https://pubmed.ncbi.nlm.nih.gov/15044389 15044389]|[https://pubmed.ncbi.nlm.nih.gov/16372382 16372382]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/8251489 8251489] [https://pubmed.ncbi.nlm.nih.gov/8251489 8251489]]|[https://pubmed.ncbi.nlm.nih.gov/8299583 8299583]|[https://pubmed.ncbi.nlm.nih.gov/1555586 1555586]|[https://pubmed.ncbi.nlm.nih.gov/7509658 7509658]|[https://pubmed.ncbi.nlm.nih.gov/1569060 1569060]|[https://pubmed.ncbi.nlm.nih.gov/16261636 16261636] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2559078 2559078] <br>
  '''definition''' : A complex N-glycan that has three branches attached to the non-reducing terminal Man residues of the trimannosyl core.[CHEBI:156252]  Each branch is initiated with a GlcNAc and can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. <br>
  '''definition''' :  <br>
  '''term_xref''' : CHEBI:156252 <br>
  '''term_xref''' : GlycoMotif:GGM.000073|GTC:G05297EK<br>
  '''synonyms''' : Triantennary complex-type <br>
  '''synonyms''' : <br>
  '''function''' :  <br>
  '''function''' :  <br>
  '''disease_associations''' :  <br>
  '''disease_associations''' :  <br>
  '''wikipedia''' :  <br>
  '''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' : <br>
  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453030/ Chapter 10]<br>




===N-acetyl GM2===
===Triantennary N-glycans===
  '''term (main_entry)''' : N-acetyl GM2 <br>
  '''term (main_entry)''' : Triantennary N-glycans <br>
  '''glycan_dictionary_accession''' : GSD000128 <br>
  '''glycan_dictionary_accession''' : GSD000170 <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G79389NT G79389NT] <br>
  '''glytoucan_accession ''' : <br>
  '''term_in_sentence''' : The appearance of the N-acetyl GM2 antigen correlated well with the degree of differentiation of the cancer cells in patients with squamous cell carcinoma and adenocarcinoma of the lung.[PMID:[https://pubmed.ncbi.nlm.nih.gov/3167861 3167861]] <br>
  '''term_in_sentence''' : Increased expression of the high-mannose M6N2 and NeuAc3H3N3M3N2F tri-antennary N-glycans in cholangiocarcinoma.[PMID:29399163] <br>
'''publication''' :[https://pubmed.ncbi.nlm.nih.gov/3167861 3167861]|[https://pubmed.ncbi.nlm.nih.gov/2153431 2153431]| [https://pubmed.ncbi.nlm.nih.gov/25673107 25673107] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29399163 29399163]|[https://pubmed.ncbi.nlm.nih.gov/22325877 22325877]|[https://pubmed.ncbi.nlm.nih.gov/18439991 18439991]|[https://pubmed.ncbi.nlm.nih.gov/24873509 24873509]|[https://pubmed.ncbi.nlm.nih.gov/11454001 11454001] <br>
  '''definition''' : beta-D-GalpNAc-(1->4)-[alpha-Neup5Ac-(2->3)]-beta-D-Galp-(1->4)-beta-D-Glcp is a branched amino tetrasaccharide consisting of the linear sequence β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the galactose via an α-(2→3) linkage. Corresponds to the carbohydrate portion of ganglioside GM2.[CHEBI:59220] <br>
  '''definition''' : Type of N-linked glycan in which three antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The three antennae can be be initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 1 GlcNAc to the _6 Man (at the 2 position) of the trimannosyl core or 1 on the _3 and 2 on the _6 Man (at the 2 and 6 positions). Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453019/ Glossary]]  <br>
  '''term_xref''' : GTC:G79389NT|GlycoEpitope:EP0051|CID: 45266845|CHEBI:59220 <br>
  '''term_xref''' : <br>
  '''synonyms''' :  <br>
  '''synonyms''' :  <br>
  '''function''' : The biological role played by a material entity when bound by a receptor of the adaptive immune system. Specific site on an antigen to which an antibody binds.[CHEBI:59220] <br>
  '''function''' : <br>
  '''disease_associations''' : lung adenocarcinoma[GlycoEpitope:EP0051]|embryonal carcinoma[GlycoEpitope:EP0051]|germ cell tumor[GlycoEpitope:EP0051]|teratocarcinoma[GlycoEpitope:EP0051]|squamous cell carcinoma[GlycoEpitope:EP0051] <br>
  '''disease_associations''' : <br>
  '''wikipedia''' :  <br>
  '''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' :  <br>
  '''essentials_of_glycobiology''' :  <br>




===N-acetyllactosamine (Type 1)===
===Triantennary sialylated===
[[File:G00056MO.png|alt=|thumb|G00056MO]]
  '''term (main_entry)''' : Triantennary sialylated <br>
  '''term (main_entry)''' : N-acetyllactosamine (Type 1)<br>
  '''glycan_dictionary_accession''' : GSD000171 <br>
  '''glycan_dictionary_accession''' : GSD000181<br>
  '''glytoucan_accession ''' : <br>
  '''glytoucan_accession ''' : [https://glygen.org/glycan/G00056MO G00056MO]<br>
'''term_in_sentence''' : LC-ESIMS/MS analysis revealed that both light chain and heavy chain were N-glycosylated mainly by A2S2 but also by triantennary sialylated glycans.[PMID:18642129] <br>
  '''term_in_sentence''' : The N-acetyllactosamine type 1 (LacNAc type 1, Galβ1,3GlcNAc) is a well-known precursor of several important blood group epitopes, such as Lewis A, Lewis B, or sialyl Lewis A [1], which are involved in many biological processes, e.g., fertilization [2] and pathogen adhesion [3]. [PMID:[https://pubmed.ncbi.nlm.nih.gov/28796164 28796164]]<br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/18642129 18642129]|[https://pubmed.ncbi.nlm.nih.gov/31964828 31964828]|[https://pubmed.ncbi.nlm.nih.gov/3979568 3979568]|[https://pubmed.ncbi.nlm.nih.gov/27936604 27936604]|[https://pubmed.ncbi.nlm.nih.gov/23681398 23681398]|[https://pubmed.ncbi.nlm.nih.gov/21538882 21538882]|[https://pubmed.ncbi.nlm.nih.gov/7579793 7579793]|[https://pubmed.ncbi.nlm.nih.gov/7613477 7613477]|[https://pubmed.ncbi.nlm.nih.gov/2223825 2223825]|[https://pubmed.ncbi.nlm.nih.gov/3539023 3539023]|[https://pubmed.ncbi.nlm.nih.gov/3674882 3674882] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28796164 28796164]|[https://pubmed.ncbi.nlm.nih.gov/28167527 28167527]<br>
  '''definition''' : A triantennary glycan with three GlcNAc branches linked to the core and the addition of one sialic acid residues. <br>
  '''definition''' : <br>
  '''term_xref''' : <br>
  '''term_xref''' : GTC:G00056MO|GlycoMotif:GGM.000005<br>
  '''synonyms''' : <br>
  '''synonyms''' : LacNAc type 1|Type 1 LN|Type-1 lactosamine<br>
  '''function''' : Appears in human serotransferrin.[PMID: 3979568] <br>
  '''function''' : <br>
  '''disease_associations''' :  <br>
  '''disease_associations''' :  <br>
  '''wikipedia''' :  <br>
  '''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' :<br>
  '''essentials_of_glycobiology''' : <br>




===N-acetyllactosamine (Type 2)===
===Triantennary trisialylated fucosylated===
[[File:G00055MO.png|thumb|G00055MO]]
  '''term (main_entry)''' : Triantennary trisialylated fucosylated <br>
  '''term (main_entry)''' : N-acetyllactosamine (Type 2)<br>
  '''glycan_dictionary_accession''' : GSD000172 <br>
  '''glycan_dictionary_accession''' : GSD000129 <br>
  '''glytoucan_accession ''' : <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00055MO G00055MO] <br>
  '''term_in_sentence''' : Diantennary monosialylated glycans and triantennary trisialylated fucosylated and non-fucosylated structures have also been identified.[PMID:[https://pubmed.ncbi.nlm.nih.gov/17591618 17591618]] <br>
  '''term_in_sentence''' : Utilising a fast and sensitive screening method based on imidazolium-tagged probes, we report unprecedented reversible activity of bacterial beta1,4-galactosyltransferases to catalyse the transgalactosylation from lactose to N-acetylglucosamine to form N-acetyllactosamine in the presence of UDP.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31165848 31165848]] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/17591618 17591618] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31165848 31165848]|[https://pubmed.ncbi.nlm.nih.gov/31126011 31126011]|[https://pubmed.ncbi.nlm.nih.gov/28796164 28796164]|[https://pubmed.ncbi.nlm.nih.gov/6236210 6236210]|[https://pubmed.ncbi.nlm.nih.gov/9751793 9751793]|[https://pubmed.ncbi.nlm.nih.gov/29740087 29740087]|[https://pubmed.ncbi.nlm.nih.gov/9151975 9151975]|[https://pubmed.ncbi.nlm.nih.gov/10567443 10567443]|[https://pubmed.ncbi.nlm.nih.gov/21472942 21472942]|[https://pubmed.ncbi.nlm.nih.gov/26477523 26477523]|[https://pubmed.ncbi.nlm.nih.gov/6548353 6548353]|[https://pubmed.ncbi.nlm.nih.gov/28167527 28167527]|[https://pubmed.ncbi.nlm.nih.gov/20056550 20056550]|[https://pubmed.ncbi.nlm.nih.gov/7737204 7737204]|[https://pubmed.ncbi.nlm.nih.gov/22052010 22052010]|[https://pubmed.ncbi.nlm.nih.gov/10223649 10223649]|[https://pubmed.ncbi.nlm.nih.gov/11323440 11323440]|[https://pubmed.ncbi.nlm.nih.gov/10420596 10420596]|[https://pubmed.ncbi.nlm.nih.gov/7766648 7766648]|[https://pubmed.ncbi.nlm.nih.gov/25257940 25257940]|[https://pubmed.ncbi.nlm.nih.gov/17977857 17977857]|[https://pubmed.ncbi.nlm.nih.gov/15556936 15556936]|[https://pubmed.ncbi.nlm.nih.gov/26541999 26541999]|[https://pubmed.ncbi.nlm.nih.gov/23650594 23650594]|[https://pubmed.ncbi.nlm.nih.gov/9692202 9692202]|[https://pubmed.ncbi.nlm.nih.gov/29429899 29429899]|[https://pubmed.ncbi.nlm.nih.gov/21062783 21062783]|[https://pubmed.ncbi.nlm.nih.gov/25034434 25034434]|[https://pubmed.ncbi.nlm.nih.gov/8985145 8985145]|[https://pubmed.ncbi.nlm.nih.gov/28503789 28503789]|[https://pubmed.ncbi.nlm.nih.gov/8720464 8720464]/ <br>
  '''definition''' : A triantennary glycan with three GlcNAc branches linked to the core and the addition of three sialic acid residues and fucose added. <br>
  '''definition''' : N-acetyllactosamine is a beta-D-galactopyranosyl-(1→4)-N-acetyl-D-glucosamine having beta-configuration at the reducing end anomeric centre. It is also known as galb1-4glcnacb or lacnac, belongs to the class of organic compounds known as acylaminosugars. These are organic compounds containing a sugar linked to a chain through N-acyl group. N-Acetyllactosamine is an extremely weak basic (essentially neutral) compound (based on its pKa). N-Acetyllactosamine exists in all living organisms, ranging from bacteria to humans.[CHEBI:16153,HMDB0001542] <br>
  '''term_xref''' : <br>
  '''term_xref''' : GTC:G00055MO|CID:439271|CHEBI:16153|MeSH:C000458|GlycoMotif:GGM.000001 <br>
  '''synonyms''' : <br>
  '''synonyms''' : LacNAc|Type 2 LN <br>
  '''function''' :  <br>
  '''function''' :  <br>
  '''disease_associations''' :  <br>
  '''disease_associations''' :  <br>
Line 125: Line 152:




===N-Glycolyl-GM2===
===Trifucosyl Lewis b antigen===
[[File:G56478LD.png|thumb|G56478LD]]
[[File:G74578MX.png|thumb|G74578MX]]
  '''term (main_entry)''' : N-Glycolyl-GM2 <br>
  '''term (main_entry)''' : Trifucosyl Lewis b antigen <br>
  '''glycan_dictionary_accession''' : GSD000130 <br>
  '''glycan_dictionary_accession''' : GSD000173 <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G56478LD G56478LD] <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G74578MX G74578MX] <br>
  '''term_in_sentence''' : The monoclonal antibodies MK2-34 and MK1-16 (both IgM), which specifically detect N-glycolyl GM2 and N-acetyl GM2, respectively, were generated by immunizing mice with liposomes containing monophosphoryl lipid A, trehalose dimycolate, and the antigenic ganglioside.[PMID:[https://pubmed.ncbi.nlm.nih.gov/3167861 3167861]] <br>
  '''term_in_sentence''' : Extended type-1 chain glycosphingolipid antigens. Isolation and characterization of trifucosyl-Leb antigen (III4V4VI2Fuc3Lc6)[PMID:[https://pubmed.ncbi.nlm.nih.gov/1735443 1735443]] <br>
  '''publication''' : [[https://pubmed.ncbi.nlm.nih.gov/3167861 3167861]|[https://pubmed.ncbi.nlm.nih.gov/11861662 11861662]|[https://pubmed.ncbi.nlm.nih.gov/17980710 17980710]|[https://pubmed.ncbi.nlm.nih.gov/3731079 3731079]| [https://pubmed.ncbi.nlm.nih.gov/25673107 25673107]] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1735443 1735443] <br>
  '''definition''' : (2S,4S,5R,6R)-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-Acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-5-[(2-hydroxyacetyl)amino]-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of carbohydrates and carbohydrate derivatives.[CHEBI:151464] <br>
  '''definition''' : N-[(2R,3R,4R,5S,6R)-4-[(2R,3R,4S,5S,6R)-4-[(2S,3R,4R,5S,6R)-3-Acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-5-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxy-6-(hydroxymethyl)-5-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]acetamide is an amino sugar.[CHEBI:153783] <br>
  '''term_xref''' : GTC:G56478LD |GlycoEpitope:EP0052|CID:91845742|CHEBI:151464|GlycoEpitope:GGM.000096  <br>
  '''term_xref''' : GlycoEpitope:EP0092|GTC:G74578MX|CID:[https://pubmed.ncbi.nlm.nih.gov/91845957 91845957]|CHEBI:153783 <br>
  '''synonyms''' : <br>
  '''synonyms''' : trifucosyl-Leb antigen <br>
  '''function''' : <br>
  '''function''' : cancer-associated antigen[GlycoEpitope: EP0092] <br>
  '''disease_associations''' : choriocarcinoma[GlycoEpitope:EP0052]|teratocarcinoma|[GlycoEpitope:EP0052]yolk sac tumor[GlycoEpitope:EP0052] <br>
  '''disease_associations''' : colonic cancer[GlycoEpitope: EP0092]|endometrial cancer[GlycoEpitope: EP0092]|liver cancer[GlycoEpitope: EP0092]|pancreatic cancer[GlycoEpitope: EP0092]|rectal cancer[GlycoEpitope: EP0092] <br>
  '''wikipedia''' :  <br>
  '''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' :  <br>
  '''essentials_of_glycobiology''' :  <br>




===N-linked glycans===
===Trifucosyl lewis y===
[[File:G78059CC.png|thumb|G78059CC]]
[[File:G74917JX.png|thumb|G74917JX]]
  '''term (main_entry)''' : N-linked glycans <br>
  '''term (main_entry)''' : Trifucosyl lewis y <br>
  '''glycan_dictionary_accession''' : GSD000131 <br>
  '''glycan_dictionary_accession''' : GSD000174 <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G78059CC G78059CC] <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G74917JX G74917JX] <br>
  '''term_in_sentence''' : Our study identifies extracellular N-linked glycans-and the glycoprotein neurexin 1β specifically-as key modulators of neuronal uptake of αSacetyl, drawing attention to the potential therapeutic value of αSacetyl-glycan interactions.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31211781 31211781]] <br>
  '''term_in_sentence''' : The third, major component, common in all eight cases, has been identified as trifucosyl Ley (lactotrifucononaosylceramide, III3FucV3FucVI2FucnLc6, Structure 2 below) based on 1H NMR spectroscopy, methylation analysis, and direct-probe electron-impact mass spectrometry.[PMID:[https://pubmed.ncbi.nlm.nih.gov/3733752 3733752]] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31211781 31211781]|[https://pubmed.ncbi.nlm.nih.gov/28384382 28384382]|[https://pubmed.ncbi.nlm.nih.gov/30305477 30305477]|[https://pubmed.ncbi.nlm.nih.gov/31364612 31364612]|[https://pubmed.ncbi.nlm.nih.gov/26899268 26899268]|[https://pubmed.ncbi.nlm.nih.gov/29945790 29945790]|[https://pubmed.ncbi.nlm.nih.gov/29652253 29652253]|[https://pubmed.ncbi.nlm.nih.gov/29723274 29723274]|[https://pubmed.ncbi.nlm.nih.gov/30962676 30962676]|[https://pubmed.ncbi.nlm.nih.gov/29778448 29778448]|[https://pubmed.ncbi.nlm.nih.gov/25325701 25325701]|[https://pubmed.ncbi.nlm.nih.gov/31100702 31100702]|[https://pubmed.ncbi.nlm.nih.gov/28898525 28898525]|[https://pubmed.ncbi.nlm.nih.gov/22944671 22944671]|[https://pubmed.ncbi.nlm.nih.gov/19277537 19277537]|[https://pubmed.ncbi.nlm.nih.gov/24473128 24473128]|[https://pubmed.ncbi.nlm.nih.gov/17957771 17957771]|[https://pubmed.ncbi.nlm.nih.gov/27554083 27554083]|[https://pubmed.ncbi.nlm.nih.gov/15189166 15189166]|[https://pubmed.ncbi.nlm.nih.gov/11269317 11269317]|[https://pubmed.ncbi.nlm.nih.gov/19577919 19577919]|[https://pubmed.ncbi.nlm.nih.gov/24303005 24303005]|[https://pubmed.ncbi.nlm.nih.gov/12042249 12042249]|[https://pubmed.ncbi.nlm.nih.gov/22191536 22191536]|[https://pubmed.ncbi.nlm.nih.gov/28324664 28324664]|[https://pubmed.ncbi.nlm.nih.gov/25965797 25965797]|[https://pubmed.ncbi.nlm.nih.gov/25434632 25434632]|[https://pubmed.ncbi.nlm.nih.gov/30484244 30484244]|[https://pubmed.ncbi.nlm.nih.gov/28110657 28110657]| [https://pubmed.ncbi.nlm.nih.gov/29865036 29865036]|[https://pubmed.ncbi.nlm.nih.gov/20129637 20129637]|[https://pubmed.ncbi.nlm.nih.gov/27346875 27346875]|[https://pubmed.ncbi.nlm.nih.gov/30280442 30280442]|[https://pubmed.ncbi.nlm.nih.gov/26911286 26911286]|[https://pubmed.ncbi.nlm.nih.gov/22491358 22491358]|[https://pubmed.ncbi.nlm.nih.gov/26582281 26582281]|[https://pubmed.ncbi.nlm.nih.gov/26398792 26398792]|[https://pubmed.ncbi.nlm.nih.gov/31548313 31548313]|[https://pubmed.ncbi.nlm.nih.gov/31066275 31066275]|[https://pubmed.ncbi.nlm.nih.gov/28331984 28331984]|[https://pubmed.ncbi.nlm.nih.gov/25482090 25482090]| [https://pubmed.ncbi.nlm.nih.gov/28518173 28518173]|[https://pubmed.ncbi.nlm.nih.gov/30733536 30733536]|[https://pubmed.ncbi.nlm.nih.gov/22326428 22326428]|[https://pubmed.ncbi.nlm.nih.gov/30063825 30063825]|[https://pubmed.ncbi.nlm.nih.gov/30315103 30315103]|[https://pubmed.ncbi.nlm.nih.gov/21558494 21558494]|[https://pubmed.ncbi.nlm.nih.gov/31676555 31676555]|[https://pubmed.ncbi.nlm.nih.gov/31256374 31256374] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3733752 3733752]|[https://pubmed.ncbi.nlm.nih.gov/2426269 2426269]<br>
  '''definition''' : The carbohydrate portion of a glycoprotein that has a glycan linked through the nitrogen of an asparagine side-chain.[CHEBI:59520] <br>
  '''definition''' : A branched heptasaccharide derivative consisting of two repeating units of β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc (joined by a (1→3)-linkage) with an α-L-fucosyl residue attached at the 2-position of the galactose residue at the non-reducing end.[CHEBI:61332] <br>
  '''term_xref''' : GTC:G78059CC|CID: 70679232|CHEBI:70967 <br>
  '''term_xref''' : GlycoEpitope: EP0094|GTC:G74917JX|CID:[https://pubmed.ncbi.nlm.nih.gov/50909806 50909806]|CHEBI:61332  <br>
  '''synonyms''' : <br>
  '''synonyms''' : trifucosyl Ley <br>
  '''function''' : N-glycans modulate the function of several cell surface proteins which involved in migration, adhesion and which are responsible for regulating myelination.[PMID: 25151374]|Affect transportation of the glycosylated proteins in the Golgi.[PMID: 25151374]|Affects cell-cell interaction, adhesion, expression, proper folding.[PMID: 25151374]|extracellular N-glycans act as key modulators of neuronal uptake of αacetyl [PMID: [https://pubmed.ncbi.nlm.nih.gov/31211781 31211781]]. <br>
  '''function''' : <br>
  '''disease_associations''' : Rheumatoid arthritis[PMID:17392038]|Type 1 Diabetes[PMID:29146600]|Lung Cancer[PMID: 23766031] <br>
  '''disease_associations''' : colonic adenocarcinomia[GlycoEpitope: EP0094] <br>
  '''wikipedia''' :  <br>
  '''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
  '''essentials_of_glycobiology''' : <br>




===Nonfucosylated===
===Trimannosyl core===
  '''term (main_entry)''' : Nonfucosylated <br>
  '''term (main_entry)''' : Trimannosyl core <br>
  '''glycan_dictionary_accession''' : GSD000132 <br>
  '''glycan_dictionary_accession''' : GSD000175 <br>
  '''glytoucan_accession ''' :  <br>
  '''glytoucan_accession ''' :  <br>
  '''term_in_sentence''' : In the carbohydrate moiety , alpha-subunit from normal pregnancy hCG contained nonfucosylated , mono- and biantennary N-linked structures (49.3 and 36.7%, means); fucosylated biantennary and triantennary oligosaccharides were also identified (7.3 and 6.9%).[PMID:[https://pubmed.ncbi.nlm.nih.gov/9449027 9449027]] <br>
  '''term_in_sentence''' : This glycoengineered H. polymorpha strain produced glycoproteins mainly containing trimannosyl core N-glycan (Man(3)GlcNAc(2)), which is the common core backbone of various human-type N-glycans.[PMID:18320567] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9449027 9449027] |[https://pubmed.ncbi.nlm.nih.gov/30258536 30258536]|[https://pubmed.ncbi.nlm.nih.gov/23554380 23554380]|[https://pubmed.ncbi.nlm.nih.gov/16675584 16675584]|[https://pubmed.ncbi.nlm.nih.gov/26747427 26747427]|[https://pubmed.ncbi.nlm.nih.gov/22457527 22457527]|[https://pubmed.ncbi.nlm.nih.gov/24362443 24362443]|[https://pubmed.ncbi.nlm.nih.gov/19657637 19657637]|[https://pubmed.ncbi.nlm.nih.gov/8811881 8811881]|[https://pubmed.ncbi.nlm.nih.gov/19218011 19218011]|[https://pubmed.ncbi.nlm.nih.gov/20022111 20022111]|[https://pubmed.ncbi.nlm.nih.gov/17363544 17363544]|[https://pubmed.ncbi.nlm.nih.gov/17368483 17368483]|[https://pubmed.ncbi.nlm.nih.gov/20564614 20564614]|[https://pubmed.ncbi.nlm.nih.gov/27054024 27054024]|[https://pubmed.ncbi.nlm.nih.gov/28397880 28397880]|[https://pubmed.ncbi.nlm.nih.gov/31490688 31490688]|[https://pubmed.ncbi.nlm.nih.gov/31860772 31860772]|[https://pubmed.ncbi.nlm.nih.gov/17012310 17012310]|[https://pubmed.ncbi.nlm.nih.gov/29633346 29633346]|[https://pubmed.ncbi.nlm.nih.gov/9442021 9442021]|[https://pubmed.ncbi.nlm.nih.gov/30350565 30350565]|[https://pubmed.ncbi.nlm.nih.gov/30296068 30296068]|[https://pubmed.ncbi.nlm.nih.gov/31800250 31800250]|[https://pubmed.ncbi.nlm.nih.gov/30021910 30021910]|[https://pubmed.ncbi.nlm.nih.gov/31133022 31133022]| [https://pubmed.ncbi.nlm.nih.gov/29224385 29224385]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/28630087 28630087] [https://pubmed.ncbi.nlm.nih.gov/28630087 28630087]]|[https://pubmed.ncbi.nlm.nih.gov/26444434 26444434]|[https://pubmed.ncbi.nlm.nih.gov/31697975 31697975]|[https://pubmed.ncbi.nlm.nih.gov/30991260 30991260] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/18320567 18320567]|[https://pubmed.ncbi.nlm.nih.gov/27629418 27629418]|[https://pubmed.ncbi.nlm.nih.gov/26514868 26514868]|[https://pubmed.ncbi.nlm.nih.gov/26821880 26821880]|[https://pubmed.ncbi.nlm.nih.gov/2477227 2477227]|[https://pubmed.ncbi.nlm.nih.gov/6213618 6213618]|[https://pubmed.ncbi.nlm.nih.gov/31747570 31747570]|[https://pubmed.ncbi.nlm.nih.gov/29273674 29273674]|[https://pubmed.ncbi.nlm.nih.gov/31064325 31064325]|[https://pubmed.ncbi.nlm.nih.gov/1291063 1291063]|[https://pubmed.ncbi.nlm.nih.gov/28353332 28353332]|[https://pubmed.ncbi.nlm.nih.gov/1421754 1421754]|[https://pubmed.ncbi.nlm.nih.gov/29666272 29666272]|[https://pubmed.ncbi.nlm.nih.gov/11421342 11421342]|[https://pubmed.ncbi.nlm.nih.gov/15648688 15648688]|[https://pubmed.ncbi.nlm.nih.gov/28179475 28179475]|[https://pubmed.ncbi.nlm.nih.gov/28903882 28903882]|[https://pubmed.ncbi.nlm.nih.gov/27189951 27189951]|[https://pubmed.ncbi.nlm.nih.gov/9455915 9455915]|[https://pubmed.ncbi.nlm.nih.gov/22768188 22768188]|[https://pubmed.ncbi.nlm.nih.gov/9254048 9254048]|[https://pubmed.ncbi.nlm.nih.gov/8721739 8721739]|[https://pubmed.ncbi.nlm.nih.gov/2249985 2249985]|[https://pubmed.ncbi.nlm.nih.gov/22933239 22933239]|[https://pubmed.ncbi.nlm.nih.gov/25629585 25629585]|[https://pubmed.ncbi.nlm.nih.gov/24489949 24489949]|[https://pubmed.ncbi.nlm.nih.gov/2981047 2981047]|[https://pubmed.ncbi.nlm.nih.gov/11067815 11067815]|[https://pubmed.ncbi.nlm.nih.gov/1729985 1729985]|[https://pubmed.ncbi.nlm.nih.gov/1710649 1710649]|[https://pubmed.ncbi.nlm.nih.gov/16672288 16672288]|[https://pubmed.ncbi.nlm.nih.gov/2719668 2719668]|[https://pubmed.ncbi.nlm.nih.gov/19003000 19003000]|[https://pubmed.ncbi.nlm.nih.gov/23025485 23025485]|[https://pubmed.ncbi.nlm.nih.gov/22500028 22500028]|[https://pubmed.ncbi.nlm.nih.gov/10409642 10409642]|[https://pubmed.ncbi.nlm.nih.gov/1325461 1325461]|[https://pubmed.ncbi.nlm.nih.gov/23136055 23136055]|[https://pubmed.ncbi.nlm.nih.gov/23085445 23085445]|[https://pubmed.ncbi.nlm.nih.gov/21656680 21656680]|[https://pubmed.ncbi.nlm.nih.gov/22448293 22448293]|[https://pubmed.ncbi.nlm.nih.gov/22132163 22132163]|[https://pubmed.ncbi.nlm.nih.gov/1425696 1425696]|[https://pubmed.ncbi.nlm.nih.gov/20696712 20696712]|[https://pubmed.ncbi.nlm.nih.gov/18056652 18056652]|[https://pubmed.ncbi.nlm.nih.gov/15084511 15084511]|[https://pubmed.ncbi.nlm.nih.gov/18633282 18633282]|[https://pubmed.ncbi.nlm.nih.gov/15814299 15814299] <br>
  '''definition''' : glycans without a fucose component/monosaccharide residue. <br>
  '''definition''' : A glycan that constitutes the core structure common to all high-mannose, complex, or hybrid N-glycans. The trimannosyl core composition is Man3 GlcNAc2 and includes a chitobiose at the reducing terminal which is extended by a single b-linked Man residue. The b-linked Man is branched by two additional a-linked Man residues, one at the 3 position and one at the 6 position. <br>
  '''term_xref''' :  <br>
  '''term_xref''' :  <br>
  '''synonyms''' :  <br>
  '''synonyms''' :  <br>
Line 172: Line 199:




===Nonfucosylated biantennary===
===Trisialylated===
  '''term (main_entry)''' : Nonfucosylated biantennary <br>
  '''term (main_entry)''' : Trisialylated <br>
  '''glycan_dictionary_accession''' : GSD000133 <br>
  '''glycan_dictionary_accession''' : GSD000176 <br>
  '''glytoucan_accession ''' :  <br>
  '''glytoucan_accession ''' :  <br>
  '''term_in_sentence''' : Structural analysis combining methylation-mass spectrometry and 400 MHz 1H-n.m.r. spectrometry of oligosaccharide alditols released from human leucocyte lactotransferrin shows the presence of two disialylated and non-fucosylated biantennary glycans of the N-acetyl-lactosaminic type.[PMID: [https://pubmed.ncbi.nlm.nih.gov/2390069 2390069]] <br>
  '''term_in_sentence''' : Many (82.7%) were found to be tetraantennary N-acetyllactosamine-type (22.8% with one, 3.6% with two and 0.4% with three N-acetyllactosamine repeats) being tetrasialylated (41%), trisialylated (29.6%) and disialylated (12.2%) |HPAE-PAD and FACE analysis suggests that they are triantennary and trisialylated with core fucosylation.[PMID:[https://pubmed.ncbi.nlm.nih.gov/8477709 8477709]] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2390069 2390069]| [https://pubmed.ncbi.nlm.nih.gov/9449027 9449027] |[https://pubmed.ncbi.nlm.nih.gov/1375510 1375510]|[https://pubmed.ncbi.nlm.nih.gov/9101715 9101715]|[https://pubmed.ncbi.nlm.nih.gov/2332109 2332109] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/6469957 6469957]|[https://pubmed.ncbi.nlm.nih.gov/18818422 18818422]|[https://pubmed.ncbi.nlm.nih.gov/18332077 18332077]|[https://pubmed.ncbi.nlm.nih.gov/21138277 21138277]|[https://pubmed.ncbi.nlm.nih.gov/9136890 9136890]|[https://pubmed.ncbi.nlm.nih.gov/10782293 10782293]|[https://pubmed.ncbi.nlm.nih.gov/19841910 19841910]|[https://pubmed.ncbi.nlm.nih.gov/20067809 20067809]|[https://pubmed.ncbi.nlm.nih.gov/14751029 14751029]|[https://pubmed.ncbi.nlm.nih.gov/8797382 8797382]|[https://pubmed.ncbi.nlm.nih.gov/16877748 16877748]|[https://pubmed.ncbi.nlm.nih.gov/19131698 19131698]|[https://pubmed.ncbi.nlm.nih.gov/20578731 20578731]|[https://pubmed.ncbi.nlm.nih.gov/24669823 24669823]|[https://pubmed.ncbi.nlm.nih.gov/22426998 22426998]|[https://pubmed.ncbi.nlm.nih.gov/27501865 27501865]|[https://pubmed.ncbi.nlm.nih.gov/2121479 2121479]|[https://pubmed.ncbi.nlm.nih.gov/24663386 24663386]|[https://pubmed.ncbi.nlm.nih.gov/32209427 32209427]|[https://pubmed.ncbi.nlm.nih.gov/32737218 32737218]|[https://pubmed.ncbi.nlm.nih.gov/33245334 33245334]|[https://pubmed.ncbi.nlm.nih.gov/26927318 26927318]|[https://pubmed.ncbi.nlm.nih.gov/30962676 30962676]|[https://pubmed.ncbi.nlm.nih.gov/28370937 28370937]|[https://pubmed.ncbi.nlm.nih.gov/30194503 30194503]|[https://pubmed.ncbi.nlm.nih.gov/26321095 26321095]|[https://pubmed.ncbi.nlm.nih.gov/30463578 30463578]|[https://pubmed.ncbi.nlm.nih.gov/31455764 31455764]|[https://pubmed.ncbi.nlm.nih.gov/31566965 31566965]|[https://pubmed.ncbi.nlm.nih.gov/31266306 31266306]|[https://pubmed.ncbi.nlm.nih.gov/29782424 29782424]|[https://pubmed.ncbi.nlm.nih.gov/31247951 31247951]|[https://pubmed.ncbi.nlm.nih.gov/30487799 30487799]|[https://pubmed.ncbi.nlm.nih.gov/2049094 2049094]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/1997323 1997323] [https://pubmed.ncbi.nlm.nih.gov/1997323 1997323]]|[https://pubmed.ncbi.nlm.nih.gov/10913832 10913832] <br>
  '''definition''' : A biantennary glycan with two GlcNAc branches linked to the core and no fucose appears. <br>
  '''definition''' : A glycan with three sialic acid components. <br>
  '''term_xref''' :  <br>
  '''term_xref''' :  <br>
  '''synonyms''' :  <br>
  '''synonyms''' :  <br>
Line 184: Line 211:
  '''disease_associations''' :  <br>
  '''disease_associations''' :  <br>
  '''wikipedia''' :  <br>
  '''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453020/ Chapter 9]<br>
  '''essentials_of_glycobiology''' : <br>




===Nonfucosylated biantennary N-Linked structures===
===Trisialylated complex-type oligosaccharide-alditols===
  '''term (main_entry)''' : Nonfucosylated biantennary N-Linked structures <br>
  '''term (main_entry)''' : Trisialylated complex-type oligosaccharide-alditols <br>
  '''glycan_dictionary_accession''' : GSD000134 <br>
  '''glycan_dictionary_accession''' : GSD000177 <br>
  '''glytoucan_accession ''' :  <br>
  '''glytoucan_accession ''' :  <br>
  '''term_in_sentence''' : The beta-subunit from normal pregnancy hCG contained fucosylated and nonfucosylated biantennary N-linked structures; however, mono- and triantennary oligosaccharides were also identified (4.6 and 13.7%).[PMID:[https://pubmed.ncbi.nlm.nih.gov/9449027 9449027]] <br>
  '''term_in_sentence''' : The structures of the two major oligosaccharide-alditols separated by ion-exchange chromatography on a Mono Q column were investigated by means of methylation analysis, glycosidase digestion, and Smith periodate degradation, and they were assigned as typical di- and trisialylated complex-type oligosaccharide-alditols with two and three peripheral chains consisting of Gal-GlcNAc sequences , respectively.[PMID:3571205] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9449027 9449027] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3571205 3571205] <br>
  '''definition''' : A biantennary N-linked glycan with two GlcNAc branches linked to the core and no fucose appears. <br>
  '''definition''' : <br>
  '''term_xref''' :  <br>
  '''term_xref''' :  <br>
  '''synonyms''' :  <br>
  '''synonyms''' :  <br>
Line 202: Line 229:




===Nonfucosylated triantennary===
===Trisialylated diantennary===
  '''term (main_entry)''' : Nonfucosylated triantennary <br>
  '''term (main_entry)''' : Trisialylated diantennary <br>
  '''glycan_dictionary_accession''' : GSD000135 <br>
  '''glycan_dictionary_accession''' : GSD000178 <br>
  '''glytoucan_accession ''' :  <br>
  '''glytoucan_accession ''' :  <br>
  '''term_in_sentence''' : Carbohydrate structures of human alpha-fetoprotein of patients with hepatocellular carcinoma: presence of fucosylated and non-fucosylated triantennary glycans.[PMID:[https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]] <br>
  '''term_in_sentence''' : Determination of glycan primary structures and characterization of a new type of trisialylated diantennary glycan.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1997323 1997323]] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]|[https://pubmed.ncbi.nlm.nih.gov/23274891 23274891] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/1997323 1997323] [https://pubmed.ncbi.nlm.nih.gov/1997323 1997323]] <br>
  '''definition''' : A triantennary N-linked glycan with three GlcNAc branches linked to the core and no fucose appears. <br>
  '''definition''' : A diantennary/biantennary glycans with three sialic acid components. <br>
  '''term_xref''' :  <br>
  '''term_xref''' :  <br>
  '''synonyms''' :  <br>
  '''synonyms''' :  <br>
  '''function''' : Appears in human alpha-fetoprotein (AFP).[PMID:[https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]] <br>
  '''function''' : <br>
  '''disease_associations''' : hepatocellular carcinoma[PMID:[https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]]. <br>
  '''disease_associations''' : <br>
  '''wikipedia''' :  <br>
  '''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' :  <br>
  '''essentials_of_glycobiology''' :  <br>




===Nonsialylated===
===Trisialylated triantennary===
  '''term (main_entry)''' : Nonsialylated <br>
  '''term (main_entry)''' : Trisialylated triantennary <br>
  '''glycan_dictionary_accession''' : GSD000136 <br>
  '''glycan_dictionary_accession''' : GSD000179 <br>
  '''glytoucan_accession ''' :  <br>
  '''glytoucan_accession ''' :  <br>
  '''term_in_sentence''' : The pattern of nonsialylated oligosaccharides was used for interpretation of the fully sialylated species using bioinformatics tools. From pooled human plasma, we find 90, 101, and 64 different glycan compositions for genetic variants ORM1*F1, ORM1*S, and ORM2, respectively. Glycan structures carry dominantly between 15 and 16 sialic acids indicating an almost complete termination of all antenae with sialic acid.[PMID:[https://pubmed.ncbi.nlm.nih.gov/30295034 30295034]] <br>
  '''term_in_sentence''' : The N-glycans are of the complex type with the core-fucosylated disialylated biantennary and trisialylated triantennary structures predominating.[PMID:8942648] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/14533820 14533820]|[https://pubmed.ncbi.nlm.nih.gov/1377689 1377689]|[https://pubmed.ncbi.nlm.nih.gov/9705949 9705949]|[https://pubmed.ncbi.nlm.nih.gov/30788437 30788437]|[https://pubmed.ncbi.nlm.nih.gov/28090561 28090561]|[https://pubmed.ncbi.nlm.nih.gov/12498371 12498371]|[https://pubmed.ncbi.nlm.nih.gov/26839900 26839900]| [https://pubmed.ncbi.nlm.nih.gov/31490688 31490688]|[https://pubmed.ncbi.nlm.nih.gov/2656426 2656426]|[https://pubmed.ncbi.nlm.nih.gov/30295034 30295034]|[https://pubmed.ncbi.nlm.nih.gov/31545048 31545048]|[https://pubmed.ncbi.nlm.nih.gov/12381155 12381155]|[https://pubmed.ncbi.nlm.nih.gov/25730103 25730103]|[https://pubmed.ncbi.nlm.nih.gov/26787879 26787879]|[https://pubmed.ncbi.nlm.nih.gov/25646460 25646460]| [https://pubmed.ncbi.nlm.nih.gov/29224385 29224385]|[https://pubmed.ncbi.nlm.nih.gov/26063435 26063435]|[https://pubmed.ncbi.nlm.nih.gov/26954852 26954852]|[https://pubmed.ncbi.nlm.nih.gov/32889432 32889432]|[https://pubmed.ncbi.nlm.nih.gov/2825412 2825412]|[https://pubmed.ncbi.nlm.nih.gov/27504786 27504786]|[https://pubmed.ncbi.nlm.nih.gov/22431161 22431161] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30194503 30194503]|[https://pubmed.ncbi.nlm.nih.gov/27501865 27501865]|[https://pubmed.ncbi.nlm.nih.gov/10998266 10998266]|[https://pubmed.ncbi.nlm.nih.gov/20578731 20578731]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/17591618 17591618] [https://pubmed.ncbi.nlm.nih.gov/17591618 17591618]]|[https://pubmed.ncbi.nlm.nih.gov/14751029 14751029]|[https://pubmed.ncbi.nlm.nih.gov/18818422 18818422]|[https://pubmed.ncbi.nlm.nih.gov/8942648 8942648]|[https://pubmed.ncbi.nlm.nih.gov/8900952 8900952] <br>
  '''definition''' : A glycan which is not sialylated. <br>
  '''definition''' : A triantennry glycan with three sialic acid components. <br>
  '''term_xref''' :  <br>
  '''term_xref''' :  <br>
  '''synonyms''' :  <br>
  '''synonyms''' :  <br>
  '''function''' :  <br>
  '''function''' :  <br>
  '''disease_associations''' :  <br>
  '''disease_associations''' :  <br>
'''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' :  <br>
  '''essentials_of_glycobiology''' :  <br>




===O-fucose glycans===
===VIM-2===
[[File:G39294YF.png|thumb|G39294YF]]
[[File:G22418PV.png|thumb|G22418PV]]
  '''term (main_entry)''' : O-fucose glycans <br>
  '''term (main_entry)''' : VIM-2 <br>
  '''glycan_dictionary_accession''' : GSD000137 <br>
  '''glycan_dictionary_accession''' : GSD000180 <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G39294YF G39294YF] <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G22418PV G22418PV] <br>
  '''term_in_sentence''' : Recently, a number of laboratories have shown that O-fucose glycans on the epidermal growth factor (EGF)-like repeats of the Notch extracellular domain modulate Notch signaling.[PMID:[https://pubmed.ncbi.nlm.nih.gov/12417415 12417415]] <br>
  '''term_in_sentence''' : Anti-SSEA-1 which binds to glycoconjugates with a Gal beta 1-4(fuc alpha 1-3)GlcNAc epitope and VIM-2 which binds to gangliosides with a NeuAc alpha 2-3GlcNAc beta-4(FUC alpha 1-3) GlcNAc beta 1-3Gal-epitope were used to determine the expression of their corresponding carbohydrate antigens in human leukocytes and leukemia cells.[PMID:1690317] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/19594638 19594638]|[https://pubmed.ncbi.nlm.nih.gov/30690220 30690220]| [https://pubmed.ncbi.nlm.nih.gov/18952191 18952191]|[https://pubmed.ncbi.nlm.nih.gov/22415200 22415200]|[https://pubmed.ncbi.nlm.nih.gov/12417415 12417415]|[https://pubmed.ncbi.nlm.nih.gov/16400812 16400812]|[https://pubmed.ncbi.nlm.nih.gov/18948267 18948267]|[https://pubmed.ncbi.nlm.nih.gov/21464368 21464368]|[https://pubmed.ncbi.nlm.nih.gov/20816394 20816394]|[https://pubmed.ncbi.nlm.nih.gov/30207383 30207383]|[https://pubmed.ncbi.nlm.nih.gov/20301232 20301232]|[https://pubmed.ncbi.nlm.nih.gov/27129198 27129198]|[https://pubmed.ncbi.nlm.nih.gov/17132502 17132502]|[https://pubmed.ncbi.nlm.nih.gov/22492969 22492969]|[https://pubmed.ncbi.nlm.nih.gov/30030822 30030822]|[https://pubmed.ncbi.nlm.nih.gov/30214079 30214079]|[https://pubmed.ncbi.nlm.nih.gov/26175457 26175457]|[https://pubmed.ncbi.nlm.nih.gov/25378397 25378397]|[https://pubmed.ncbi.nlm.nih.gov/18272537 18272537]|[https://pubmed.ncbi.nlm.nih.gov/28729422 28729422]|[https://pubmed.ncbi.nlm.nih.gov/11524432 11524432]|[https://pubmed.ncbi.nlm.nih.gov/31722217 31722217]|[https://pubmed.ncbi.nlm.nih.gov/23045360 23045360]|[https://pubmed.ncbi.nlm.nih.gov/24803430 24803430]|[https://pubmed.ncbi.nlm.nih.gov/28876865 28876865]|[https://pubmed.ncbi.nlm.nih.gov/25700513 25700513]|[https://pubmed.ncbi.nlm.nih.gov/32518939 32518939]|[https://pubmed.ncbi.nlm.nih.gov/30523691 30523691]|[https://pubmed.ncbi.nlm.nih.gov/18227520 18227520]|[https://pubmed.ncbi.nlm.nih.gov/20816217 20816217]|[https://pubmed.ncbi.nlm.nih.gov/24909690 24909690]|[https://pubmed.ncbi.nlm.nih.gov/17964136 17964136]|[https://pubmed.ncbi.nlm.nih.gov/12036964 12036964]|[https://pubmed.ncbi.nlm.nih.gov/27268051 27268051]|[https://pubmed.ncbi.nlm.nih.gov/15653671 15653671]|[https://pubmed.ncbi.nlm.nih.gov/19948734 19948734]|[https://pubmed.ncbi.nlm.nih.gov/31590629 31590629]|[https://pubmed.ncbi.nlm.nih.gov/32201074 32201074]|[https://pubmed.ncbi.nlm.nih.gov/15189151 15189151]|[https://pubmed.ncbi.nlm.nih.gov/17263732 17263732]|[https://pubmed.ncbi.nlm.nih.gov/32913123 32913123]|[https://pubmed.ncbi.nlm.nih.gov/12909620 12909620]|[https://pubmed.ncbi.nlm.nih.gov/28785176 28785176]|[https://pubmed.ncbi.nlm.nih.gov/17132500 17132500]|[https://pubmed.ncbi.nlm.nih.gov/22949680 22949680]|[https://pubmed.ncbi.nlm.nih.gov/25053492 25053492]|[https://pubmed.ncbi.nlm.nih.gov/28939751 28939751] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27834790 27834790]|[https://pubmed.ncbi.nlm.nih.gov/31523406 31523406]|[https://pubmed.ncbi.nlm.nih.gov/29978304 29978304]|[https://pubmed.ncbi.nlm.nih.gov/29575185 29575185]|[https://pubmed.ncbi.nlm.nih.gov/27326514 27326514]|[https://pubmed.ncbi.nlm.nih.gov/29029114 29029114]|[https://pubmed.ncbi.nlm.nih.gov/32450200 32450200]|[https://pubmed.ncbi.nlm.nih.gov/29432937 29432937]|[https://pubmed.ncbi.nlm.nih.gov/31906402 31906402]|[https://pubmed.ncbi.nlm.nih.gov/28739428 28739428]|[https://pubmed.ncbi.nlm.nih.gov/29298123 29298123]|[https://pubmed.ncbi.nlm.nih.gov/30976429 30976429]|[https://pubmed.ncbi.nlm.nih.gov/29091730 29091730]|[https://pubmed.ncbi.nlm.nih.gov/27770796 27770796]|[https://pubmed.ncbi.nlm.nih.gov/31330771 31330771]|[https://pubmed.ncbi.nlm.nih.gov/31138570 31138570]|[https://pubmed.ncbi.nlm.nih.gov/27154587 27154587]|[https://pubmed.ncbi.nlm.nih.gov/31542553 31542553]|[https://pubmed.ncbi.nlm.nih.gov/30519059 30519059]|[https://pubmed.ncbi.nlm.nih.gov/30590504 30590504]|[https://pubmed.ncbi.nlm.nih.gov/25880997 25880997]|[https://pubmed.ncbi.nlm.nih.gov/27490501 27490501]|[https://pubmed.ncbi.nlm.nih.gov/29981456 29981456]|[https://pubmed.ncbi.nlm.nih.gov/28559273 28559273]|[https://pubmed.ncbi.nlm.nih.gov/28193652 28193652]|[https://pubmed.ncbi.nlm.nih.gov/26638216 26638216]|[https://pubmed.ncbi.nlm.nih.gov/25897818 25897818]|[https://pubmed.ncbi.nlm.nih.gov/26238337 26238337]|[https://pubmed.ncbi.nlm.nih.gov/19553129 19553129]|[https://pubmed.ncbi.nlm.nih.gov/29644540 29644540]|[https://pubmed.ncbi.nlm.nih.gov/26242685 26242685]|[https://pubmed.ncbi.nlm.nih.gov/28487556 28487556]|[https://pubmed.ncbi.nlm.nih.gov/32622213 32622213]|[https://pubmed.ncbi.nlm.nih.gov/30248413 30248413]|[https://pubmed.ncbi.nlm.nih.gov/24762211 24762211]|[https://pubmed.ncbi.nlm.nih.gov/11451678 11451678]|[https://pubmed.ncbi.nlm.nih.gov/33169865 33169865]|[https://pubmed.ncbi.nlm.nih.gov/11897589 11897589]|[https://pubmed.ncbi.nlm.nih.gov/31479607 31479607] <br>
  '''definition''' : Form of glycosylation where the protein is modified by a fucose residue and can be extended futher to form a tetrasaccharide in certain cases. alpha-linked o-fucose have a consensus motif of C2X4(s/T)C3 where C2 and C3 are conserved cysteines number 2 and 3 respectively of the EGFR like repeats. [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453017/ Chapter13]] <br>
  '''definition''' : α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-β-D-GlcpNAc-(1→3)-β-D-Galp-(1→4)-[α-L-Fucp-(1→3)]-D-GlcpNAc in which the anomeric configuration of the N-acetyl-D-glucosamine residue at the reducing end is β.[CHEBI:85946] <br>
  '''term_xref''' : GTC:G39294YF|GlycoEpitope:EP0005<br>
  '''term_xref''' : GTC:G22418PV |GlycoEpitope:EP0019|CID:[https://pubmed.ncbi.nlm.nih.gov/91825708 91825708]|CHEBI:85946|GlycoMotif:GGM.000033  <br>
  '''synonyms''' :  <br>
  '''synonyms''' :  <br>
  '''function''' : modification of Notch signaling.[GlycoEpitope:EP0005] <br>
  '''function''' : CDw65 have been shown to interact with the ELAM-1 molecule on activated endothelium.[GlycoEpitope:EP0019] <br>
  '''disease_associations''' : <br>
  '''disease_associations''' : chronic myelogenous leukemia.[GlycoEpitope:EP0019] <br>
  '''wikipedia''' :  <br>
  '''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' :  <br>
  '''essentials_of_glycobiology''' :  <br>




===O-GlcNAc===
==Terms (by Glycan Dictionary Accessions)==
[[File:G49108TO.png|thumb|G49108TO]]
===GSD000001===
  '''term (main_entry)''' : O-GlcNAc <br>
  '''term (main_entry)''' : 2,6-Branched O-mannose <br>
  '''glycan_dictionary_accession''' : GSD000138 <br>
  '''glycan_dictionary_accession''' : GSD000001 <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G49108TO G49108TO] <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G06953DR G06953DR] <br>
  '''term_in_sentence''' : A better understanding of the mechanisms of OGT/OGA action would enable us to derive therapeutic benefits of resetting cellular O-GlcNAc levels within an optimal range.[PMID:[https://pubmed.ncbi.nlm.nih.gov/30464755 30464755]] <br>
  '''term_in_sentence''' : Collectively, these results strongly suggest that GnT-IX may be a novel beta1,6-N-acetylglucosaminyltransferase that is responsible for the formation of the 2,6-branched structure in the brain O-mannosyl glycan.[PMID:[https://pubmed.ncbi.nlm.nih.gov/14617637 14617637]] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30464755 30464755]|[https://pubmed.ncbi.nlm.nih.gov/29049853 29049853]|[https://pubmed.ncbi.nlm.nih.gov/29594839 29594839]|[https://pubmed.ncbi.nlm.nih.gov/31654859 31654859]|[https://pubmed.ncbi.nlm.nih.gov/29404877 29404877]|[https://pubmed.ncbi.nlm.nih.gov/30105004 30105004]|[https://pubmed.ncbi.nlm.nih.gov/30669087 30669087]|[https://pubmed.ncbi.nlm.nih.gov/29790000 29790000]|[https://pubmed.ncbi.nlm.nih.gov/28408483 28408483]|[https://pubmed.ncbi.nlm.nih.gov/26862193 26862193]|[https://pubmed.ncbi.nlm.nih.gov/30523150 30523150]|[https://pubmed.ncbi.nlm.nih.gov/30037904 30037904]|[https://pubmed.ncbi.nlm.nih.gov/28408480 28408480]|[https://pubmed.ncbi.nlm.nih.gov/29352075 29352075]|[https://pubmed.ncbi.nlm.nih.gov/29456783 29456783]|[https://pubmed.ncbi.nlm.nih.gov/29577901 29577901]|[https://pubmed.ncbi.nlm.nih.gov/29223644 29223644]|[https://pubmed.ncbi.nlm.nih.gov/28638491 28638491]|[https://pubmed.ncbi.nlm.nih.gov/30221662 30221662]|[https://pubmed.ncbi.nlm.nih.gov/29904918 29904918]|[https://pubmed.ncbi.nlm.nih.gov/32155042 32155042]|[https://pubmed.ncbi.nlm.nih.gov/30298013 30298013]|[https://pubmed.ncbi.nlm.nih.gov/31630803 31630803]|[https://pubmed.ncbi.nlm.nih.gov/31847126 31847126]|[https://pubmed.ncbi.nlm.nih.gov/29784830 29784830]|[https://pubmed.ncbi.nlm.nih.gov/30181664 30181664]|[https://pubmed.ncbi.nlm.nih.gov/28768194 28768194]|[https://pubmed.ncbi.nlm.nih.gov/30134155 30134155]|[https://pubmed.ncbi.nlm.nih.gov/25336654 25336654]|[https://pubmed.ncbi.nlm.nih.gov/30356792 30356792]|[https://pubmed.ncbi.nlm.nih.gov/30199580 30199580]|[https://pubmed.ncbi.nlm.nih.gov/32329777 32329777]|[https://pubmed.ncbi.nlm.nih.gov/28408494 28408494]|[https://pubmed.ncbi.nlm.nih.gov/29774032 29774032]|[https://pubmed.ncbi.nlm.nih.gov/29044951 29044951]|[https://pubmed.ncbi.nlm.nih.gov/23836420 23836420]|[https://pubmed.ncbi.nlm.nih.gov/20301273 20301273]|[https://pubmed.ncbi.nlm.nih.gov/29772801 29772801]|[https://pubmed.ncbi.nlm.nih.gov/28922739 28922739]|[https://pubmed.ncbi.nlm.nih.gov/30100348 30100348]|[https://pubmed.ncbi.nlm.nih.gov/30793403 30793403]|[https://pubmed.ncbi.nlm.nih.gov/30657688 30657688]|[https://pubmed.ncbi.nlm.nih.gov/31237748 31237748]|[https://pubmed.ncbi.nlm.nih.gov/29756380 29756380]|[https://pubmed.ncbi.nlm.nih.gov/29954943 29954943]|[https://pubmed.ncbi.nlm.nih.gov/30018219 30018219]|[https://pubmed.ncbi.nlm.nih.gov/32207184 32207184]|[https://pubmed.ncbi.nlm.nih.gov/25566193 25566193]|[https://pubmed.ncbi.nlm.nih.gov/30626734 30626734]|[https://pubmed.ncbi.nlm.nih.gov/24759912 24759912]| <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/14617637 14617637]|[https://pubmed.ncbi.nlm.nih.gov/10469154 10469154] <br>
'''definition''' : Form of glycosylation which exclusively occurs in the mitochondrial, cytoplasmic or nuclear compartments of the cell where the protein is modified by a GlcNAc monosaccharide on the serine or threonine residues and is generally not modified or elongated further to form more complex structures. [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453063/ Chapter19]] <br>
'''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-5-acetamido-6-[[(2R,3S,4S,5S,6S)-5-[(2S,3R,4R,5S,6R)-3-acetamido-5-[(2S,3R,4S,5S,6R)-4-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4,6-trihydroxyoxan-2-yl]methoxy]-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.[CHEBI:157265] <br>
  '''term_xref''' : GTC:G49108TO|GlycoEpitope:EP0004|CID:24139|HMDB:HMDB0000803 <br>
  '''term_xref''' : CHEBI:157265|GlycoMotif:GGM.000056|GTC:G06953DR <br>
  '''synonyms''' : <br>
  '''synonyms''' : 5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)-beta-D-galacto-hexopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1→2)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)-beta-D-galacto-hexopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1→6)]-alpha-D-manno-hexopyranose|NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-2)[NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-6)]a-Man <br>
  '''function''' :  <br>
  '''function''' :  <br>
  '''disease_associations''' :  <br>
  '''disease_associations''' :  <br>
Line 264: Line 290:




===O-linked glycans===
===GSD000002===
  '''term (main_entry)''' : O-linked glycans <br>
  '''term (main_entry)''' : 2,6-sialyl-Sulfo-LN <br>
  '''glycan_dictionary_accession''' : GSD000139 <br>
  '''glycan_dictionary_accession''' : GSD000002 <br>
  '''glytoucan_accession ''' : <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G41145LF G41145LF] <br>
  '''term_in_sentence''' : Among these, six fucosylated N-linked glycansand four O-linked glycans exhibited significantly increased expression levels in GC, while five fucosylated N-linked glycans and ten fucosylated O-linked glycans exhibited significantly decreased expression levels in GC.[PMID:[https://pubmed.ncbi.nlm.nih.gov/29865036 29865036]] <br>
  '''term_in_sentence''' : The alpha2-6-sialylated 6-sulfo-LacNAc determinant defined by the antibody was significantly expressed on a majority of normal human peripheral B-lymphocytes as well as follicular B-lymphocytes in peripheral lymph nodes.[PMID:[https://pubmed.ncbi.nlm.nih.gov/17728258 17728258]] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29865036 29865036]|[https://pubmed.ncbi.nlm.nih.gov/30952424 30952424]|[https://pubmed.ncbi.nlm.nih.gov/31611643 31611643]|[https://pubmed.ncbi.nlm.nih.gov/19577919 19577919]|[https://pubmed.ncbi.nlm.nih.gov/32019882 32019882]|[https://pubmed.ncbi.nlm.nih.gov/19139197 19139197]|[https://pubmed.ncbi.nlm.nih.gov/26184710 26184710]|[https://pubmed.ncbi.nlm.nih.gov/11159917 11159917]|[https://pubmed.ncbi.nlm.nih.gov/21536259 21536259]|[https://pubmed.ncbi.nlm.nih.gov/25186198 25186198]|[https://pubmed.ncbi.nlm.nih.gov/19277556 19277556]|[https://pubmed.ncbi.nlm.nih.gov/22261557 22261557]|[https://pubmed.ncbi.nlm.nih.gov/24115046 24115046]|[https://pubmed.ncbi.nlm.nih.gov/18725413 18725413]|[https://pubmed.ncbi.nlm.nih.gov/15966855 15966855]|[https://pubmed.ncbi.nlm.nih.gov/24256304 24256304]|[https://pubmed.ncbi.nlm.nih.gov/25477510 25477510]|[https://pubmed.ncbi.nlm.nih.gov/10359703 10359703]|[https://pubmed.ncbi.nlm.nih.gov/24406064 24406064]|[https://pubmed.ncbi.nlm.nih.gov/22259135 22259135]|[https://pubmed.ncbi.nlm.nih.gov/29279989 29279989]| [https://pubmed.ncbi.nlm.nih.gov/15966855 15966855]|[https://pubmed.ncbi.nlm.nih.gov/30619255 30619255]|[https://pubmed.ncbi.nlm.nih.gov/9673446 9673446]| [https://pubmed.ncbi.nlm.nih.gov/31676555 31676555]|[https://pubmed.ncbi.nlm.nih.gov/28745859 28745859]|[https://pubmed.ncbi.nlm.nih.gov/28196325 28196325]|[https://pubmed.ncbi.nlm.nih.gov/27975143 27975143]|[https://pubmed.ncbi.nlm.nih.gov/30591584 30591584]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/28518173 28518173] [https://pubmed.ncbi.nlm.nih.gov/28518173 28518173]]|[https://pubmed.ncbi.nlm.nih.gov/17522109 17522109]| [https://pubmed.ncbi.nlm.nih.gov/26328495 26328495]|[https://pubmed.ncbi.nlm.nih.gov/32178593 32178593]|[https://pubmed.ncbi.nlm.nih.gov/27529638 27529638]|[https://pubmed.ncbi.nlm.nih.gov/24663386 24663386]|[https://pubmed.ncbi.nlm.nih.gov/22474328 22474328]|[https://pubmed.ncbi.nlm.nih.gov/28096352 28096352]|[https://pubmed.ncbi.nlm.nih.gov/27496768 27496768]| [https://pubmed.ncbi.nlm.nih.gov/18952191 18952191]|[https://pubmed.ncbi.nlm.nih.gov/11135308 11135308]|[https://pubmed.ncbi.nlm.nih.gov/24917611 24917611]|[https://pubmed.ncbi.nlm.nih.gov/11532966 11532966]|[https://pubmed.ncbi.nlm.nih.gov/22786570 22786570]|[https://pubmed.ncbi.nlm.nih.gov/11891229 11891229]|[https://pubmed.ncbi.nlm.nih.gov/18332077 18332077]|[https://pubmed.ncbi.nlm.nih.gov/26867212 26867212]|[https://pubmed.ncbi.nlm.nih.gov/26925665 26925665]|[https://pubmed.ncbi.nlm.nih.gov/16769205 16769205]|[https://pubmed.ncbi.nlm.nih.gov/23475718 23475718]|[https://pubmed.ncbi.nlm.nih.gov/16005634 16005634]|[https://pubmed.ncbi.nlm.nih.gov/28785176 28785176] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/17728258 17728258] <br>
  '''definition''' : The carbohydrate portion of a glycoprotein that has a glycan linked through the hydroxyl oxygen of serine, threonine, hydroxylysine or hydroxyproline side-chains.[CHEBI:59521] <br>
  '''definition''' : <br>
  '''term_xref''' : CHEBI:59521 <br>
  '''term_xref''' : GlycoMotif:GGM.000026|GTC:G41145LF <br>
  '''synonyms''' : <br>
  '''synonyms''' : 6-sialyl-6-sulfo LN <br>
  '''function''' : Affects several important activities like protein stability, modulation of signaling molecules and enzyme activity.[PMID:[https://pubmed.ncbi.nlm.nih.gov/9673446 9673446]] <br>
  '''function''' : B-cell interaction with blood vessels and trafficking[PMID: [https://pubmed.ncbi.nlm.nih.gov/17728258 17728258]] <br>
  '''disease_associations''' : <br>
  '''disease_associations''' : <br>
  '''wikipedia''' :  <br>
  '''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' :  <br>
  '''essentials_of_glycobiology''' :  <br>




===O-linked mannose===
===GSD000003===
[[File:G59126YU.png|thumb|G59126YU]]
  '''term (main_entry)''' : 2-Fucosyl-GD1b <br>
  '''term (main_entry)''' : O-linked mannose <br>
  '''glycan_dictionary_accession''' : GSD000003 <br>
  '''glycan_dictionary_accession''' : GSD000140 <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G67383AR G67383AR] <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G59126YU G59126YU] <br>
  '''term_in_sentence''' : They were fucosyl-Gv., fucoSyl-GDlb, and two uni que fucogangliosides having GMl or GOlb bas ic structure containing a substituent with the blood group B determinant. [PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/3654655 3654655] [https://pubmed.ncbi.nlm.nih.gov/3654655 3654655]]] <br>
  '''term_in_sentence''' : Protein O-linked mannose beta-1,4-N-acetylglucosaminyltransferase 2 (POMGNT2) catalyzes the first step toward the functional matriglycan structure on alpha-dystroglycan that is responsible for binding extracellular matrix proteins and certain arenaviruses.[PMID: [https://pubmed.ncbi.nlm.nih.gov/27932460 27932460]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/3654655 3654655] [https://pubmed.ncbi.nlm.nih.gov/3654655 3654655]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27932460 27932460]|[https://pubmed.ncbi.nlm.nih.gov/24526361 24526361]|[https://pubmed.ncbi.nlm.nih.gov/25381909 25381909]|[https://pubmed.ncbi.nlm.nih.gov/26644575 26644575]|[https://pubmed.ncbi.nlm.nih.gov/23851827 23851827]|[https://pubmed.ncbi.nlm.nih.gov/28810660 28810660]|[https://pubmed.ncbi.nlm.nih.gov/19054127 19054127]|[https://pubmed.ncbi.nlm.nih.gov/23929950 23929950]|[https://pubmed.ncbi.nlm.nih.gov/21684258 21684258]|[https://pubmed.ncbi.nlm.nih.gov/22608994 22608994]|[https://pubmed.ncbi.nlm.nih.gov/28973932 28973932]|[https://pubmed.ncbi.nlm.nih.gov/24733390 24733390]|[https://pubmed.ncbi.nlm.nih.gov/31851597 31851597]|[https://pubmed.ncbi.nlm.nih.gov/29884773 29884773]|[https://pubmed.ncbi.nlm.nih.gov/28711406 28711406]|[https://pubmed.ncbi.nlm.nih.gov/14577328 14577328]|[https://pubmed.ncbi.nlm.nih.gov/21089343 21089343]|[https://pubmed.ncbi.nlm.nih.gov/14617637 14617637]|[https://pubmed.ncbi.nlm.nih.gov/9838223 9838223]|[https://pubmed.ncbi.nlm.nih.gov/17072003 17072003]| [https://pubmed.ncbi.nlm.nih.gov/26328495 26328495]|[https://pubmed.ncbi.nlm.nih.gov/11181560 11181560]|[https://pubmed.ncbi.nlm.nih.gov/31949166 31949166]|[https://pubmed.ncbi.nlm.nih.gov/31988979 31988979]|[https://pubmed.ncbi.nlm.nih.gov/20362685 20362685]|[https://pubmed.ncbi.nlm.nih.gov/27733679 27733679]|[https://pubmed.ncbi.nlm.nih.gov/27493216 27493216]|[https://pubmed.ncbi.nlm.nih.gov/20044576 20044576]|[https://pubmed.ncbi.nlm.nih.gov/30643095 30643095]|[https://pubmed.ncbi.nlm.nih.gov/29732660 29732660]|[https://pubmed.ncbi.nlm.nih.gov/10580142 10580142]|[https://pubmed.ncbi.nlm.nih.gov/14568618 14568618]|[https://pubmed.ncbi.nlm.nih.gov/28079948 28079948]|[https://pubmed.ncbi.nlm.nih.gov/15467391 15467391]|[https://pubmed.ncbi.nlm.nih.gov/27812179 27812179]|[https://pubmed.ncbi.nlm.nih.gov/23761899 23761899]|[https://pubmed.ncbi.nlm.nih.gov/25737452 25737452]|[https://pubmed.ncbi.nlm.nih.gov/32930586 32930586]|[https://pubmed.ncbi.nlm.nih.gov/25381372 25381372]|[https://pubmed.ncbi.nlm.nih.gov/23434682 23434682]|[https://pubmed.ncbi.nlm.nih.gov/16857188 16857188]|[https://pubmed.ncbi.nlm.nih.gov/21452199 21452199]|[https://pubmed.ncbi.nlm.nih.gov/19429925 19429925]|[https://pubmed.ncbi.nlm.nih.gov/25361541 25361541]|[https://pubmed.ncbi.nlm.nih.gov/24297939 24297939]|[https://pubmed.ncbi.nlm.nih.gov/30322079 30322079]|[https://pubmed.ncbi.nlm.nih.gov/23428289 23428289]|[https://pubmed.ncbi.nlm.nih.gov/28427937 28427937]|[https://pubmed.ncbi.nlm.nih.gov/22746206 22746206]|[https://pubmed.ncbi.nlm.nih.gov/27533452 27533452]|[https://pubmed.ncbi.nlm.nih.gov/17502374 17502374]|[https://pubmed.ncbi.nlm.nih.gov/20816174 20816174]|[https://pubmed.ncbi.nlm.nih.gov/27496765 27496765] <br>
  '''definition''' : (2S,4S,5R,6R)-5-Acetamido-6-[(1S,2R)-2-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-1,3-dihydroxypropyl]-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxyoxane-2-carboxylic acid.[CHEBI:156680] <br>
  '''definition''' : O-linked glycans that are initiated by the addtion of a Man residue to Ser or Thr. Subsequent extension of the Man defines the O-Man core type, either M1, M2, or M3. The M1 type is initated by addition of a GlcNAc in β-linkage to the 2 position of the Man residue. M2 is initiated by addition of another GlcNAc to the 6 position of the M1 core. M3 is initiated by the addition of a GlcNAc in β-linkage to the 4 position of the Man residue. M1 and M2 type core glycans can be extended and branched with Gal, Fuc, Sialic Acid, and GlcA. The M3 core is uniquely extended by a multienzyme system to generate the matriglycan polysaccharide, a protein-specific modification found only on alpha-dystroglycan. [CHEBI:87761] <br>
  '''term_xref''' : CHEBI:156680|GlycoMotif:GGM.000103|GTC:G67383AR<br>
  '''term_xref''' : GlycoMotif:GGM.000055|GTC:G59126YU|CHEBI:87761|GlycoEpitope:EP0002|CID: 91859038<br>
  '''synonyms''' : 6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)-beta-D-galacto-hexopyranosyl-(1→3)-2-acetamido-2-deoxy-beta-D-galacto-hexopyranosyl-(1→4)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→8)-5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)]-beta-D-galacto-hexopyranosyl-(1→4)-D-gluco-hexopyranose|Fuc(a1-2)Gal(b1-3)GalNAc(b1-4)[NeuAc(a2-8)NeuAc(a2-3)]Gal(b1-4)Glc <br>
  '''synonyms''' : O-mannosyl glycan <br>
  '''function''' :  <br>
  '''function''' :  <br>
  '''disease_associations''' : MEB/muscle-eye-brain disease[GlycoEpitope:EP0002]|WWS/walker-warburg syndrome |muscular dystrophy[GlycoEpitope:EP0002]|neuronal migration disorder[GlycoEpitope:EP0002]|Muscle-Eye-Brain disease (MEB) and Walker-Warburg Syndrome (WWS) have mutations in genes encoding glycosyltransferases needed for O -mannosyl oligosaccharide synthesis[GlycoEpitope:EP0002]|Muscular dystrophy and neuronal migration disorder are caused by mutations in a glycosyltransferase, POMGnT1.[GlycoEpitope:EP0002] <br>
  '''disease_associations''' : <br>
  '''wikipedia''' :  <br>
  '''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' :  <br>
  '''essentials_of_glycobiology''' :  <br>




===P1 antigen===
===GSD000004===
[[File:G12460DL.png|thumb|G12460DL]]
  '''term (main_entry)''' : 2-Fucosyl-GM1 <br>
  '''term (main_entry)''' : P1 antigen <br>
  '''glycan_dictionary_accession''' : GSD000004 <br>
  '''glycan_dictionary_accession''' : GSD000141 <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G56526JU G56526JU] <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G12460DL G12460DL] <br>
  '''term_in_sentence''' : These glycolipid products were identified as asialo-Gs.., GM h and fucosyl-Gq, by comparison with authentic glycolipid samples.[PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/3654655 3654655] [https://pubmed.ncbi.nlm.nih.gov/3654655 3654655]]] <br>
  '''term_in_sentence''' : The P1 antigen was disovered in 1927 by Landsteiner and Levine, and Pk and NOR were described in 1951 and 1982, respectively.[PMID: [https://pubmed.ncbi.nlm.nih.gov/24046920 24046920]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/3654655 3654655] [https://pubmed.ncbi.nlm.nih.gov/3654655 3654655]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29622537 29622537]|[https://pubmed.ncbi.nlm.nih.gov/26773500 26773500]|[https://pubmed.ncbi.nlm.nih.gov/24046920 24046920]|[https://pubmed.ncbi.nlm.nih.gov/6207232 6207232]|[https://pubmed.ncbi.nlm.nih.gov/8550516 8550516]|[https://pubmed.ncbi.nlm.nih.gov/6609976 6609976]|[https://pubmed.ncbi.nlm.nih.gov/6375319 6375319]|817855|[https://pubmed.ncbi.nlm.nih.gov/2428855 2428855]|[https://pubmed.ncbi.nlm.nih.gov/3312011 3312011]|[https://pubmed.ncbi.nlm.nih.gov/15364312 15364312]|[https://pubmed.ncbi.nlm.nih.gov/1937801 1937801]|[https://pubmed.ncbi.nlm.nih.gov/7729906 7729906] <br>
  '''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.[CHEBI:151476] <br>
  '''definition''' : An amino pentasaccharide consisting of α-D-galactose, β-D-galactose N-acetyl-α-D-glucosamine, β-D-galactose, and β-D-glucose residues joined in sequence with ((1→4)-, (1→4)-, (1→3)- and (1→4)-linkages, respectively.[CHEBI:68484] <br>
  '''term_xref''' : KEGG:G12241|CHEBI:151476|CID:[https://pubmed.ncbi.nlm.nih.gov/91849786 91849786]|GlycoMotif:GGM.000101|GTC:G56526JU <br>
  '''term_xref''' : GlycoMotif:GGM.000069|GTC:G12460DL|CID:71296137|CHEBI:68484|SugarBind_Ligand:160 <br>
  '''synonyms''' : Fuc(a1-2)Gal(b1-3)GalNAc(b1-4)[NeuAc(a2-3)]Gal(b1-4)Glc|6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)-beta-D-galacto-hexopyranosyl-(1→3)-2-acetamido-2-deoxy-beta-D-galacto-hexopyranosyl-(1→4)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)]-beta-D-galacto-hexopyranosyl-(1→4)-D-gluco-hexopyranose <br>
  '''synonyms''' : <br>
  '''function''' :  <br>
  '''function''' :  <br>
  '''disease_associations''' : Shigellosis[SugarBind_Ligand:160] <br>
  '''disease_associations''' : <br>
  '''wikipedia''' :  <br>
  '''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453054/ Chapter 23]<br>
  '''essentials_of_glycobiology''' : <br>




===Para-Forssman glycolipid===
===GSD000005===
[[File:G51699SI.png|thumb|G51699SI]]
  '''term (main_entry)''' : 3-Sialyl-LN (type 2) <br>
  '''term (main_entry)''' : Para-Forssman glycolipid <br>
  '''glycan_dictionary_accession''' : GSD000005 <br>
  '''glycan_dictionary_accession''' : GSD000142 <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G10203DW G10203DW] <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G51699SI G51699SI] <br>
  '''term_in_sentence''' : Using new crystal structures, we also provide the atomic resolution basis for the differential recognition of 3′ and 6′SiaLacNAc1–4 (with the Galβ1–4 linkage known as Type 2 backbone16; Scheme 1) by TgMIC1-MARR, and make comparisons with the Type 1 chain isomer of 3′SiaLacNAc1–4 (designated 3′SiaLacNAc1–3).[PMID:[https://pubmed.ncbi.nlm.nih.gov/19593815 19593815]] <br>
  '''term_in_sentence''' : A novel pentaglycosyl ceramide containing di-beta-N-acetylgalactos-aminyl residue (Para-Forssman glycolipid) isolated from human erythrocyte membrane. [PMID:[https://pubmed.ncbi.nlm.nih.gov/6814203 6814203]] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/19593815 19593815]|[https://pubmed.ncbi.nlm.nih.gov/15659615 15659615]|[https://pubmed.ncbi.nlm.nih.gov/2414279 2414279]|[https://pubmed.ncbi.nlm.nih.gov/8586620 8586620]|[https://pubmed.ncbi.nlm.nih.gov/2111348 2111348]|[https://pubmed.ncbi.nlm.nih.gov/23747419 23747419] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/6814203 6814203] <br>
  '''definition''' : A linear amino trisaccharide consisting of α-neuraminyl, β-D-galactosyl and N-acetyl-D-glucosamine residues linked in a (2→3) and (1→4) sequence.[CHEBI:52472] <br>
  '''definition''' : GalNAcβ1→3GalNAcβ1→3Galα1→4Galβ1→4Glcβ1→1Cer [https://doi.org/10.1016/S0040-4039(01)93814-6<nowiki>] </nowiki><br>
  '''term_xref''' : GTC:G10203DW|KEGG:G00253|SugarBind_Ligand:109|GlycoEpitope:EP0314|CHEBI:52472|GlycoMotif:GGM.000034 <br>
  '''term_xref''' : GlycoMotif:GGM.000085|GTC:G51699SI|CID:56836111|KEGG:G00096|SugarBind_Ligand:19|CHEBI:151565 <br>
  '''synonyms''' : <br>
  '''synonyms''' : <br>
  '''function''' :  <br>
  '''function''' :  <br>
  '''disease_associations''' : Actinomycosis[SugarBind_Ligand:19] <br>
  '''disease_associations''' : Chronic gastritis[SugarBind_Ligand:109]|Toxoplasmosis[SugarBind_Ligand:109]|Peptic ulcers[SugarBind_Ligand:109]|Gastric cancer[SugarBind_Ligand:109] <br>
  '''wikipedia''' : https://en.wikipedia.org/wiki/P1PK_blood_group_system <br>
  '''wikipedia''' : <br>
  '''essentials_of_glycobiology''' :  <br>
  '''essentials_of_glycobiology''' :  <br>




===Paragloboside===
===GSD000006===
[[File:G58896AZ.png|thumb|G58896AZ]]
  '''term (main_entry)''' : 3'-Sulfo-Lewis a <br>
  '''term (main_entry)''' : Paragloboside <br>
  '''glycan_dictionary_accession''' : GSD000006 <br>
  '''glycan_dictionary_accession''' : GSD000143 <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G78706CK G78706CK] <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G58896AZ G58896AZ] <br>
  '''term_in_sentence''' : A remodeling system of the 3'-sulfo-Lewis a and 3'-sulfo-Lewis x epitopes.[PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/11504739 11504739] [https://pubmed.ncbi.nlm.nih.gov/11504739 11504739]]] <br>
  '''term_in_sentence''' : Galactosyltransferase activities in sera of cancer patients were determined by assaying the formation of paragloboside from UDP-galactose and lactotriaosylceramide immobilized on microtiter plates by means of the enzyme-linked immunosorbent assay using a monoclonal antibody, H-11, directed to paragloboside. [PMID: [https://pubmed.ncbi.nlm.nih.gov/1551117 1551117]] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/11504739 11504739] [https://pubmed.ncbi.nlm.nih.gov/11504739 11504739]]|[https://pubmed.ncbi.nlm.nih.gov/17499486 17499486]|[https://pubmed.ncbi.nlm.nih.gov/17691854 17691854]|[https://pubmed.ncbi.nlm.nih.gov/12944557 12944557]|[https://pubmed.ncbi.nlm.nih.gov/19394320 19394320]|[https://pubmed.ncbi.nlm.nih.gov/7534477 7534477]|[https://pubmed.ncbi.nlm.nih.gov/11604107 11604107]|[https://pubmed.ncbi.nlm.nih.gov/28025252 28025252]|[https://pubmed.ncbi.nlm.nih.gov/9061363 9061363]|[https://pubmed.ncbi.nlm.nih.gov/9878545 9878545]|[https://pubmed.ncbi.nlm.nih.gov/11918697 11918697]|[https://pubmed.ncbi.nlm.nih.gov/24239607 24239607]|[https://pubmed.ncbi.nlm.nih.gov/28628803 28628803]|[https://pubmed.ncbi.nlm.nih.gov/25339106 25339106]|[https://pubmed.ncbi.nlm.nih.gov/21400496 21400496]|[https://pubmed.ncbi.nlm.nih.gov/17998215 17998215]|[https://pubmed.ncbi.nlm.nih.gov/12626387 12626387]|[https://pubmed.ncbi.nlm.nih.gov/11425799 11425799]|[https://pubmed.ncbi.nlm.nih.gov/12219077 12219077]|[https://pubmed.ncbi.nlm.nih.gov/10955596 10955596]|[https://pubmed.ncbi.nlm.nih.gov/9453593 9453593] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3345524 3345524]|850070|[https://pubmed.ncbi.nlm.nih.gov/10569746 10569746]|[https://pubmed.ncbi.nlm.nih.gov/30624951 30624951]|[https://pubmed.ncbi.nlm.nih.gov/29438961 29438961]|[https://pubmed.ncbi.nlm.nih.gov/6816790 6816790]|[https://pubmed.ncbi.nlm.nih.gov/1551117 1551117]|[https://pubmed.ncbi.nlm.nih.gov/6865961 6865961]|[https://pubmed.ncbi.nlm.nih.gov/25039255 25039255] <br>
  '''definition''' : A branched amino trisaccharide consisting of N-acetylglucosamine having a fucosyl residue attached at the 4-position via an α-linkage and a 3-sulfated galactosyl residue attached at the 3-position via a β-linkage.[CHEBI:65149] <br>
  '''definition''' : α-Neup5Ac-(2→3)-β-D-Galp-(1→3)-D-GalpNAc in which the configuration at the GalNAc anomeric carbon is α.[CHEBI:65257] <br>
  '''term_xref''' : GTC:G78706CK|GlycoEpitope:EP0009|CID:[https://pubmed.ncbi.nlm.nih.gov/5289352 5289352]|GlycoMotif:GGM.000030 <br>
  '''term_xref''' : GlycoMotif:GGM.000077|GTC:G58896AZ|CID: 21670519|CHEBI:65257|GlycoEpitope:EP0075|SugarBind_Ligand:15  <br>
  '''synonyms''' : 3'-Sulfo-Lea|SuLe(a)|3'-sulpho-Le(a)|3-O-sulfo-Le(A)|3'-Sulfo Le^a|3'-Sulfo Lea|3'-Sulfo Lewis a <br>
  '''synonyms''' : <br>
  '''function''' : SO3-3-Gal and the SO3-3-Lea blood group antigen bound to H.pylori.[GlycoEpitope:EP0009] <br>
  '''function''' : <br>
  '''disease_associations''' : <br>
  '''disease_associations''' : Pharyngitis[SugarBind_Ligand:15]|Tracheobronchitis[SugarBind_Ligand:15]|Gonorrhea[SugarBind_Ligand:15]|Actinomycosis[SugarBind_Ligand:15]|Diarrhea[SugarBind_Ligand:15]|Hemorrhagic colitis[SugarBind_Ligand:15]|Chronic gastritis[SugarBind_Ligand:15]|Peptic ulcers[SugarBind_Ligand:15]|Gastric cancer[SugarBind_Ligand:15]|Influenza[SugarBind_Ligand:15] <br>
  '''wikipedia''' :  <br>
  '''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
  '''essentials_of_glycobiology''' : <br>




===Paucimannose===
===GSD000007===
  '''term (main_entry)''' : Paucimannose <br>
  '''term (main_entry)''' : 3'-Sulfo-Lewis x <br>
  '''glycan_dictionary_accession''' : GSD000144 <br>
  '''glycan_dictionary_accession''' : GSD000007 <br>
  '''glytoucan_accession ''' :  <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G12295TB G12295TB] <br>
'''term_in_sentence''' : The galactosylation of core fucose (GalFuc epitope) in paucimannose and complex-type N-glycans is characteristic of protostome organisms, including flatworms (planarians).[PMID:[https://pubmed.ncbi.nlm.nih.gov/29475940 29475940]] <br>
  '''term_in_sentence''' : A remodeling system of the 3'-sulfo-Lewis a and 3'-sulfo-Lewis x epitopes.[PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/11504739 11504739] [https://pubmed.ncbi.nlm.nih.gov/11504739 11504739]]] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29475940 29475940]|[https://pubmed.ncbi.nlm.nih.gov/29803109 29803109]|[https://pubmed.ncbi.nlm.nih.gov/12603202 12603202]|[https://pubmed.ncbi.nlm.nih.gov/31817246 31817246]|[https://pubmed.ncbi.nlm.nih.gov/31719144 31719144]|[https://pubmed.ncbi.nlm.nih.gov/21057214 21057214]|[https://pubmed.ncbi.nlm.nih.gov/31932305 31932305]|[https://pubmed.ncbi.nlm.nih.gov/17132514 17132514]|[https://pubmed.ncbi.nlm.nih.gov/30382146 30382146]|[https://pubmed.ncbi.nlm.nih.gov/27731363 27731363]|[https://pubmed.ncbi.nlm.nih.gov/31325506 31325506]|[https://pubmed.ncbi.nlm.nih.gov/25746926 25746926]|[https://pubmed.ncbi.nlm.nih.gov/26513758 26513758]|[https://pubmed.ncbi.nlm.nih.gov/16522637 16522637]|[https://pubmed.ncbi.nlm.nih.gov/21169367 21169367]|[https://pubmed.ncbi.nlm.nih.gov/25190359 25190359]|[https://pubmed.ncbi.nlm.nih.gov/27928741 27928741]|[https://pubmed.ncbi.nlm.nih.gov/22496646 22496646]|[https://pubmed.ncbi.nlm.nih.gov/27384337 27384337]|[https://pubmed.ncbi.nlm.nih.gov/16897177 16897177]|[https://pubmed.ncbi.nlm.nih.gov/15228383 15228383]|[https://pubmed.ncbi.nlm.nih.gov/27379103 27379103]|[https://pubmed.ncbi.nlm.nih.gov/27189951 27189951]|[https://pubmed.ncbi.nlm.nih.gov/23475714 23475714]|[https://pubmed.ncbi.nlm.nih.gov/24907509 24907509]|[https://pubmed.ncbi.nlm.nih.gov/20558211 20558211]|[https://pubmed.ncbi.nlm.nih.gov/28060516 28060516]|[https://pubmed.ncbi.nlm.nih.gov/20441997 20441997]|[https://pubmed.ncbi.nlm.nih.gov/27720757 27720757]|[https://pubmed.ncbi.nlm.nih.gov/28817611 28817611]|[https://pubmed.ncbi.nlm.nih.gov/24550396 24550396]|[https://pubmed.ncbi.nlm.nih.gov/19494052 19494052]|[https://pubmed.ncbi.nlm.nih.gov/19515361 19515361]|[https://pubmed.ncbi.nlm.nih.gov/28630087 28630087]|[https://pubmed.ncbi.nlm.nih.gov/31320997 31320997]|[https://pubmed.ncbi.nlm.nih.gov/30651366 30651366]|[https://pubmed.ncbi.nlm.nih.gov/30253927 30253927]|[https://pubmed.ncbi.nlm.nih.gov/25922361 25922361]|[https://pubmed.ncbi.nlm.nih.gov/31655162 31655162]|[https://pubmed.ncbi.nlm.nih.gov/18056652 18056652]|[https://pubmed.ncbi.nlm.nih.gov/24467287 24467287]|[https://pubmed.ncbi.nlm.nih.gov/32367383 32367383] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/11504739 11504739] [https://pubmed.ncbi.nlm.nih.gov/11504739 11504739]]|[https://pubmed.ncbi.nlm.nih.gov/20695481 20695481]|[https://pubmed.ncbi.nlm.nih.gov/8688428 8688428]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10536036 10536036] [https://pubmed.ncbi.nlm.nih.gov/10536036 10536036]]|[https://pubmed.ncbi.nlm.nih.gov/12770775 12770775]|[https://pubmed.ncbi.nlm.nih.gov/11352731 11352731]|[https://pubmed.ncbi.nlm.nih.gov/9784103 9784103]|[https://pubmed.ncbi.nlm.nih.gov/9022803 9022803] <br>
  '''definition''' : Any N-linked glycan derivative with composition Man1-4Fuc0-1 GlcNAc2, in which the chitobiose core (GlcNAc2) is intact. Found in relatively large amounts in invertebrates and plants, they are formed by removal of the non-reducing terminal GlcNAc (\added by GlcNAcT1) from GlcNAcMan3-5GlcNAc2 by a Golgi hexosaminidase and subsequent removal of Man residues by Golgi mannosidases. Pauscimannose glycans have also been detected in vertebrates.[CHEBI:144386] <br>
'''definition''' : An amino trisaccharide that consists of ''N''-acetyl-β-<small>D</small>-glucosamine having an α-<small>L</small>-fucosyl residue attached at position 3 and a 3-sulfated β-<small>D</small>-galactosyl residue attached at position 4; β-<small>D</small>-Gal''p''3S-(1→4)-[α-<small>L</small>-Fuc''p''-(1→3)]-<small>D</small>-Glc''p''NAc in which the configuration at the anomeric centre of the reducing-end residue is β. [CHEBI:65171] <br>
'''term_xref''' : CHEBI:144386 <br>
'''term_xref''' : GTC:G12295TB|GlycoEpitope:EP0013|CID:[https://pubmed.ncbi.nlm.nih.gov/5289353 5289353]|CHEBI:65171|GlycoMotif:GGM.000029  <br>
'''synonyms''' :  <br>
  '''synonyms''' : 3'-sulfo-Le(x)|3'-Sulfo Lewis x|3'-sulfo Le^x|3'-sulfo Lex <br>
  '''function''' :  <br>
  '''function''' :  <br>
  '''disease_associations''' :  <br>
  '''disease_associations''' :  <br>
Line 358: Line 380:




===Polysialic acid===
===GSD000008===
  '''term (main_entry)''' : Polysialic acid<br>
  '''term (main_entry)''' : 6,6'-bisSulfo-Lewis x <br>
  '''glycan_dictionary_accession''' : GSD000182<br>
  '''glycan_dictionary_accession''' : GSD000008 <br>
  '''glytoucan_accession ''' : <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00659GQ G00659GQ] <br>
  '''term_in_sentence''' : Polysialic acid (PSA) is a carbohydrate composed of a linear polymer of α2,8-linked sialic acids, primarily attached to the Neural Cell Adhesion Molecule (NCAM). [PMID:36076963]<br>
  '''term_in_sentence''' : Comparison of the reactivity pattern of HEV with the reactivity of the pure 6-sulfo, 6'-sulfo, or 6,6'-bissulfo sialyl Lewis X determinant with hitherto known anti-sialyl Lewis X antibodies strongly suggested 6-sulfo sialyl Lewis X to be the best candidate for the major sulfated sialyl Lewis X determinant on HEV, followed by 6,6'-bissulfo sialyl Lewis X, whereas 6'-sulfo sialyl Lewis X was unlikely. [PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9556613 9556613] [https://pubmed.ncbi.nlm.nih.gov/9556613 9556613]] [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9556613 9556613] [https://pubmed.ncbi.nlm.nih.gov/9556613 9556613]]]] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/36076963 36076963]|[https://pubmed.ncbi.nlm.nih.gov/35222358 35222358]<br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/19756298 19756298]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/14593101 14593101] [https://pubmed.ncbi.nlm.nih.gov/14593101 14593101]]|[https://pubmed.ncbi.nlm.nih.gov/15175329 15175329]|[https://pubmed.ncbi.nlm.nih.gov/14568956 14568956]|[https://pubmed.ncbi.nlm.nih.gov/12163379 12163379]|[https://pubmed.ncbi.nlm.nih.gov/11919403 11919403]|[https://pubmed.ncbi.nlm.nih.gov/11520459 11520459]|[https://pubmed.ncbi.nlm.nih.gov/10728707 10728707]|[https://pubmed.ncbi.nlm.nih.gov/10200296 10200296]|[https://pubmed.ncbi.nlm.nih.gov/10528213 10528213]|[https://pubmed.ncbi.nlm.nih.gov/9712885 9712885]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9556613 9556613] [https://pubmed.ncbi.nlm.nih.gov/9556613 9556613]] [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9556613 9556613] [https://pubmed.ncbi.nlm.nih.gov/9556613 9556613]]]|[https://pubmed.ncbi.nlm.nih.gov/9456330 9456330]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9556613 9556613] [https://pubmed.ncbi.nlm.nih.gov/9556613 9556613]] [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9556613 9556613] [https://pubmed.ncbi.nlm.nih.gov/9556613 9556613]]]|[https://pubmed.ncbi.nlm.nih.gov/9257857 9257857]|[https://pubmed.ncbi.nlm.nih.gov/9164959 9164959]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9015359 9015359] [https://pubmed.ncbi.nlm.nih.gov/9015359 9015359]]|[https://pubmed.ncbi.nlm.nih.gov/8958810 8958810]|[https://pubmed.ncbi.nlm.nih.gov/7560094 7560094]|[https://pubmed.ncbi.nlm.nih.gov/7485559 7485559]|[https://pubmed.ncbi.nlm.nih.gov/7538131 7538131]|[https://pubmed.ncbi.nlm.nih.gov/8161542 8161542]|[https://pubmed.ncbi.nlm.nih.gov/7684905 7684905] <br>
  '''definition''' : <br>
  '''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-5-acetamido-6-hydroxy-2-(sulfooxymethyl)-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(sulfooxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.[CHEBI:146095] <br>
  '''term_xref''' : GlycoMotif:GGM.000252<br>
  '''term_xref''' : GlycoEpitope:EP0016|CHEBI:146095|GlycoMotif:GGM.000028|GTC:G00659GQ  <br>
  '''synonyms''' : polySia|PSA<br>
  '''synonyms''' : 6,6'-DiSulfo Sialyl Lewis x|6,6-bisSulfo-Lewis x (6,60-bissulfo Lewis x )|6,6'- Disulfo Sialyl Lewis x|6,6'-bisSulfo-Lewis x|6,6'-bissulfo Lex|6,6'-Disulfo Sialyl Lewis x|6,6'-bissulfo Le^x <br>
  '''function''' : <br>
  '''function''' : lymphocyte homing[GlycoEpitope:EP0016] <br>
  '''disease_associations''' :  <br>
  '''disease_associations''' :  <br>
  '''wikipedia''' :  <br>
  '''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' : <br>
  '''essentials_of_glycobiology''' : <br>




===Sd(A)/Cad===
===GSD000009===
[[File:G41052GC.png|thumb|G41052GC]]
  '''term (main_entry)''' : 6-Sialyl-GalNAc <br>
  '''term (main_entry)''' : Sd(A)/Cad <br>
  '''glycan_dictionary_accession''' : GSD000009 <br>
  '''glycan_dictionary_accession''' : GSD000145 <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G08371CD G08371CD] <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G41052GC G41052GC] <br>
  '''term_in_sentence''' : mmunohistochemical distributions of carbohydrate antigens based on the type 2 chain in normal as well as fetal and neoplastic tissues of human gastrointestinal tract were investigated with a monoclonal antibody (MAb) H11 (specific for type 2 chain) alone and in combination with the two MAbs MSG15 (for alpha 2----6 sialylated type 2 chain) and IB9 (for the alpha 2----6 sialylated type 2 chain and glycoproteins having NeuAc alpha 2----6Gal-NAc), and 188C1 (for short- and long-chain Lex antigens) and FH2 (for the long-chain Lex antigen). [PMID: [https://pubmed.ncbi.nlm.nih.gov/1618643 1618643]] <br>
  '''term_in_sentence''' : The expanding roles of the Sd(a)/Cad carbohydrate antigen and its cognate glycosyltransferase B4GALNT2.[PMID:[https://pubmed.ncbi.nlm.nih.gov/24112972 24112972]] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1618643 1618643]|[https://pubmed.ncbi.nlm.nih.gov/6194157 6194157] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/24112972 24112972]|[https://pubmed.ncbi.nlm.nih.gov/11577689 11577689]|[https://pubmed.ncbi.nlm.nih.gov/30067891 30067891]|[https://pubmed.ncbi.nlm.nih.gov/15361072 15361072] <br>
  '''definition''' : An amino disaccharide composed of N-acetylneuraminic acid and 2-(acetylamino)-2-deoxy-D-galactopyranose residues joined by an (α-2→6) glycosidic bond.[CHEBI:146820] <br>
  '''definition''' : A branched amino tetrasaccharide comprised of a trisaccharide chain of N-acetyl-α-neuraminic acid, β-D-galactose and N-acetyl-β-D-glucosamine residues linked sequentially (2→3) and (1→4), to the galactose residue of which is also linked (1→4) an N-acetyl-β-L-galactosamine residue.
  '''term_xref''' : GlycoEpitope:EP0352|KEGG:G00455|KEGG:G10625|CHEBI:146820|CID:[https://pubmed.ncbi.nlm.nih.gov/11409652 11409652]|GlycoMotif:GGM.000035|GTC:G08371CD <br>
[CHEBI:71561] <br>
  '''synonyms''' : Sialyl Tn antigen|6-Sialyl-GalNAc|6-Sialyl LN|6-Sialyl LN (type 1)|6-Sialyl LN (type 2) <br>
  '''term_xref''' : GlycoMotif:GGM.000051|GTC:G41052GC|CID:70698375|CHEBI:71561 <br>
  '''synonyms''' : Sd^a /Cad <br>
  '''function''' :  <br>
  '''function''' :  <br>
  '''disease_associations''' :  <br>
  '''disease_associations''' :  <br>
  '''wikipedia''' :  <br>
  '''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453020/ Chapter 9] <br>
  '''essentials_of_glycobiology''' : <br>




===SDlex===
===GSD000010===
[[File:G19619KS.png|thumb|G19619KS]]
  '''term (main_entry)''' : 6-Sulfo LacNac <br>
  '''term (main_entry)''' : SDlex <br>
  '''glycan_dictionary_accession''' : GSD000010 <br>
  '''glycan_dictionary_accession''' : GSD000146 <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G13157WZ G13157WZ] <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G19619KS G19619KS] <br>
  '''term_in_sentence''' : In the search for an additional marker to better dissect the two subsets we have explored the marker 6-sulfo LacNAc (slan).[PMID:[https://pubmed.ncbi.nlm.nih.gov/31572354 31572354]] <br>
  '''term_in_sentence''' : Hepatic expression of sialylated difucosyl Lex antigen (SDLex, NeuAc alpha 2-3Gal beta 1-4(Fuc alpha 1-3)GlcNAc beta 1-3Gal beta 1-4(Fuc alpha 1-3)GlcNAc beta 1-) was studied with monoclonal antibody FH6, which defines this structure.[PMID: [https://pubmed.ncbi.nlm.nih.gov/3341453 3341453]] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31572354 31572354]|[https://pubmed.ncbi.nlm.nih.gov/31191513 31191513]|[https://pubmed.ncbi.nlm.nih.gov/29977237 29977237]|[https://pubmed.ncbi.nlm.nih.gov/29900053 29900053]|[https://pubmed.ncbi.nlm.nih.gov/30984181 30984181]|[https://pubmed.ncbi.nlm.nih.gov/28732748 28732748]|[https://pubmed.ncbi.nlm.nih.gov/26510404 26510404]|[https://pubmed.ncbi.nlm.nih.gov/28769928 28769928]|[https://pubmed.ncbi.nlm.nih.gov/31154896 31154896]|[https://pubmed.ncbi.nlm.nih.gov/27541644 27541644]|[https://pubmed.ncbi.nlm.nih.gov/25262889 25262889]|[https://pubmed.ncbi.nlm.nih.gov/26155414 26155414]|[https://pubmed.ncbi.nlm.nih.gov/28499587 28499587]|[https://pubmed.ncbi.nlm.nih.gov/27086951 27086951]|[https://pubmed.ncbi.nlm.nih.gov/27315572 27315572]|[https://pubmed.ncbi.nlm.nih.gov/26162403 26162403]|[https://pubmed.ncbi.nlm.nih.gov/26391152 26391152]|[https://pubmed.ncbi.nlm.nih.gov/31730025 31730025]|[https://pubmed.ncbi.nlm.nih.gov/12354382 12354382]|[https://pubmed.ncbi.nlm.nih.gov/27318477 27318477]|[https://pubmed.ncbi.nlm.nih.gov/23879812 23879812]|[https://pubmed.ncbi.nlm.nih.gov/25340085 25340085]|[https://pubmed.ncbi.nlm.nih.gov/24682513 24682513]|[https://pubmed.ncbi.nlm.nih.gov/21377044 21377044]|[https://pubmed.ncbi.nlm.nih.gov/21098395 21098395]|[https://pubmed.ncbi.nlm.nih.gov/18942710 18942710]|[https://pubmed.ncbi.nlm.nih.gov/23559493 23559493]|[https://pubmed.ncbi.nlm.nih.gov/23890755 23890755]|[https://pubmed.ncbi.nlm.nih.gov/22643330 22643330]|[https://pubmed.ncbi.nlm.nih.gov/23460612 23460612]|[https://pubmed.ncbi.nlm.nih.gov/23402811 23402811]|[https://pubmed.ncbi.nlm.nih.gov/22890025 22890025]|[https://pubmed.ncbi.nlm.nih.gov/19589615 19589615]|[https://pubmed.ncbi.nlm.nih.gov/32939325 32939325]|[https://pubmed.ncbi.nlm.nih.gov/20210806 20210806]|[https://pubmed.ncbi.nlm.nih.gov/17616642 17616642]|[https://pubmed.ncbi.nlm.nih.gov/22907335 22907335]|[https://pubmed.ncbi.nlm.nih.gov/16782032 16782032]|[https://pubmed.ncbi.nlm.nih.gov/22188261 22188261]|[https://pubmed.ncbi.nlm.nih.gov/21283706 21283706]|[https://pubmed.ncbi.nlm.nih.gov/29875315 29875315]|[https://pubmed.ncbi.nlm.nih.gov/32413173 32413173]|[https://pubmed.ncbi.nlm.nih.gov/19546436 19546436]|[https://pubmed.ncbi.nlm.nih.gov/19384158 19384158]|[https://pubmed.ncbi.nlm.nih.gov/1429720 1429720]|[https://pubmed.ncbi.nlm.nih.gov/30519676 30519676] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30226570 30226570]|[https://pubmed.ncbi.nlm.nih.gov/3341453 3341453]|[https://pubmed.ncbi.nlm.nih.gov/12725333 12725333] <br>
  '''definition''' : An oligosaccharide sulfate that is N-acetyllactosamine in which the hydroxy group at position 6 of the N-acetylglucosamine ring has been converted into its hydrogen sulfate derivative.[CHEBI:148005] <br>
  '''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6S)-5-acetamido-6-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-5-acetamido-6-hydroxy-2-(hydroxymethyl)-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-(hydroxymethyl)-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of neuraminic acids.[CHEBI:148203] <br>
  '''term_xref''' : GlycoEpitope:EP0141|GTC:G13157WZ|CID:[https://pubmed.ncbi.nlm.nih.gov/10322152 10322152]|CHEBI:148005<br>
  '''term_xref''' : GlycoMotif:GGM.000032|GTC:G19619KS|CID:91856705|CHEBI:148203  <br>
  '''synonyms''' : 6-Sulfo LacNAc <br>
  '''synonyms''' : Sdlex|SDLe^x|SDLex <br>
  '''function''' :  <br>
  '''function''' :  <br>
  '''disease_associations''' :  <br>
  '''disease_associations''' :  <br>
  '''wikipedia''' :  <br>
  '''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
'''essentials_of_glycobiology''' :  <br>
 
 
===GSD000011===
[[File:G00672PE.png|thumb|G00672PE]]
'''term (main_entry)''' : 6'-Sulfo Sialyl Lewis x <br>
'''glycan_dictionary_accession''' : GSD000011 <br>
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00672PE G00672PE] <br>
'''term_in_sentence''' : Studies using sulfotransferase-deficient mice showed that 6-sulfo sialyl Lewis X (6-sulfo sLe(x)), a major ligand for L-selectin that is expressed on the high endothelial venules (HEVs), plays critical roles in lymphocyte homing to the peripheral lymph nodes.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2288521 2288521]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2288521 2288521]|[https://pubmed.ncbi.nlm.nih.gov/26137907 26137907]|[https://pubmed.ncbi.nlm.nih.gov/9400621 9400621]|[https://pubmed.ncbi.nlm.nih.gov/32744401 32744401]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9556613 9556613] [https://pubmed.ncbi.nlm.nih.gov/9556613 9556613]] [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9556613 9556613] [https://pubmed.ncbi.nlm.nih.gov/9556613 9556613]]]|[https://pubmed.ncbi.nlm.nih.gov/15972893 15972893]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9015359 9015359] [https://pubmed.ncbi.nlm.nih.gov/9015359 9015359]]|[https://pubmed.ncbi.nlm.nih.gov/22691873 22691873]|[https://pubmed.ncbi.nlm.nih.gov/18652681 18652681]|[https://pubmed.ncbi.nlm.nih.gov/9722682 9722682]|[https://pubmed.ncbi.nlm.nih.gov/10435581 10435581]|[https://pubmed.ncbi.nlm.nih.gov/19458105 19458105]|[https://pubmed.ncbi.nlm.nih.gov/19359410 19359410]|[https://pubmed.ncbi.nlm.nih.gov/15228275 15228275]|[https://pubmed.ncbi.nlm.nih.gov/18250165 18250165]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10536036 10536036] [https://pubmed.ncbi.nlm.nih.gov/10536036 10536036]]|[https://pubmed.ncbi.nlm.nih.gov/17944600 17944600]|[https://pubmed.ncbi.nlm.nih.gov/10460836 10460836]|[https://pubmed.ncbi.nlm.nih.gov/27993973 27993973]|[https://pubmed.ncbi.nlm.nih.gov/19149511 19149511]|[https://pubmed.ncbi.nlm.nih.gov/19150806 19150806]|[https://pubmed.ncbi.nlm.nih.gov/17172261 17172261]|[https://pubmed.ncbi.nlm.nih.gov/17142960 17142960]|[https://pubmed.ncbi.nlm.nih.gov/27956273 27956273]|[https://pubmed.ncbi.nlm.nih.gov/7578028 7578028]|[https://pubmed.ncbi.nlm.nih.gov/22260995 22260995]|[https://pubmed.ncbi.nlm.nih.gov/24519996 24519996]|[https://pubmed.ncbi.nlm.nih.gov/21596021 21596021]|[https://pubmed.ncbi.nlm.nih.gov/21982762 21982762]|[https://pubmed.ncbi.nlm.nih.gov/21775439 21775439]|[https://pubmed.ncbi.nlm.nih.gov/17334369 17334369]|[https://pubmed.ncbi.nlm.nih.gov/9710564 9710564]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/14593101 14593101] [https://pubmed.ncbi.nlm.nih.gov/14593101 14593101]]|[https://pubmed.ncbi.nlm.nih.gov/16227985 16227985]|[https://pubmed.ncbi.nlm.nih.gov/11895802 11895802]|[https://pubmed.ncbi.nlm.nih.gov/22750968 22750968]|[https://pubmed.ncbi.nlm.nih.gov/15157883 15157883]|[https://pubmed.ncbi.nlm.nih.gov/19067429 19067429] <br>
'''definition''' : A branched amino tetrasaccharide comprised of a trisaccharide chain of N-acetyl-α-neuraminic acid, 6-O-sulfo-β-D-glactose and N-acetyl-β-D-glucosamine residues linked sequentially (2→3) and (1→4), to the GlcNAC residue of which is also linked (1→3) an α-L-fucose residue.[CHEBI:71558] <br>
'''term_xref''' : GlycoMotif:GGM.000025|GTC:G00672PE|CID:[https://pubmed.ncbi.nlm.nih.gov/70698387 70698387]|GlycoEpitope:EP0014|CHEBI:71558|SugarBind_Ligand:128  <br>
'''synonyms''' : 6'-sulfated sialyl Lewis x-|6'-sulfo-sLe(x)|Su-SaiLex|Su-Slex|6'-Sulfo-sialyl Lewis x <br>
'''function''' : lymphocyte homing[GlycoEpitope:EP0014] <br>
'''disease_associations''' : Influenza[SugarBind_Ligand:128] <br>
'''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14] <br>




===Seminolipid===
===GSD000012===
[[File:G72548RZ.png|thumb|G72548RZ]]
  '''term (main_entry)''' : 9-O-Acetyl GD3 <br>
  '''term (main_entry)''' : Seminolipid <br>
  '''glycan_dictionary_accession''' : GSD000012 <br>
  '''glycan_dictionary_accession''' : GSD000147 <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G74121RX G74121RX] <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G72548RZ G72548RZ] <br>
  '''term_in_sentence''' : To determine whether 9-O-acetyl GD3 (acGD3) has a general antiapoptotic potential, the apoptosis-sensitive Jurkat cell line and an apoptosis-sensitive variant of the cell line Molt-4 were preincubated with micromolar concentrations of acGD3 and then treated with inducers of apoptosis.[PMID:[https://pubmed.ncbi.nlm.nih.gov/16432837 16432837]] <br>
  '''term_in_sentence''' : A concise total synthesis of seminolipid, a sulfoglycolipid, has been achieved; key features include regioselective, tin-free sulfation of allyl β-d-galactopyranoside using 2,6-bis(trifluoromethyl)phenylboronic acid as protective reagent, stereoselective epoxidation, and site-selective acylation. [PMID: [https://pubmed.ncbi.nlm.nih.gov/31353379 31353379]] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/16432837 16432837]|[https://pubmed.ncbi.nlm.nih.gov/21507905 21507905]|[https://pubmed.ncbi.nlm.nih.gov/17512674 17512674]|[https://pubmed.ncbi.nlm.nih.gov/21930212 21930212]|[https://pubmed.ncbi.nlm.nih.gov/18194438 18194438]|[https://pubmed.ncbi.nlm.nih.gov/20739294 20739294]|[https://pubmed.ncbi.nlm.nih.gov/3216430 3216430]|[https://pubmed.ncbi.nlm.nih.gov/14724245 14724245]|[https://pubmed.ncbi.nlm.nih.gov/31373393 31373393]|[https://pubmed.ncbi.nlm.nih.gov/7558412 7558412]|[https://pubmed.ncbi.nlm.nih.gov/11273644 11273644]|[https://pubmed.ncbi.nlm.nih.gov/17385751 17385751]|[https://pubmed.ncbi.nlm.nih.gov/30694652 30694652]|[https://pubmed.ncbi.nlm.nih.gov/22894715 22894715]|[https://pubmed.ncbi.nlm.nih.gov/12973826 12973826]|[https://pubmed.ncbi.nlm.nih.gov/7859075 7859075]|[https://pubmed.ncbi.nlm.nih.gov/9749956 9749956]|[https://pubmed.ncbi.nlm.nih.gov/9874495 9874495]|[https://pubmed.ncbi.nlm.nih.gov/12486096 12486096]|[https://pubmed.ncbi.nlm.nih.gov/1989525 1989525]|[https://pubmed.ncbi.nlm.nih.gov/25330147 25330147]|[https://pubmed.ncbi.nlm.nih.gov/23478187 23478187]|[https://pubmed.ncbi.nlm.nih.gov/21807667 21807667]|[https://pubmed.ncbi.nlm.nih.gov/8486686 8486686]|[https://pubmed.ncbi.nlm.nih.gov/11465673 11465673]|[https://pubmed.ncbi.nlm.nih.gov/9511990 9511990]|[https://pubmed.ncbi.nlm.nih.gov/29270199 29270199]|[https://pubmed.ncbi.nlm.nih.gov/9268945 9268945]|[https://pubmed.ncbi.nlm.nih.gov/25045067 25045067]|[https://pubmed.ncbi.nlm.nih.gov/21618115 21618115]|[https://pubmed.ncbi.nlm.nih.gov/16434401 16434401]|[https://pubmed.ncbi.nlm.nih.gov/12493756 12493756]|[https://pubmed.ncbi.nlm.nih.gov/2302705 2302705]|[https://pubmed.ncbi.nlm.nih.gov/2198284 2198284]|[https://pubmed.ncbi.nlm.nih.gov/2685488 2685488]|[https://pubmed.ncbi.nlm.nih.gov/9328574 9328574]|[https://pubmed.ncbi.nlm.nih.gov/4055789 4055789]|[https://pubmed.ncbi.nlm.nih.gov/10096568 10096568]|[https://pubmed.ncbi.nlm.nih.gov/1644805 1644805]|[https://pubmed.ncbi.nlm.nih.gov/2582447 2582447] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31353379 31353379]|[https://pubmed.ncbi.nlm.nih.gov/31736776 31736776]|[https://pubmed.ncbi.nlm.nih.gov/12810822 12810822]|[https://pubmed.ncbi.nlm.nih.gov/19582571 19582571]|[https://pubmed.ncbi.nlm.nih.gov/19542524 19542524]|[https://pubmed.ncbi.nlm.nih.gov/20670037 20670037]|[https://pubmed.ncbi.nlm.nih.gov/15659616 15659616]|[https://pubmed.ncbi.nlm.nih.gov/20817833 20817833]|[https://pubmed.ncbi.nlm.nih.gov/870059 870059]|[https://pubmed.ncbi.nlm.nih.gov/10801776 10801776]|[https://pubmed.ncbi.nlm.nih.gov/21965315 21965315]|[https://pubmed.ncbi.nlm.nih.gov/8095813 8095813]|[https://pubmed.ncbi.nlm.nih.gov/1280685 1280685]|[https://pubmed.ncbi.nlm.nih.gov/4690236 4690236]|[https://pubmed.ncbi.nlm.nih.gov/34199863 34199863]|[https://pubmed.ncbi.nlm.nih.gov/4207869 4207869]|[https://pubmed.ncbi.nlm.nih.gov/2373957 2373957]|[https://pubmed.ncbi.nlm.nih.gov/845131 845131] <br>
  '''definition''' :  <br>
  '''definition''' :  <br>
  '''term_xref''' : GlycoMotif:GGM.000062|GTC:G72548RZ<br>
  '''term_xref''' : GTC:G74121RX|GlycoEpitope:EP0064|CID:[https://pubmed.ncbi.nlm.nih.gov/91852520 91852520]|GlycoMotif:GGM.000093 <br>
  '''synonyms''' : <br>
  '''synonyms''' : acGD3|9-O-Acetylated GD3|9-O-Acetyl-GD3|9-O-Ac-GD3|CD60b <br>
  '''function''' :  <br>
  '''function''' :  <br>
  '''disease_associations''' : <br>
  '''disease_associations''' : pancreas cancer[GlycoEpitope:EP0064] <br>
  '''wikipedia''' :  <br>
  '''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
  '''essentials_of_glycobiology''' : <br>




===Sialopentaosylceramide===
===GSD000013===
[[File:G13224CR.png|thumb|G13224CR]]
  '''term (main_entry)''' : 9-O-Acetyl sialic acid <br>
  '''term (main_entry)''' : Sialopentaosylceramide <br>
  '''glycan_dictionary_accession''' : GSD000013 <br>
  '''glycan_dictionary_accession''' : GSD000148 <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G47325QT G47325QT] <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G13224CR G13224CR] <br>
  '''term_in_sentence''' : Levels of 9-O-acetyl sialic acid provide a distinct way to define progenitors and thus facilitate the study of hematopoietic differentiation.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31411667 31411667]] <br>
  '''term_in_sentence''' : Sialylpentaosylceramide detected with anti-GM2 monoclonal antibody. Structural characterization and complementary expression with GM2 in gastric cancer and normal gastric mucosap[PMID: [https://pubmed.ncbi.nlm.nih.gov/2139874 2139874]] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31411667 31411667]|[https://pubmed.ncbi.nlm.nih.gov/27936566 27936566]|[https://pubmed.ncbi.nlm.nih.gov/2509478 2509478]|[https://pubmed.ncbi.nlm.nih.gov/10049046 10049046]|[https://pubmed.ncbi.nlm.nih.gov/1826463 1826463] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2139874 2139874] <br>
  '''definition''' : N-acetyl-9-O-acetyl-alpha-neuraminic acid is a member of the class of N-acetylneuraminic acids that is alpha-neuraminic acid which has acetylated on N-5 and O-9. It has functional parent alpha-neuraminic acid.[CHEBI:84941] <br>
  '''definition''' : A ganglioside in which the oligosaccharide portion is composed of a pentasaccharide containing one or more sialic acid residues.[CHEBI:36542] <br>
  '''term_xref''' : GTC:G47325QT|GlycoEpitope:EP0065|CID:[https://pubmed.ncbi.nlm.nih.gov/13991612 13991612]|CHEBI:84941  <br>
  '''term_xref''' : GlycoMotif:GGM.000097|GTC:G13224CR|CID: 91859576|CHEBI:148045|KEGG:G00883|CHEBI:36542 <br>
  '''synonyms''' :  <br>
  '''synonyms''' :  <br>
  '''function''' :  <br>
  '''function''' :  <br>
  '''disease_associations''' :  <br>
  '''disease_associations''' :  <br>
  '''wikipedia''' :  <br>
  '''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' : <br>
  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453082/ Chapter 15]<br>




===Sialosyl paragloboside===
===GSD000014===
[[File:G50123ZO.png|thumb|G50123ZO]]
  '''term (main_entry)''' : Blood group A (Type 2) <br>
  '''term (main_entry)''' : Sialosyl paragloboside <br>
  '''glycan_dictionary_accession''' : GSD000014 <br>
  '''glycan_dictionary_accession''' : GSD000149 <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G74353FF G74353FF] <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G50123ZO G50123ZO] <br>
  '''term_in_sentence''' : One hybridoma antibody (AH16), obtained on immunization with human gastric cancer cell MKN45, was directed to the blood group A determinant carried by both type 1 and type 2 chains. [PMID:[https://pubmed.ncbi.nlm.nih.gov/6583282 6583282]] <br>
  '''term_in_sentence''' : Unlike CNS myelin, human peripheral nerve myelin has the acidic glycosphingolipids sialosyl paragloboside (SPG), sialosyl lactosaminyl paragloboside (SLPG), and sulfated glucuronyl paragloboside (SGPG).[PMID:[https://pubmed.ncbi.nlm.nih.gov/8862128 8862128]] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27196314 27196314]|[https://pubmed.ncbi.nlm.nih.gov/6583282 6583282]|[https://pubmed.ncbi.nlm.nih.gov/8340255 8340255]|[https://pubmed.ncbi.nlm.nih.gov/18701592 18701592]|[https://pubmed.ncbi.nlm.nih.gov/21901093 21901093]|[https://pubmed.ncbi.nlm.nih.gov/2413709 2413709]|[https://pubmed.ncbi.nlm.nih.gov/8036794 8036794]|[https://pubmed.ncbi.nlm.nih.gov/1615929 1615929]|[https://pubmed.ncbi.nlm.nih.gov/3285099 3285099] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/8862128 8862128]|[https://pubmed.ncbi.nlm.nih.gov/7236652 7236652]|[https://pubmed.ncbi.nlm.nih.gov/2370108 2370108]|[https://pubmed.ncbi.nlm.nih.gov/3133978 3133978]|[https://pubmed.ncbi.nlm.nih.gov/2905604 2905604]|[https://pubmed.ncbi.nlm.nih.gov/1749114 1749114]|[https://pubmed.ncbi.nlm.nih.gov/1573418 1573418] <br>
  '''definition''' : A branched amino tetrasaccharide comprising N-acetyl-β-D-glucosamine at the reducing end with a N-acetyl-α-D-galactosaminyl-(1→3)-[α-L-fucosyl-(1→2)]-β-D-galactosyl moiety attached at the 4-position.[CHEBI:62486] <br>
  '''definition''' : α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-D-GlcpNAc with β configuration at the anomeric position of the reducing-end N-acetyl-D-glucosamine residue.[CHEBI:71612] <br>
  '''term_xref''' : GTC:G74353FF|CID:[https://pubmed.ncbi.nlm.nih.gov/53262376 53262376]|GlycoEpitope:EP0257|CHEBI:62486|GlycoMotif:GGM.000038 <br>
  '''term_xref''' : GlycoMotif:GGM.000081|GTC:G50123ZO|CID:91845504|KEGG:G01429|CHEBI:151914  <br>
  '''synonyms''' : A Type 2|Blood group A type 2 chain<br>
  '''synonyms''' : <br>
  '''function''' :  <br>
  '''function''' :  <br>
  '''disease_associations''' :  <br>
  '''disease_associations''' :  <br>
  '''wikipedia''' :  <br>
  '''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' : <br>
  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>




===Sialyl Lewis a===
===GSD000016===
[[File:G00053MO.png|thumb|G00053MO]]
  '''term (main_entry)''' : Alpha-gal antigen <br>
  '''term (main_entry)''' : Sialyl Lewis a <br>
  '''glycan_dictionary_accession''' : GSD000016 <br>
  '''glycan_dictionary_accession''' : GSD000150 <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G24432YB G24432YB] <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00053MO G00053MO] <br>
  '''term_in_sentence''' : Therefore, alpha-gal antigen might be eliminated after a prolonged culture, when using human cells.[PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/31267683 31267683] [https://pubmed.ncbi.nlm.nih.gov/31267683 31267683]]] <br>
  '''term_in_sentence''' : By comparing the serum O-glycan profiles from healthy controls with those of cancer patients, we identified a marker candidate, core 1 sialyl Lewis A (NeuAcα2-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Gal) (abbreviated C1SLA), whose concentration appeared to be weakly correlated with CA19-9 values.[PMID:[https://pubmed.ncbi.nlm.nih.gov/26641888 26641888]] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/31267683 31267683] [https://pubmed.ncbi.nlm.nih.gov/31267683 31267683]]|[https://pubmed.ncbi.nlm.nih.gov/29319188 29319188]|[https://pubmed.ncbi.nlm.nih.gov/29481481 29481481]|[https://pubmed.ncbi.nlm.nih.gov/26140655 26140655]|[https://pubmed.ncbi.nlm.nih.gov/30337555 30337555]|[https://pubmed.ncbi.nlm.nih.gov/29235434 29235434]|[https://pubmed.ncbi.nlm.nih.gov/22909134 22909134]|[https://pubmed.ncbi.nlm.nih.gov/28280265 28280265]|[https://pubmed.ncbi.nlm.nih.gov/7532618 7532618]|[https://pubmed.ncbi.nlm.nih.gov/23390540 23390540]|[https://pubmed.ncbi.nlm.nih.gov/22808845 22808845]|[https://pubmed.ncbi.nlm.nih.gov/29898796 29898796]|[https://pubmed.ncbi.nlm.nih.gov/22262104 22262104]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/31267683 31267683] [https://pubmed.ncbi.nlm.nih.gov/31267683 31267683]]|[https://pubmed.ncbi.nlm.nih.gov/25430953 25430953]|[https://pubmed.ncbi.nlm.nih.gov/22993330 22993330]|[https://pubmed.ncbi.nlm.nih.gov/23578170 23578170]|[https://pubmed.ncbi.nlm.nih.gov/21043478 21043478]|[https://pubmed.ncbi.nlm.nih.gov/28294277 28294277]|[https://pubmed.ncbi.nlm.nih.gov/27696820 27696820]|[https://pubmed.ncbi.nlm.nih.gov/15814276 15814276]|[https://pubmed.ncbi.nlm.nih.gov/17991149 17991149]|[https://pubmed.ncbi.nlm.nih.gov/25577211 25577211]|[https://pubmed.ncbi.nlm.nih.gov/30578545 30578545]|[https://pubmed.ncbi.nlm.nih.gov/19895316 19895316]|[https://pubmed.ncbi.nlm.nih.gov/28068870 28068870]|[https://pubmed.ncbi.nlm.nih.gov/18546155 18546155]|[https://pubmed.ncbi.nlm.nih.gov/32907757 32907757]|[https://pubmed.ncbi.nlm.nih.gov/26485996 26485996]|[https://pubmed.ncbi.nlm.nih.gov/9771839 9771839]|[https://pubmed.ncbi.nlm.nih.gov/12042247 12042247]|[https://pubmed.ncbi.nlm.nih.gov/27567275 27567275]|[https://pubmed.ncbi.nlm.nih.gov/12131678 12131678]|[https://pubmed.ncbi.nlm.nih.gov/23114154 23114154]|[https://pubmed.ncbi.nlm.nih.gov/19184002 19184002]|[https://pubmed.ncbi.nlm.nih.gov/29577591 29577591]|[https://pubmed.ncbi.nlm.nih.gov/29806570 29806570]|[https://pubmed.ncbi.nlm.nih.gov/15638815 15638815]|[https://pubmed.ncbi.nlm.nih.gov/21118731 21118731] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/26641888 26641888]|[https://pubmed.ncbi.nlm.nih.gov/31424423 31424423]|[https://pubmed.ncbi.nlm.nih.gov/26530370 26530370]|[https://pubmed.ncbi.nlm.nih.gov/17760270 17760270]|[https://pubmed.ncbi.nlm.nih.gov/18343410 18343410]|[https://pubmed.ncbi.nlm.nih.gov/16033091 16033091]|[https://pubmed.ncbi.nlm.nih.gov/8829184 8829184]|[https://pubmed.ncbi.nlm.nih.gov/11907351 11907351]|[https://pubmed.ncbi.nlm.nih.gov/20592391 20592391]|[https://pubmed.ncbi.nlm.nih.gov/26641888 26641888]|[https://pubmed.ncbi.nlm.nih.gov/24128856 24128856]|[https://pubmed.ncbi.nlm.nih.gov/30249386 30249386]|[https://pubmed.ncbi.nlm.nih.gov/10773785 10773785]|[https://pubmed.ncbi.nlm.nih.gov/16149606 16149606]|[https://pubmed.ncbi.nlm.nih.gov/10996727 10996727]|[https://pubmed.ncbi.nlm.nih.gov/10436809 10436809]|[https://pubmed.ncbi.nlm.nih.gov/10667238 10667238]|[https://pubmed.ncbi.nlm.nih.gov/7720892 7720892]|[https://pubmed.ncbi.nlm.nih.gov/7630017 7630017]|[https://pubmed.ncbi.nlm.nih.gov/10612415 10612415]|[https://pubmed.ncbi.nlm.nih.gov/9836451 9836451]|[https://pubmed.ncbi.nlm.nih.gov/12511721 12511721]|[https://pubmed.ncbi.nlm.nih.gov/22623153 22623153] <br>
  '''definition''' : A glycosylgalactose that consists of β-D-galactose having an α-D-galactosyl residue at the 3-position.[CHEBI:62330] <br>
  '''definition''' : A sialyated version of Lewis A with a branched structure of amino tetrasaccharide consisting of a sialyl residue, linked (2→3) to a galactosyl residue that in turn is linked (1→3) to a glucosaminyl residue at the reducing end, which is also carrying a fucosyl residue at the 4-position.[CHEBI:62681] <br>
  '''term_xref''' : GTC:G24432YB|GlycoMotif:GGM.000015|CID:[https://pubmed.ncbi.nlm.nih.gov/52939789 52939789]|CHEBI:62330  <br>
  '''term_xref''' : GTC:G00053MO|GlycoEpitope:EP0008|CID:53356732|CHEBI:62681|GlycoMotif:GGM.000024<br>
  '''synonyms''' : a-Gal antigen <br>
  '''synonyms''' : SLea|CA19-9|CA19-9 antigen|SLe^a|Slea <br>
  '''function''' : Has role as a carbohydrate allergen, epitope or an antigen.[CHEBI:62330] <br>
  '''function''' : The carbohydrate determinants,Sialyl Lea and Sialyl Lex,which are frequently expressed on human cancer cells,serve as ligands for a cell adhesion molecule of the selectin family,E-selectin,which is expressed on vascular endothelial cells. These carbohydrate determinants are involved in the adhesion of cancer cells to vascular endothelium and thus contribute to hematogenous metastasis of cancer.[GlycoEpitope:EP0008] <br>
  '''disease_associations''' : <br>
  '''disease_associations''' : pancreatic adenocarcinoma[GlycoEpitope:EP0008]|hepatocellular cancer[GlycoEpitope:EP0008]|cholangiocellular cancer[GlycoEpitope:EP0008]|gastric cancer|[GlycoEpitope:EP0008]colorectal cancer[GlycoEpitope:EP0008]|ovarian cancer[GlycoEpitope:EP0008]|lung cancer[GlycoEpitope:EP0008]|breast cancer[GlycoEpitope:EP0008]|uterine cancer[GlycoEpitope:EP0008] <br>
  '''wikipedia''' :  <br>
  '''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' : <br>
  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>




===Sialyl Lewis x===
===GSD000017===
[[File:G00054MO.png|thumb|G00054MO]]
  '''term (main_entry)''' : Alpha-galactosylceramide <br>
  '''term (main_entry)''' : Sialyl Lewis x <br>
  '''glycan_dictionary_accession''' : GSD000017 <br>
  '''glycan_dictionary_accession''' : GSD000151 <br>
  '''glytoucan_accession ''' : <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00054MO G00054MO] <br>
  '''term_in_sentence''' : From 24 weeks of age, NZB/NZW F1 mice were injected with alpha-galactosylceramide (α-GalCer) or vehicle once a week for four weeks.[PMID:[https://pubmed.ncbi.nlm.nih.gov/29844470 29844470]] <br>
  '''term_in_sentence''' : As sialyl Lewis X is a lignad of the selectin family, it has been proposed that sialyl Lewis X-rich colon cancer cells metastasize to the liver by adhesion to selectins on hepatic endothelial cells.[PMID:[https://pubmed.ncbi.nlm.nih.gov/12828079 12828079]] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29844470 29844470]|[https://pubmed.ncbi.nlm.nih.gov/30421497 30421497]|[https://pubmed.ncbi.nlm.nih.gov/31575643 31575643]|[https://pubmed.ncbi.nlm.nih.gov/30745361 30745361]|[https://pubmed.ncbi.nlm.nih.gov/30953000 30953000]|[https://pubmed.ncbi.nlm.nih.gov/30556652 30556652]|[https://pubmed.ncbi.nlm.nih.gov/29617191 29617191]|[https://pubmed.ncbi.nlm.nih.gov/31689579 31689579]|[https://pubmed.ncbi.nlm.nih.gov/28872688 28872688]|[https://pubmed.ncbi.nlm.nih.gov/30195979 30195979]|[https://pubmed.ncbi.nlm.nih.gov/29940370 29940370]|[https://pubmed.ncbi.nlm.nih.gov/27004737 27004737]|[https://pubmed.ncbi.nlm.nih.gov/27198610 27198610]|[https://pubmed.ncbi.nlm.nih.gov/28743554 28743554]|[https://pubmed.ncbi.nlm.nih.gov/31649670 31649670]|[https://pubmed.ncbi.nlm.nih.gov/31484693 31484693]|[https://pubmed.ncbi.nlm.nih.gov/25752588 25752588]|[https://pubmed.ncbi.nlm.nih.gov/21383248 21383248]|[https://pubmed.ncbi.nlm.nih.gov/25527277 25527277]|[https://pubmed.ncbi.nlm.nih.gov/30821985 30821985]|[https://pubmed.ncbi.nlm.nih.gov/28947140 28947140]|[https://pubmed.ncbi.nlm.nih.gov/31244823 31244823]|[https://pubmed.ncbi.nlm.nih.gov/29311431 29311431]|[https://pubmed.ncbi.nlm.nih.gov/30803854 30803854]|[https://pubmed.ncbi.nlm.nih.gov/29576533 29576533]|[https://pubmed.ncbi.nlm.nih.gov/26101952 26101952]|[https://pubmed.ncbi.nlm.nih.gov/31213291 31213291]|[https://pubmed.ncbi.nlm.nih.gov/22412194 22412194]|[https://pubmed.ncbi.nlm.nih.gov/28067024 28067024]|[https://pubmed.ncbi.nlm.nih.gov/31199716 31199716]|[https://pubmed.ncbi.nlm.nih.gov/27354638 27354638]|[https://pubmed.ncbi.nlm.nih.gov/24465013 24465013]|[https://pubmed.ncbi.nlm.nih.gov/25445911 25445911]|[https://pubmed.ncbi.nlm.nih.gov/28120096 28120096]|[https://pubmed.ncbi.nlm.nih.gov/15630427 15630427]|[https://pubmed.ncbi.nlm.nih.gov/27803187 27803187]|[https://pubmed.ncbi.nlm.nih.gov/21392534 21392534]|[https://pubmed.ncbi.nlm.nih.gov/31075434 31075434]|[https://pubmed.ncbi.nlm.nih.gov/22683545 22683545]|[https://pubmed.ncbi.nlm.nih.gov/26191196 26191196]|[https://pubmed.ncbi.nlm.nih.gov/26811064 26811064]|[https://pubmed.ncbi.nlm.nih.gov/23935988 23935988]|[https://pubmed.ncbi.nlm.nih.gov/28623127 28623127]|[https://pubmed.ncbi.nlm.nih.gov/24913977 24913977]|[https://pubmed.ncbi.nlm.nih.gov/25434827 25434827]|[https://pubmed.ncbi.nlm.nih.gov/23420533 23420533]|[https://pubmed.ncbi.nlm.nih.gov/21839133 21839133]|[https://pubmed.ncbi.nlm.nih.gov/25314062 25314062]|[https://pubmed.ncbi.nlm.nih.gov/27325450 27325450]|[https://pubmed.ncbi.nlm.nih.gov/23874157 23874157] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12828079 12828079]|[https://pubmed.ncbi.nlm.nih.gov/8940172 8940172]|[https://pubmed.ncbi.nlm.nih.gov/10075923 10075923]|[https://pubmed.ncbi.nlm.nih.gov/19054801 19054801]|[https://pubmed.ncbi.nlm.nih.gov/9642161 9642161]|[https://pubmed.ncbi.nlm.nih.gov/31054033 31054033]|[https://pubmed.ncbi.nlm.nih.gov/15229399 15229399]|[https://pubmed.ncbi.nlm.nih.gov/29061785 29061785]|[https://pubmed.ncbi.nlm.nih.gov/16033070 16033070]|[https://pubmed.ncbi.nlm.nih.gov/10728707 10728707]|[https://pubmed.ncbi.nlm.nih.gov/9556613 9556613]|[https://pubmed.ncbi.nlm.nih.gov/8940172 8940172]|[https://pubmed.ncbi.nlm.nih.gov/9298692 9298692]|[https://pubmed.ncbi.nlm.nih.gov/18607721 18607721]|[https://pubmed.ncbi.nlm.nih.gov/22593503 22593503]|[https://pubmed.ncbi.nlm.nih.gov/25944902 25944902]| [https://pubmed.ncbi.nlm.nih.gov/9642161 9642161]|[https://pubmed.ncbi.nlm.nih.gov/15780091 15780091]|[https://pubmed.ncbi.nlm.nih.gov/20401888 20401888] <br>
  '''definition''' : <br>
  '''definition''' : A sialylated version of Lewis X antigen expressed on cell surfaces with structure alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAcis α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-[α-L-Fucp-(1→3)]-D-GlcpNAc in which the anomeric configuration of the reducing-end N-acetyl-beta-D-glucosamine residue is beta. It is a ligand for selectins. [MESH:2030970],CHEI:71622 <br>
  '''term_xref''' : <br>
  '''term_xref''' : GTC:G00054MO |GlycoEpitope:EP0012|CID: 44456859|CHEBI:71622|MESH:2030970|GlycoMotif:GGM.000022 <br>
  '''synonyms''' : alpha-GalCer|alpha-GalCers|α-GalCer <br>
  '''synonyms''' : SLe(x)|SLe^x|SLex|Slex <br>
  '''function''' : <br>
  '''function''' : Sialyl Lex was shown to be a specific ligand on human leukocytes for vascular E- and P-selectins,and was shown to mediate leukocyte recruitment.[GlycoEpitope:EP0012]|The determinant is also frequently expressed on human cancer cells,and is involved in the adhesion of cancer cells to vascular endothelium and thus contribute to hematogenous metastasis of cancer.[GlycoEpitope:EP0012] <br>
  '''disease_associations''' : <br>
  '''disease_associations''' : colon cancer[GlycoEpitope:EP0012]|colorectal cancer[GlycoEpitope:EP0012] <br>
  '''wikipedia''' :  <br>
  '''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' :  <br>
  '''essentials_of_glycobiology''' :  <br>




===Sialyl Lewis x-i===
===GSD000018===
[[File:G06597DS.png|thumb|G06597DS]]
  '''term (main_entry)''' : Asialo-biantennary <br>
  '''term (main_entry)''' : Sialyl Lewis x-i <br>
  '''glycan_dictionary_accession''' : GSD000018 <br>
  '''glycan_dictionary_accession''' : GSD000152 <br>
  '''glytoucan_accession ''' : <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G06597DS G06597DS] <br>
  '''term_in_sentence''' : Typical crystallizable fragment (Fc) glycans attached to the CH2 domain in therapeutic monoclonal antibodies (mAbs) are core-fucosylated and asialo-biantennary complex-type glycans, e.g., G2F (full galactosylation), G1aF (terminal galactosylation on the Man α1-6 arm), G1bF (terminal galactosylation on the Man α1-3 arm), and G0F (non-galactosylation).[PMID:[https://pubmed.ncbi.nlm.nih.gov/30990348 30990348]] <br>
  '''term_in_sentence''' : Univariate analysis showed that survival of NSCLC patients with high (more than 100 units/ml) sialyl Lewis X-i antigen levels was significantly poorer than that of patients with low antigen levels (P = 0.0001).[PMID:[https://pubmed.ncbi.nlm.nih.gov/9815711 9815711]] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30990348 30990348]|[https://pubmed.ncbi.nlm.nih.gov/17645671 17645671]|[https://pubmed.ncbi.nlm.nih.gov/20959391 20959391]|[https://pubmed.ncbi.nlm.nih.gov/18615430 18615430]|[https://pubmed.ncbi.nlm.nih.gov/16945378 16945378]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2065054 2065054] [https://pubmed.ncbi.nlm.nih.gov/2065054 2065054]]|[https://pubmed.ncbi.nlm.nih.gov/3084472 3084472]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2386787 2386787] [https://pubmed.ncbi.nlm.nih.gov/2386787 2386787]] [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2386787 2386787] [https://pubmed.ncbi.nlm.nih.gov/2386787 2386787]]]|[https://pubmed.ncbi.nlm.nih.gov/22911097 22911097]|[https://pubmed.ncbi.nlm.nih.gov/24692304 24692304]|[https://pubmed.ncbi.nlm.nih.gov/17013932 17013932]|[https://pubmed.ncbi.nlm.nih.gov/7513972 7513972]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/6626573 6626573] [https://pubmed.ncbi.nlm.nih.gov/6626573 6626573]]|[https://pubmed.ncbi.nlm.nih.gov/10835250 10835250]|[https://pubmed.ncbi.nlm.nih.gov/9684342 9684342] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9815711 9815711]|[https://pubmed.ncbi.nlm.nih.gov/9730796 9730796]|[https://pubmed.ncbi.nlm.nih.gov/11867833 11867833]|[https://pubmed.ncbi.nlm.nih.gov/9713476 9713476]|[https://pubmed.ncbi.nlm.nih.gov/2819663 2819663]|[https://pubmed.ncbi.nlm.nih.gov/9372327 9372327]|[https://pubmed.ncbi.nlm.nih.gov/9615762 9615762]|[https://pubmed.ncbi.nlm.nih.gov/1352835 1352835]|[https://pubmed.ncbi.nlm.nih.gov/2575680 2575680]|[https://pubmed.ncbi.nlm.nih.gov/9330526 9330526]|[https://pubmed.ncbi.nlm.nih.gov/8753037 8753037]|[https://pubmed.ncbi.nlm.nih.gov/2210805 2210805]|[https://pubmed.ncbi.nlm.nih.gov/12680155 12680155]|[https://pubmed.ncbi.nlm.nih.gov/11974864 11974864]|[https://pubmed.ncbi.nlm.nih.gov/10453898 10453898]|[https://pubmed.ncbi.nlm.nih.gov/2565704 2565704]|[https://pubmed.ncbi.nlm.nih.gov/17144590 17144590] <br>
  '''definition''' :  <br>
  '''definition''' :  <br>
  '''term_xref''' : GTC:G06597DS|GlycoEpitope:EP0043|CID: 91855346|CHEBI:147019 <br>
  '''term_xref''' : <br>
  '''synonyms''' : <br>
  '''synonyms''' : asialo diantennary <br>
  '''function''' : hematogenous metastasis[GlycoEpitope:EP0043]|the progression of inflammation[GlycoEpitope:EP0043] <br>
  '''function''' : <br>
  '''disease_associations''' : lung cancer[GlycoEpitope:EP0043]|ovarian cancer[GlycoEpitope:EP0043]|pancreatic adenocarcinoma[GlycoEpitope:EP0043] <br>
  '''disease_associations''' : <br>
  '''wikipedia''' :  <br>
  '''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' :  <br>
  '''essentials_of_glycobiology''' :  <br>




===Sialyl T antigen===
===GSD000019===
[[File:G65562ZE.png|thumb|G65562ZE]]
[[File:G21856LC.png|thumb|G21856LC]]
  '''term (main_entry)''' : Sialyl T antigen <br>
  '''term (main_entry)''' : Asialo-GM1 <br>
  '''glycan_dictionary_accession''' : GSD000153 <br>
  '''glycan_dictionary_accession''' : GSD000019 <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G65562ZE G65562ZE] <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G21856LC G21856LC] <br>
  '''term_in_sentence''' : The expression and functional analysis of the sialyl-T antigen in prostate cancer.[PMID:[https://pubmed.ncbi.nlm.nih.gov/32583304 32583304]] <br>
  '''term_in_sentence''' : We compared the lateral structure of giant unilamellar vesicles (GUVs) composed of three pseudo binary mixtures of different glycosphingolipid (GSL), i.e. sulfatide, asialo-GM1 or GM1, with POPC.[PMID:[https://pubmed.ncbi.nlm.nih.gov/29106974 29106974]] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/32583304 32583304]|[https://pubmed.ncbi.nlm.nih.gov/31897478 31897478]|[https://pubmed.ncbi.nlm.nih.gov/31719620 31719620]| [https://pubmed.ncbi.nlm.nih.gov/10365852 10365852]|[https://pubmed.ncbi.nlm.nih.gov/25727149 25727149]|[https://pubmed.ncbi.nlm.nih.gov/11523928 11523928]|[https://pubmed.ncbi.nlm.nih.gov/20407596 20407596]|[https://pubmed.ncbi.nlm.nih.gov/25464017 25464017]|[https://pubmed.ncbi.nlm.nih.gov/30864133 30864133]|[https://pubmed.ncbi.nlm.nih.gov/26391208 26391208]|[https://pubmed.ncbi.nlm.nih.gov/19811634 19811634]|[https://pubmed.ncbi.nlm.nih.gov/29796594 29796594]|[https://pubmed.ncbi.nlm.nih.gov/23725156 23725156]|[https://pubmed.ncbi.nlm.nih.gov/8905873 8905873]|[https://pubmed.ncbi.nlm.nih.gov/11192238 11192238]|[https://pubmed.ncbi.nlm.nih.gov/18275089 18275089]|[https://pubmed.ncbi.nlm.nih.gov/27037304 27037304]|[https://pubmed.ncbi.nlm.nih.gov/11949946 11949946]|[https://pubmed.ncbi.nlm.nih.gov/15604091 15604091]|[https://pubmed.ncbi.nlm.nih.gov/24118321 24118321] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29106974 29106974]|[https://pubmed.ncbi.nlm.nih.gov/3418980 3418980]|[https://pubmed.ncbi.nlm.nih.gov/26975993 26975993]|[https://pubmed.ncbi.nlm.nih.gov/8613364 8613364]|[https://pubmed.ncbi.nlm.nih.gov/9288228 9288228]|[https://pubmed.ncbi.nlm.nih.gov/26710925 26710925]|[https://pubmed.ncbi.nlm.nih.gov/24922516 24922516]|[https://pubmed.ncbi.nlm.nih.gov/6839313 6839313]|[https://pubmed.ncbi.nlm.nih.gov/1828259 1828259]|[https://pubmed.ncbi.nlm.nih.gov/2581667 2581667]|[https://pubmed.ncbi.nlm.nih.gov/8210226 8210226]|[https://pubmed.ncbi.nlm.nih.gov/25062498 25062498]|[https://pubmed.ncbi.nlm.nih.gov/9671150 9671150]|[https://pubmed.ncbi.nlm.nih.gov/10377092 10377092]|[https://pubmed.ncbi.nlm.nih.gov/6171919 6171919]|[https://pubmed.ncbi.nlm.nih.gov/3093429 3093429]|[https://pubmed.ncbi.nlm.nih.gov/6652964 6652964]|[https://pubmed.ncbi.nlm.nih.gov/3124753 3124753]|[https://pubmed.ncbi.nlm.nih.gov/8905612 8905612]|[https://pubmed.ncbi.nlm.nih.gov/18788941 18788941]|[https://pubmed.ncbi.nlm.nih.gov/1467432 1467432]|[https://pubmed.ncbi.nlm.nih.gov/8225593 8225593]|[https://pubmed.ncbi.nlm.nih.gov/2083955 2083955]|[https://pubmed.ncbi.nlm.nih.gov/6171918 6171918]|[https://pubmed.ncbi.nlm.nih.gov/7806377 7806377]|[https://pubmed.ncbi.nlm.nih.gov/1802483 1802483]|[https://pubmed.ncbi.nlm.nih.gov/7927723 7927723]|[https://pubmed.ncbi.nlm.nih.gov/9209156 9209156]|[https://pubmed.ncbi.nlm.nih.gov/21174147 21174147]|[https://pubmed.ncbi.nlm.nih.gov/2584393 2584393]|[https://pubmed.ncbi.nlm.nih.gov/12137200 12137200]|[https://pubmed.ncbi.nlm.nih.gov/6175621 6175621]|[https://pubmed.ncbi.nlm.nih.gov/2936802 2936802]|[https://pubmed.ncbi.nlm.nih.gov/8610366 8610366]|[https://pubmed.ncbi.nlm.nih.gov/21490162 21490162]|[https://pubmed.ncbi.nlm.nih.gov/1548508 1548508]|[https://pubmed.ncbi.nlm.nih.gov/3486908 3486908]|[https://pubmed.ncbi.nlm.nih.gov/26453755 26453755]|[https://pubmed.ncbi.nlm.nih.gov/7910939 7910939]|[https://pubmed.ncbi.nlm.nih.gov/3756909 3756909]|[https://pubmed.ncbi.nlm.nih.gov/1639356 1639356]|[https://pubmed.ncbi.nlm.nih.gov/3259967 3259967]|[https://pubmed.ncbi.nlm.nih.gov/2443562 2443562]|[https://pubmed.ncbi.nlm.nih.gov/3112077 3112077]|[https://pubmed.ncbi.nlm.nih.gov/2572647 2572647]|[https://pubmed.ncbi.nlm.nih.gov/25137483 25137483]|[https://pubmed.ncbi.nlm.nih.gov/2168971 2168971]|[https://pubmed.ncbi.nlm.nih.gov/6950172 6950172] <br>
  '''definition''' : Alpha-Neup5Ac-(2→3)-beta-D-Galp-(1→3)-alpha-D-GalpNAc is alpha-Neup5Ac-(2→3)-beta-D-Galp-(1→3)-D-GalpNAc in which the configuration at the GalNAc anomeric carbon is alpha. It has a role as an epitope.[CHEBI:65257] <br>
  '''definition''' : <br>
  '''term_xref''' : GlycoMotif:GGM.000013|GTC:G65562ZE|CID:44611726|CHEBI:65257 <br>
  '''term_xref''' : GlycoMotif:GGM.000099|GTC:G21856LC|CID:[https://pubmed.ncbi.nlm.nih.gov/10169040 10169040]|GlycoEpitope:EP0047|CHEBI:59216 <br>
  '''synonyms''' : <br>
  '''synonyms''' : as-GM1|GA-1|Gangliotetraosylceramide|GgO4|Gg4|Asialo-GM1a|ganglio-N-tetraosylceramide <br>
  '''function''' :  <br>
  '''function''' :  <br>
  '''disease_associations''' : <br>
  '''disease_associations''' : Pleuropneumonia[SugarBind_Ligand:2]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:2]|Actinomycosis[SugarBind_Ligand:2]|Lazy leukocyte syndrome[SugarBind_Ligand:2]|Pertussis[SugarBind_Ligand:2]|Cutaneous lesions[SugarBind_Ligand:2]|Melioidosis[SugarBind_Ligand:2]|Candidiasis[SugarBind_Ligand:2]|Taiwan acute respiratory agent[SugarBind_Ligand:2]|Trachoma[SugarBind_Ligand:2]|Cystitis[SugarBind_Ligand:2]|Chronic gastritis[SugarBind_Ligand:2]|Peptic ulcers[SugarBind_Ligand:2]|Gastric cancer[SugarBind_Ligand:2]|Klebsiella pneumonia infection[SugarBind_Ligand:2]|Pneumonia[SugarBind_Ligand:2]|Legionnaires' disease[SugarBind_Ligand:2]|Gonorrhea[SugarBind_Ligand:2]|Gastroenteritis[SugarBind_Ligand:2]|Toxoplasmosis[SugarBind_Ligand:2]|Plague[SugarBind_Ligand:2]|Diarrhea[SugarBind_Ligand:2] <br>
  '''wikipedia''' :  <br>
  '''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' :  <br>
  '''essentials_of_glycobiology''' :  <br>




===Sialylated biantennary===
===GSD000020===
  '''term (main_entry)''' : Sialylated biantennary <br>
  '''term (main_entry)''' : B-GD1B <br>
  '''glycan_dictionary_accession''' : GSD000154 <br>
  '''glycan_dictionary_accession''' : GSD000020 <br>
  '''glytoucan_accession ''' : <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G72557NR G72557NR] <br>
  '''term_in_sentence''' : Simbucus nigra agglutinin or an antibody specific to sialylated lactosamine with a preference for Neu5Acalpha2-6Gal rather than Neu5Acalpha2-3Gal reduced sperm binding to oviduct isthmic cells, as did occupying putative receptors on sperm with sialylated biantennary glycans.[PMID:[https://pubmed.ncbi.nlm.nih.gov/23115267 23115267]] <br>
  '''term_in_sentence''' : The Molecular Modelling and 10 ns MD simulation of Botulinum Neuro Toxin/B-GD1A and BoNT/B-GD1B complex revealed that this toxin can interact with GD1A in the single binding mode and with GD1B in two binding modes.[PMID:[https://pubmed.ncbi.nlm.nih.gov/22929125 22929125]] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/23115267 23115267]|[https://pubmed.ncbi.nlm.nih.gov/31510952 31510952]|[https://pubmed.ncbi.nlm.nih.gov/29265394 29265394]|[https://pubmed.ncbi.nlm.nih.gov/31589880 31589880]|[https://pubmed.ncbi.nlm.nih.gov/3979568 3979568]|[https://pubmed.ncbi.nlm.nih.gov/26045275 26045275]|[https://pubmed.ncbi.nlm.nih.gov/29029079 29029079]|[https://pubmed.ncbi.nlm.nih.gov/30252064 30252064] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27956354 27956354]|[https://pubmed.ncbi.nlm.nih.gov/22929125 22929125] <br>
'''definition''' : A binantennary glycan with one or two sialic acid residues as non-reducing terminal residues on one or both antennae. [RN] <br>
'''definition''' :  <br>
'''term_xref''' :  <br>
'''term_xref''' : GlycoMotif:GGM.000104|GTC:G72557NR|CID:[https://pubmed.ncbi.nlm.nih.gov/91847819 91847819]|KEGG:G01803|CHEBI:153361 <br>
  '''synonyms''' : sialyl biantennary <br>
  '''synonyms''' : B-GD1b <br>
  '''function''' :  <br>
  '''function''' :  <br>
  '''disease_associations''' :  <br>
  '''disease_associations''' :  <br>
Line 533: Line 562:




===Sialylated complex-type===
===GSD000021===
  '''term (main_entry)''' : Sialylated complex-type <br>
  '''term (main_entry)''' : B-GM1 <br>
  '''glycan_dictionary_accession''' : GSD000155 <br>
  '''glycan_dictionary_accession''' : GSD000021 <br>
  '''glytoucan_accession ''' : <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G11485ID G11485ID] <br>
  '''term_in_sentence''' : By using 1H-NMR spectroscopy we were able to establish that our product contains a single N-linked biantennary , fully sialylated complex-type oligosaccharide , typical of human hepatomas.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1694115 1694115]] <br>
  '''term_in_sentence''' : The contribution of GM3 and GD3, which accounted for 95% of the ganglioside sialic acid at birth, decreased during the first 3 weeks of life. GM1, fucosyl-GM1, and B-GM1 were not detected at birth. [PMID: [https://pubmed.ncbi.nlm.nih.gov/3680254 3680254]] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1694115 1694115]|[https://pubmed.ncbi.nlm.nih.gov/15201278 15201278]|[https://pubmed.ncbi.nlm.nih.gov/30471292 30471292]|[https://pubmed.ncbi.nlm.nih.gov/30969765 30969765]|[https://pubmed.ncbi.nlm.nih.gov/11058758 11058758]|[https://pubmed.ncbi.nlm.nih.gov/28342150 28342150] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3680254 3680254] <br>
  '''definition''' : Complex N-linked glycan that have added GlcNAc residues at both the α-3 and α-6 mannose sites and do not contain mannose residues apart from the core structure but with sialic acid residues. <br>
  '''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-5-hydroxy-4-[(2R,3R,4S,5S,6R)-5-hydroxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of neuraminic acids.[CHEBI:147588] <br>
  '''term_xref''' : <br>
  '''term_xref''' : GlycoMotif:GGM.000102|GTC:G11485ID|CID:[https://pubmed.ncbi.nlm.nih.gov/91853157 91853157]|CHEBI:147588|SugarBind_Ligand:181 <br>
  '''synonyms''' : sialo-complex type <br>
  '''synonyms''' : <br>
  '''function''' : enhance the signaling activity of soluble intercellular adhesion molecule-1 in mouse astrocytes [PMID: [https://pubmed.ncbi.nlm.nih.gov/15201278 15201278]] Appears in IgG-Fc.[PMID:[https://pubmed.ncbi.nlm.nih.gov/20647032 20647032] ] <br>
  '''function''' : <br>
  '''disease_associations''' : <br>
  '''disease_associations''' : Cholera[SugarBind_Ligand:181] <br>
  '''wikipedia''' :  <br>
  '''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453030/ Chapter 10]<br>
  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453032/ Chapter 37]<br>




===Sialylated LacdiNAc===
===GSD000022===
[[File:G55583HW.png|thumb|G55583HW]]
  '''term (main_entry)''' : Biantennary <br>
  '''term (main_entry)''' : Sialylated LacdiNAc<br>
  '''glycan_dictionary_accession''' : GSD000022 <br>
  '''glycan_dictionary_accession''' : GSD000192<br>
  '''glytoucan_accession ''' : <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G55583HW G55583HW] <br>
  '''term_in_sentence''' : We found an efficient isopropylidenation reaction that selectively protects the terminal Gal-3,4-OH of a biantennary complex-type nonasaccharide isolated from a natural source.[PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/29249147 29249147] [https://pubmed.ncbi.nlm.nih.gov/29249147 29249147]]] <br>
  '''term_in_sentence''' : The major non-reducing epitopes in the complex-type glycans are: Gal beta 1-4GlcNAc (lacNAc), GalNAc beta 1-4GlcNAc (lacdiNAc), NeuAc alpha 2-6Gal beta 1-4GlcNAc (sialylated lacNAc), NeuAc alpha 2-6Gal beta 1-4GlcNAc (sialylated lacdiNAc), Gal beta 1-4(Fuc alpha 1-3)GlcNAc (Lewisx), and GalNAc beta 1-4(Fuc alpha 1-3)GlcNAc (lacdiNAc analogue of Lewisx).[PMID:7592613]<br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/29249147 29249147] [https://pubmed.ncbi.nlm.nih.gov/29249147 29249147]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/24991291 24991291] [https://pubmed.ncbi.nlm.nih.gov/24991291 24991291]]|[https://pubmed.ncbi.nlm.nih.gov/29409839 29409839]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/30325416 30325416] [https://pubmed.ncbi.nlm.nih.gov/30325416 30325416]]|[https://pubmed.ncbi.nlm.nih.gov/18083109 18083109]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/26926155 26926155] [https://pubmed.ncbi.nlm.nih.gov/26926155 26926155]]|[https://pubmed.ncbi.nlm.nih.gov/16715395 16715395]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/12634321 12634321] [https://pubmed.ncbi.nlm.nih.gov/12634321 12634321]]|[https://pubmed.ncbi.nlm.nih.gov/24211369 24211369]|[https://pubmed.ncbi.nlm.nih.gov/23115267 23115267]|[https://pubmed.ncbi.nlm.nih.gov/31907993 31907993]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/23360551 23360551] [https://pubmed.ncbi.nlm.nih.gov/23360551 23360551]]|[https://pubmed.ncbi.nlm.nih.gov/20861009 20861009]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/33142198 33142198] [https://pubmed.ncbi.nlm.nih.gov/33142198 33142198]]|[https://pubmed.ncbi.nlm.nih.gov/11442281 11442281]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/18687680 18687680] [https://pubmed.ncbi.nlm.nih.gov/18687680 18687680]]|[https://pubmed.ncbi.nlm.nih.gov/15680603 15680603]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/31888963 31888963] [https://pubmed.ncbi.nlm.nih.gov/31888963 31888963]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/14686925 14686925] [https://pubmed.ncbi.nlm.nih.gov/14686925 14686925]] [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/14686925 14686925] [https://pubmed.ncbi.nlm.nih.gov/14686925 14686925]]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/15819890 15819890] [https://pubmed.ncbi.nlm.nih.gov/15819890 15819890]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/22530754 22530754] [https://pubmed.ncbi.nlm.nih.gov/22530754 22530754]] [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/22530754 22530754] [https://pubmed.ncbi.nlm.nih.gov/22530754 22530754]]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/22098756 22098756] [https://pubmed.ncbi.nlm.nih.gov/22098756 22098756]]|[https://pubmed.ncbi.nlm.nih.gov/9346821 9346821]|[https://pubmed.ncbi.nlm.nih.gov/19341309 19341309]|[https://pubmed.ncbi.nlm.nih.gov/18529007 18529007]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/20580347 20580347] [https://pubmed.ncbi.nlm.nih.gov/20580347 20580347]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/11784152 11784152] [https://pubmed.ncbi.nlm.nih.gov/11784152 11784152]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/7773775 7773775] [https://pubmed.ncbi.nlm.nih.gov/7773775 7773775]]|[https://pubmed.ncbi.nlm.nih.gov/10913832 10913832]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/8547276 8547276] [https://pubmed.ncbi.nlm.nih.gov/8547276 8547276]]|[https://pubmed.ncbi.nlm.nih.gov/10463590 10463590]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9404657 9404657] [https://pubmed.ncbi.nlm.nih.gov/9404657 9404657]]|[https://pubmed.ncbi.nlm.nih.gov/30525457 30525457]|[https://pubmed.ncbi.nlm.nih.gov/15316280 15316280]|[https://pubmed.ncbi.nlm.nih.gov/8068637 8068637]|[https://pubmed.ncbi.nlm.nih.gov/3881425 3881425]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/6425277 6425277] [https://pubmed.ncbi.nlm.nih.gov/6425277 6425277]]|[https://pubmed.ncbi.nlm.nih.gov/8576139 8576139]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/29956878 29956878] [https://pubmed.ncbi.nlm.nih.gov/29956878 29956878]]|[https://pubmed.ncbi.nlm.nih.gov/1576211 1576211]|[https://pubmed.ncbi.nlm.nih.gov/11129583 11129583]|[https://pubmed.ncbi.nlm.nih.gov/30421263 30421263]|[https://pubmed.ncbi.nlm.nih.gov/8069634 8069634]|[https://pubmed.ncbi.nlm.nih.gov/30973186 30973186]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/16704415 16704415] [https://pubmed.ncbi.nlm.nih.gov/16704415 16704415]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/21612260 21612260] [https://pubmed.ncbi.nlm.nih.gov/21612260 21612260]]|[https://pubmed.ncbi.nlm.nih.gov/29806066 29806066]|[https://pubmed.ncbi.nlm.nih.gov/29443078 29443078] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/7592613 7592613]|[https://pubmed.ncbi.nlm.nih.gov/34192302 34192302]|[https://pubmed.ncbi.nlm.nih.gov/19756298 19756298]|[https://pubmed.ncbi.nlm.nih.gov/16286643 16286643]<br>
  '''definition''' : Type of N-linked glycan in which two antenna are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). Each antenna can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453019/ Glossary]] <br>
  '''definition''' : <br>
  '''term_xref''' : <br>
  '''term_xref''' : GlycoMotif:GGM.000050<br>
  '''synonyms''' : diantennary <br>
  '''synonyms''' : sialylated-LacdiNAc|Sialylated LDN<br>
  '''function''' :  <br>
  '''function''' :  <br>
  '''disease_associations''' :  <br>
  '''disease_associations''' :  <br>
  '''wikipedia''' :  <br>
  '''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' : <br>
  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453020/ Chapter 9] <br>




===Sialylated tetraantennary===
===GSD000023===
  '''term (main_entry)''' : Sialylated tetraantennary <br>
  '''term (main_entry)''' : Biantennary complex <br>
  '''glycan_dictionary_accession''' : GSD000156 <br>
  '''glycan_dictionary_accession''' : GSD000023 <br>
  '''glytoucan_accession ''' :  <br>
  '''glytoucan_accession ''' :  <br>
  '''term_in_sentence''' : A small amount of sialylated tetraantennary oligosaccharide was detected.[PMID:[https://pubmed.ncbi.nlm.nih.gov/16321355 16321355]] <br>
  '''term_in_sentence''' : The crystal structure of Pterocarpus angolensis lectin is determined in its ligand-free state, in complex with the fucosylated biantennary complex type decasaccharide NA2F, and in complex with a series of smaller oligosaccharide constituents of NA2F.[PMID:[https://pubmed.ncbi.nlm.nih.gov/16704415 16704415]] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/16321355 16321355]|[https://pubmed.ncbi.nlm.nih.gov/1940447 1940447]|[https://pubmed.ncbi.nlm.nih.gov/27501865 27501865] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/16704415 16704415]|[https://pubmed.ncbi.nlm.nih.gov/3731182 3731182]|[https://pubmed.ncbi.nlm.nih.gov/26747427 26747427]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/32597008 32597008] [https://pubmed.ncbi.nlm.nih.gov/32597008 32597008]]|[https://pubmed.ncbi.nlm.nih.gov/6626573 6626573]|[https://pubmed.ncbi.nlm.nih.gov/29249147 29249147]|[https://pubmed.ncbi.nlm.nih.gov/28597152 28597152]|[https://pubmed.ncbi.nlm.nih.gov/25045879 25045879]|[https://pubmed.ncbi.nlm.nih.gov/30325416 30325416]|[https://pubmed.ncbi.nlm.nih.gov/12634321 12634321]|[https://pubmed.ncbi.nlm.nih.gov/31888963 31888963]|[https://pubmed.ncbi.nlm.nih.gov/26926155 26926155]|[https://pubmed.ncbi.nlm.nih.gov/23360551 23360551]|[https://pubmed.ncbi.nlm.nih.gov/33142198 33142198]|[https://pubmed.ncbi.nlm.nih.gov/9404657 9404657]|[https://pubmed.ncbi.nlm.nih.gov/29956878 29956878]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/14686925 14686925] [https://pubmed.ncbi.nlm.nih.gov/14686925 14686925]]|[https://pubmed.ncbi.nlm.nih.gov/18687680 18687680]|[https://pubmed.ncbi.nlm.nih.gov/11784152 11784152]|[https://pubmed.ncbi.nlm.nih.gov/7773775 7773775]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/22530754 22530754] [https://pubmed.ncbi.nlm.nih.gov/22530754 22530754]]|[https://pubmed.ncbi.nlm.nih.gov/20580347 20580347]|[https://pubmed.ncbi.nlm.nih.gov/22098756 22098756]|[https://pubmed.ncbi.nlm.nih.gov/21612260 21612260]|[https://pubmed.ncbi.nlm.nih.gov/6425277 6425277]|[https://pubmed.ncbi.nlm.nih.gov/7691595 7691595]|[https://pubmed.ncbi.nlm.nih.gov/26780731 26780731]|[https://pubmed.ncbi.nlm.nih.gov/16285669 16285669]|[https://pubmed.ncbi.nlm.nih.gov/15819890 15819890]|[https://pubmed.ncbi.nlm.nih.gov/3924097 3924097]|[https://pubmed.ncbi.nlm.nih.gov/30448401 30448401]|[https://pubmed.ncbi.nlm.nih.gov/8547276 8547276]|[https://pubmed.ncbi.nlm.nih.gov/17049014 17049014]|[https://pubmed.ncbi.nlm.nih.gov/29408873 29408873] <br>
  '''definition''' : A tetraantennary glycan with four GlcNAc branches linked to the core and the addition of one sialic acid residues. <br>
  '''definition''' : A complex N-glycan that has two branches attached to the non-reducing terminal Man residues of the trimannosyl core. . Each branch is initiated with a GlcNAc and can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [CHEBI:156251] <br>
  '''term_xref''' : <br>
  '''term_xref''' : CHEBI:156251 <br>
  '''synonyms''' : <br>
  '''synonyms''' : diantennary complex type <br>
  '''function''' :  <br>
  '''function''' :  <br>
  '''disease_associations''' :  <br>
  '''disease_associations''' :  <br>
Line 579: Line 607:




===Sialyl-Tn antigen===
===GSD000024===
[[File:G36123IU.png|thumb|G36123IU]]
  '''term (main_entry)''' : Bisecting GlcNac <br>
  '''term (main_entry)''' : Sialyl-Tn antigen <br>
  '''glycan_dictionary_accession''' : GSD000024 <br>
  '''glycan_dictionary_accession''' : GSD000157 <br>
  '''glytoucan_accession ''' : <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G36123IU G36123IU] <br>
  '''term_in_sentence''' : The presence of a bisecting GlcNAc and the occurrence of alpha 2-6-linked Neu5Ac in the most abundant N-glycans, are new features for hCG-beta.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1374031 1374031]] <br>
  '''term_in_sentence''' : The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-β secretion from monocytes/macrophages through the DAP12-Syk pathway.[PMID:[https://pubmed.ncbi.nlm.nih.gov/23035012 23035012]] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1374031 1374031]|[https://pubmed.ncbi.nlm.nih.gov/29909448 29909448]|[https://pubmed.ncbi.nlm.nih.gov/29274553 29274553]|[https://pubmed.ncbi.nlm.nih.gov/32719771 32719771]|[https://pubmed.ncbi.nlm.nih.gov/22476631 22476631]|[https://pubmed.ncbi.nlm.nih.gov/31375533 31375533]|[https://pubmed.ncbi.nlm.nih.gov/26467158 26467158]|[https://pubmed.ncbi.nlm.nih.gov/27429195 27429195]|[https://pubmed.ncbi.nlm.nih.gov/20816221 20816221]|[https://pubmed.ncbi.nlm.nih.gov/26109616 26109616]|[https://pubmed.ncbi.nlm.nih.gov/30542567 30542567]|[https://pubmed.ncbi.nlm.nih.gov/30144245 30144245]|[https://pubmed.ncbi.nlm.nih.gov/25727145 25727145]|[https://pubmed.ncbi.nlm.nih.gov/29593568 29593568]|[https://pubmed.ncbi.nlm.nih.gov/32612952 32612952]|[https://pubmed.ncbi.nlm.nih.gov/9006930 9006930]|[https://pubmed.ncbi.nlm.nih.gov/19508951 19508951]|[https://pubmed.ncbi.nlm.nih.gov/16000695 16000695]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/32597008 32597008] [https://pubmed.ncbi.nlm.nih.gov/32597008 32597008]]|[https://pubmed.ncbi.nlm.nih.gov/19053837 19053837]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/22530754 22530754] [https://pubmed.ncbi.nlm.nih.gov/22530754 22530754]]|[https://pubmed.ncbi.nlm.nih.gov/30405631 30405631]|[https://pubmed.ncbi.nlm.nih.gov/19940114 19940114]|[https://pubmed.ncbi.nlm.nih.gov/32719549 32719549]|[https://pubmed.ncbi.nlm.nih.gov/9560299 9560299]|[https://pubmed.ncbi.nlm.nih.gov/29655002 29655002]|[https://pubmed.ncbi.nlm.nih.gov/10589784 10589784]|[https://pubmed.ncbi.nlm.nih.gov/29959030 29959030]|[https://pubmed.ncbi.nlm.nih.gov/20661133 20661133]|[https://pubmed.ncbi.nlm.nih.gov/9061364 9061364]|[https://pubmed.ncbi.nlm.nih.gov/31065629 31065629]|[https://pubmed.ncbi.nlm.nih.gov/20395209 20395209]|[https://pubmed.ncbi.nlm.nih.gov/29549127 29549127]|[https://pubmed.ncbi.nlm.nih.gov/30305426 30305426]|[https://pubmed.ncbi.nlm.nih.gov/29632412 29632412]|[https://pubmed.ncbi.nlm.nih.gov/24108122 24108122]|[https://pubmed.ncbi.nlm.nih.gov/24282611 24282611]|[https://pubmed.ncbi.nlm.nih.gov/27821068 27821068]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/14686925 14686925] [https://pubmed.ncbi.nlm.nih.gov/14686925 14686925]]|[https://pubmed.ncbi.nlm.nih.gov/10816579 10816579]|[https://pubmed.ncbi.nlm.nih.gov/25032906 25032906]|[https://pubmed.ncbi.nlm.nih.gov/30025558 30025558]|[https://pubmed.ncbi.nlm.nih.gov/9661906 9661906]|[https://pubmed.ncbi.nlm.nih.gov/8542600 8542600]|[https://pubmed.ncbi.nlm.nih.gov/31585439 31585439]|[https://pubmed.ncbi.nlm.nih.gov/29699572 29699572]|[https://pubmed.ncbi.nlm.nih.gov/27443163 27443163]|[https://pubmed.ncbi.nlm.nih.gov/30315103 30315103]|[https://pubmed.ncbi.nlm.nih.gov/23808883 23808883]|[https://pubmed.ncbi.nlm.nih.gov/18812317 18812317]|[https://pubmed.ncbi.nlm.nih.gov/19776078 19776078] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/23035012 23035012]|[https://pubmed.ncbi.nlm.nih.gov/29273237 29273237]|[https://pubmed.ncbi.nlm.nih.gov/15770530 15770530]|[https://pubmed.ncbi.nlm.nih.gov/31595388 31595388]|[https://pubmed.ncbi.nlm.nih.gov/26617889 26617889]|[https://pubmed.ncbi.nlm.nih.gov/1720922 1720922]|[https://pubmed.ncbi.nlm.nih.gov/15466199 15466199]|[https://pubmed.ncbi.nlm.nih.gov/10971172 10971172]|[https://pubmed.ncbi.nlm.nih.gov/14652017 14652017]|[https://pubmed.ncbi.nlm.nih.gov/8616877 8616877]|[https://pubmed.ncbi.nlm.nih.gov/1543361 1543361]|[https://pubmed.ncbi.nlm.nih.gov/16965854 16965854]|[https://pubmed.ncbi.nlm.nih.gov/21566901 21566901]|[https://pubmed.ncbi.nlm.nih.gov/9269833 9269833]|[https://pubmed.ncbi.nlm.nih.gov/9834267 9834267]|[https://pubmed.ncbi.nlm.nih.gov/24970145 24970145]|[https://pubmed.ncbi.nlm.nih.gov/22367369 22367369]|[https://pubmed.ncbi.nlm.nih.gov/10778170 10778170]|[https://pubmed.ncbi.nlm.nih.gov/30018351 30018351]|[https://pubmed.ncbi.nlm.nih.gov/28628803 28628803]|[https://pubmed.ncbi.nlm.nih.gov/16149605 16149605]|[https://pubmed.ncbi.nlm.nih.gov/32134186 32134186]|[https://pubmed.ncbi.nlm.nih.gov/28632300 28632300]|[https://pubmed.ncbi.nlm.nih.gov/11308020 11308020]| [https://pubmed.ncbi.nlm.nih.gov/10365852 10365852]|[https://pubmed.ncbi.nlm.nih.gov/17195456 17195456]|[https://pubmed.ncbi.nlm.nih.gov/23567325 23567325]|[https://pubmed.ncbi.nlm.nih.gov/11014575 11014575]|[https://pubmed.ncbi.nlm.nih.gov/2342728 2342728]|[https://pubmed.ncbi.nlm.nih.gov/8575847 8575847]|[https://pubmed.ncbi.nlm.nih.gov/1851822 1851822]|[https://pubmed.ncbi.nlm.nih.gov/11735169 11735169]|[https://pubmed.ncbi.nlm.nih.gov/20960853 20960853]|[https://pubmed.ncbi.nlm.nih.gov/7846011 7846011] <br>
  '''definition''' : The bisecting GlcNAc is a modification of hybrid or complex N-linked glycans in which a single GlcNAc is added to the 3 position of the b-linked Man found in the trimannosyl core structure. The modification is catalyzed by beta 1,4-N-acetylglucosaminyltransferase III (GlcNAcT-III) or MGAT3 (E.C. 2.4.1.144). The addition of a bisecting GlcNAc on a hybrid or trimmed hybrid glycan prevents the subsequent action of N-glycan branching glycosyltransferases GlcNAcT-IV and GlcNAcT-V, but GlcNAcT3 can add a bisecting GlcNAc to the products of these enzymes. [PMID: [https://pubmed.ncbi.nlm.nih.gov/22476631 22476631]] <br>
  '''definition''' : N-acetyl-alpha-neuraminyl-(2→6)-N-acetyl-alpha-D-galactosamine is an N-acetyl-alpha-neuraminyl-(2→6)-N-acetyl-D-galactosamine in which the carbon bearing the anomeric hydroxy group has alpha configuration. It has a role as an epitope. It derives from a N-acetyl-alpha-D-galactosamine and a N-acetyl-alpha-neuraminic acid.[CHEBI:61818] <br>
  '''term_xref''' : SID:163312364|KEGG:G13066<br>
  '''term_xref''' : GTC:G36123IU|GlycoEpitope:EP0022|CID:51351800|CHEBI:61818 <br>
  '''synonyms''' :  <br>
  '''synonyms''' :  <br>
  '''function''' : apoptosis of monocyte-derived dendritic cells[GlycoEpitope:EP0022]|decrease of adhesion and increase of migration[GlycoEpitope:EP0022]|increase of tumor growth[GlycoEpitope:EP0022]|associated with morphological changes, decreased growth and increased migration of MDA-MB-231 cells.[GlycoEpitope:EP0022] <br>
  '''function''' : The bisecting GlcNAc of N-glycans regulates cellular signaling and tumor progression through modulating N-glycan/galectin interactions.[PMID: [https://pubmed.ncbi.nlm.nih.gov/22476631 22476631]]Inhibits growth factor signaling and retards mammary tumor progression[PMID: [https://pubmed.ncbi.nlm.nih.gov/20395209 20395209]]Integrin-mediated cell adhesion [PMID: [https://pubmed.ncbi.nlm.nih.gov/20816221 20816221]]Important in fertilization and fetal development, neuritogenesis, immune tolerance, immunoglobulin G (IgG)[PMID: [https://pubmed.ncbi.nlm.nih.gov/32719771 32719771]] <br>
'''disease_associations''' : anaplastic meningioma[GlycoEpitope:EP0022]|Barrett's esophagus[GlycoEpitope:EP0022]|bladder cancer[GlycoEpitope:EP0022]|breast cancer[GlycoEpitope:EP0022]|colon cancer[GlycoEpitope:EP0022]|colorectal cancer[GlycoEpitope:EP0022]|erythroblastic leukemia[GlycoEpitope:EP0022]|esophageal cancer[GlycoEpitope:EP0022]|gastric cancer[GlycoEpitope:EP0022]|helicobacter pylori chronic gastritis(HpCG)[GlycoEpitope:EP0022]|liver cancer[GlycoEpitope:EP0022]|iterome cancer[GlycoEpitope:EP0022]|ovary tumor[GlycoEpitope:EP0022]|pancreas cancer[GlycoEpitope:EP0022] <br>
'''disease_associations''' : mammary tumor.[PMID: [https://pubmed.ncbi.nlm.nih.gov/20395209 20395209]] <br>
  '''wikipedia''' :  <br>
  '''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453027/ Chapter 56]<br>
  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453020/ Chapter 9]<br>




===SLex Core 2 O-glycan===
===GSD000025===
  '''term (main_entry)''' : SLex Core 2 O-glycan <br>
  '''term (main_entry)''' : Bisialo-biantennary <br>
  '''glycan_dictionary_accession''' : GSD000158 <br>
  '''glycan_dictionary_accession''' : GSD000025 <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G97345NY G97345NY] <br>
  '''glytoucan_accession ''' : <br>
  '''term_in_sentence''' : In particular, the sLeX-modified core 2 O-glycan structure C2-O-sLeX has been directly demonstrated to confer significantly higher affinity selectin binding than sLeX.[PMID:[https://pubmed.ncbi.nlm.nih.gov/15596301 15596301]] <br>
  '''term_in_sentence''' : Using anion-exchange liquid chromatography mapping of the oligosaccharide units cleaved from the proteins by glycopeptidase F, compared with elution positions of standard oligosaccharide structures, coupled with monosaccharide compositional analysis, we find that the human plasma protein contained only bisialo-biantennary complex-type carbohydrate and asialo-biantennary complex carbohydrate, confirming earlier work published by this laboratory. <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/15596301 15596301] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2386787 2386787] [https://pubmed.ncbi.nlm.nih.gov/2386787 2386787]]|[https://pubmed.ncbi.nlm.nih.gov/2065054 2065054] <br>
  '''definition''' : <br>
  '''definition''' : A binantennary glycan with sialic acid residues as non-reducing terminal residues on both antennae. <br>
  '''term_xref''' : GlycoMotif:GGM.000053|GTC:G97345NY <br>
  '''term_xref''' : <br>
  '''synonyms''' : SLe^x Core 2 O-glycan <br>
  '''synonyms''' : disialo biantennary|disialo diantennary|disialylated biantennary|disialylated diantennary <br>
  '''function''' :  <br>
  '''function''' :  <br>
  '''disease_associations''' :  <br>
  '''disease_associations''' :  <br>
Line 610: Line 637:




===SSEA-1===
===GSD000026===
[[File:G85497PI.png|thumb|G85497PI]]
  '''term (main_entry)''' : Bisialo-biantennary complex-type <br>
  '''term (main_entry)''' : SSEA-1 <br>
  '''glycan_dictionary_accession''' : GSD000026 <br>
  '''glycan_dictionary_accession''' : GSD000159 <br>
  '''glytoucan_accession ''' : <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G85497PI G85497PI] <br>
  '''term_in_sentence''' : Using anion-exchange liquid chromatography mapping of the oligosaccharide units cleaved from the proteins by glycopeptidase F , compared with elution positions of standard oligosaccharide structures , coupled with monosaccharide compositional analysis, we find that the human plasma protein contained only bisialo-biantennary complex-type carbohydrate and asialo-biantennary complex carbohydrate , confirming earlier work published by this laboratory.[PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2386787 2386787] [https://pubmed.ncbi.nlm.nih.gov/2386787 2386787]]] <br>
  '''term_in_sentence''' : Our findings suggest that expression of SSEA-1 immunoreactivity in thyroid neoplasms was associated with more aggressive thyroid carcinomas.[PMID:[https://pubmed.ncbi.nlm.nih.gov/27550342 27550342]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2386787 2386787] [https://pubmed.ncbi.nlm.nih.gov/2386787 2386787]]|[https://pubmed.ncbi.nlm.nih.gov/26966183 26966183] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27550342 27550342]|[https://pubmed.ncbi.nlm.nih.gov/25564944 25564944]|[https://pubmed.ncbi.nlm.nih.gov/30987116 30987116]|[https://pubmed.ncbi.nlm.nih.gov/10778174 10778174]|[https://pubmed.ncbi.nlm.nih.gov/19427293 19427293]|[https://pubmed.ncbi.nlm.nih.gov/24923741 24923741]|[https://pubmed.ncbi.nlm.nih.gov/28092949 28092949]|[https://pubmed.ncbi.nlm.nih.gov/16499901 16499901]|[https://pubmed.ncbi.nlm.nih.gov/10470652 10470652]|[https://pubmed.ncbi.nlm.nih.gov/18787210 18787210]|[https://pubmed.ncbi.nlm.nih.gov/2885312 2885312]|[https://pubmed.ncbi.nlm.nih.gov/16149609 16149609]|[https://pubmed.ncbi.nlm.nih.gov/17003364 17003364]|[https://pubmed.ncbi.nlm.nih.gov/27363517 27363517]|[https://pubmed.ncbi.nlm.nih.gov/15505339 15505339]|[https://pubmed.ncbi.nlm.nih.gov/27990704 27990704]|[https://pubmed.ncbi.nlm.nih.gov/2568298 2568298]|[https://pubmed.ncbi.nlm.nih.gov/20491542 20491542]|[https://pubmed.ncbi.nlm.nih.gov/23572256 23572256]|[https://pubmed.ncbi.nlm.nih.gov/1977666 1977666]|[https://pubmed.ncbi.nlm.nih.gov/9553168 9553168]|[https://pubmed.ncbi.nlm.nih.gov/20458727 20458727]|[https://pubmed.ncbi.nlm.nih.gov/2566639 2566639]|[https://pubmed.ncbi.nlm.nih.gov/14577357 14577357]|[https://pubmed.ncbi.nlm.nih.gov/20960856 20960856]|[https://pubmed.ncbi.nlm.nih.gov/15547746 15547746]|[https://pubmed.ncbi.nlm.nih.gov/9096265 9096265]|[https://pubmed.ncbi.nlm.nih.gov/30639212 30639212]|[https://pubmed.ncbi.nlm.nih.gov/1357195 1357195]|[https://pubmed.ncbi.nlm.nih.gov/1359630 1359630]|[https://pubmed.ncbi.nlm.nih.gov/20181261 20181261]|[https://pubmed.ncbi.nlm.nih.gov/20508065 20508065]|[https://pubmed.ncbi.nlm.nih.gov/2907526 2907526]|[https://pubmed.ncbi.nlm.nih.gov/22624699 22624699]|[https://pubmed.ncbi.nlm.nih.gov/22988836 22988836]|[https://pubmed.ncbi.nlm.nih.gov/17183690 17183690]|[https://pubmed.ncbi.nlm.nih.gov/27188587 27188587]|[https://pubmed.ncbi.nlm.nih.gov/7908065 7908065]|[https://pubmed.ncbi.nlm.nih.gov/10400391 10400391]|[https://pubmed.ncbi.nlm.nih.gov/6137429 6137429]|[https://pubmed.ncbi.nlm.nih.gov/1979260 1979260]|[https://pubmed.ncbi.nlm.nih.gov/2898921 2898921]|[https://pubmed.ncbi.nlm.nih.gov/14736812 14736812]|[https://pubmed.ncbi.nlm.nih.gov/30919971 30919971] <br>
  '''definition''' : A binantennary glycan with sialic acid residues as non-reducing terminal residues on both antennae. <br>
  '''definition''' :  <br>
  '''term_xref''' :  <br>
  '''term_xref''' : GTC:G85497PI |GlycoEpitope:EP0042|CID:91851144|CHEBI:154343 <br>
  '''synonyms''' : Fully sialylated biantennary N-glycan <br>
  '''synonyms''' : <br>
  '''function''' : <br>
  '''function''' : This determinant is specifically recognized by the antibody raised against stage-specific embryonic antigen-1 (SSEA-1)[GlycoEpitope:EP0042]. The SSEA-1 antibody requires Lex hapten carried by i-antigenic structure (e.g.,nor-nLc6Cer).[GlycoEpitope:EP0042] <br>
  '''disease_associations''' :  <br>
  '''disease_associations''' :  <br>
  '''wikipedia''' :  <br>
  '''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453030/ Chapter 10]<br>
  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453089/ Chapter 25]<br>




===SSEA-3===
===GSD000027===
[[File:G25129BT.png|thumb|G25129BT]]
  '''term (main_entry)''' : Blood group A (Type 2) - Lewis y <br>
  '''term (main_entry)''' : SSEA-3 <br>
  '''glycan_dictionary_accession''' : GSD000027 <br>
  '''glycan_dictionary_accession''' : GSD000160 <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G54826OZ G54826OZ] <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G25129BT G25129BT] <br>
  '''term_in_sentence''' : Monoclonal antibodies defining blood group A variants with difucosyl type 1 chain (ALeb) and difucosyl type 2 chain (ALey).[PMID:[https://pubmed.ncbi.nlm.nih.gov/2417620 2417620]] <br>
  '''term_in_sentence''' : Glycosphingolipids (GSLs), such as the globo-series GSLs stage-specific embryonic antigen 3 (SSEA-3), SSEA-4, and Globo-H, are specifically expressed on pluripotent stem cells and cancer cells, and are known to be associated with various biological processes such as cell recognition, cell adhesion, and signal transduction.[PMID: [https://pubmed.ncbi.nlm.nih.gov/31817926 31817926]] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2417620 2417620] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31817926 31817926]|[https://pubmed.ncbi.nlm.nih.gov/30271856 30271856]|[https://pubmed.ncbi.nlm.nih.gov/32684574 32684574]|[https://pubmed.ncbi.nlm.nih.gov/26677875 26677875]|[https://pubmed.ncbi.nlm.nih.gov/23175153 23175153]|[https://pubmed.ncbi.nlm.nih.gov/32525407 32525407]| [https://pubmed.ncbi.nlm.nih.gov/29227830 29227830]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/18773292 18773292] [https://pubmed.ncbi.nlm.nih.gov/18773292 18773292]]|[https://pubmed.ncbi.nlm.nih.gov/25561682 25561682]|[https://pubmed.ncbi.nlm.nih.gov/10837462 10837462]|[https://pubmed.ncbi.nlm.nih.gov/2412924 2412924]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/21149348 21149348] [https://pubmed.ncbi.nlm.nih.gov/21149348 21149348]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/17008424 17008424] [https://pubmed.ncbi.nlm.nih.gov/17008424 17008424]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2874662 2874662] [https://pubmed.ncbi.nlm.nih.gov/2874662 2874662]]|[https://pubmed.ncbi.nlm.nih.gov/25171543 25171543]|[https://pubmed.ncbi.nlm.nih.gov/31304790 31304790]|[https://pubmed.ncbi.nlm.nih.gov/31642560 31642560]|[https://pubmed.ncbi.nlm.nih.gov/30484221 30484221]|[https://pubmed.ncbi.nlm.nih.gov/30525067 30525067]|[https://pubmed.ncbi.nlm.nih.gov/21161592 21161592]|[https://pubmed.ncbi.nlm.nih.gov/27325407 27325407]|[https://pubmed.ncbi.nlm.nih.gov/28170296 28170296]|[https://pubmed.ncbi.nlm.nih.gov/29637816 29637816]| [https://pubmed.ncbi.nlm.nih.gov/27318475 27318475]|[https://pubmed.ncbi.nlm.nih.gov/31346146 31346146]|[https://pubmed.ncbi.nlm.nih.gov/7648586 7648586]|[https://pubmed.ncbi.nlm.nih.gov/24236059 24236059]|[https://pubmed.ncbi.nlm.nih.gov/21964054 21964054]|[https://pubmed.ncbi.nlm.nih.gov/27456773 27456773]|[https://pubmed.ncbi.nlm.nih.gov/30558911 30558911]|[https://pubmed.ncbi.nlm.nih.gov/21559451 21559451]|[https://pubmed.ncbi.nlm.nih.gov/29312455 29312455]|[https://pubmed.ncbi.nlm.nih.gov/27549315 27549315]|[https://pubmed.ncbi.nlm.nih.gov/30599359 30599359]|[https://pubmed.ncbi.nlm.nih.gov/6141938 6141938]|[https://pubmed.ncbi.nlm.nih.gov/28883415 28883415]|[https://pubmed.ncbi.nlm.nih.gov/30733757 30733757]|[https://pubmed.ncbi.nlm.nih.gov/26041528 26041528]|[https://pubmed.ncbi.nlm.nih.gov/16643871 16643871] <br>
  '''definition''' : A branched amino pentasaccharide consisting of the linear trisaccharide N-acetyl-α-D-galactosaminyl-(1→3)-β-D-galactosyl-(1→4)-N-acetyl-β-D-glucosamine having α-L-fucosyl residues attached at position 2 of the galactose and position 3 of the glucosamine. Corresponds to a partial structure of blood group A type 2 oligosaccharide.[CHEBI:62990] <br>
  '''definition''' : An amino trisaccharide consisting of β-D-galactopyranose, 2-acetamido-2-deoxy-β-D-galactopyranose and α-D-galactopyranose residues joined in sequence by (1→3) glycosidic linkages.[CHEBI:149071] <br>
  '''term_xref''' : GlycoEpitope:EP0261|GTC:G54826OZ|CHEBI:62990|CID:[https://pubmed.ncbi.nlm.nih.gov/5289011 5289011]|GlycoMotif:GGM.000039  <br>
  '''term_xref''' : GTC:G25129BT|GlycoEpitope:EP0039|CID:91855781|CHEBI:149071|GlycoMotif:GGM.000079 <br>
  '''synonyms''' : Blood group A (type 2) (A-Ley)|Blood Group A Type 2 (difucosyl)|Blood group A (type 2) (A-Lewis Y)|A-Ley|A-Le^y <br>
  '''synonyms''' : <br>
  '''function''' :  <br>
  '''function''' :  <br>
  '''disease_associations''' : embryonal carcinoma[GlycoEpitope:EP0039]|teratocarcinoma[GlycoEpitope:EP0039]|yolk sac carcinoma[GlycoEpitope:EP0039] <br>
  '''disease_associations''' : <br>
  '''wikipedia''' :  <br>
  '''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' :  <br>
  '''essentials_of_glycobiology''' :  <br>




===SSEA-4===
===GSD000028===
[[File:G84263XI.png|thumb|G84263XI]]
  '''term (main_entry)''' : Blood group A (Type 4) <br>
  '''term (main_entry)''' : SSEA-4 <br>
  '''glycan_dictionary_accession''' : GSD000028 <br>
  '''glycan_dictionary_accession''' : GSD000161 <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G37830TX G37830TX] <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G84263XI G84263XI] <br>
  '''term_in_sentence''' : Moreover, we have found that αGal, but not αGalNAc, is a weak binder itself for DC-SIGN, which could endow an additional binding mode for the blood group B antigen, but not for blood group A.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31283166 31283166]] <br>
  '''term_in_sentence''' : Glycosphingolipids (GSLs), such as the globo-series GSLs stage-specific embryonic antigen 3 (SSEA-3), SSEA-4, and Globo-H, are specifically expressed on pluripotent stem cells and cancer cells, and are known to be associated with various biological processes such as cell recognition, cell adhesion, and signal transduction.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31817926 31817926]] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/7800218 7800218]|[https://pubmed.ncbi.nlm.nih.gov/7521740 7521740]|[https://pubmed.ncbi.nlm.nih.gov/2458640 2458640]|[https://pubmed.ncbi.nlm.nih.gov/31283166 31283166] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27845370 27845370]|[https://pubmed.ncbi.nlm.nih.gov/31817926 31817926]|[https://pubmed.ncbi.nlm.nih.gov/26295543 26295543]| [https://pubmed.ncbi.nlm.nih.gov/25171543 25171543]|[https://pubmed.ncbi.nlm.nih.gov/25978997 25978997]|[https://pubmed.ncbi.nlm.nih.gov/30296654 30296654]|[https://pubmed.ncbi.nlm.nih.gov/25853231 25853231]|[https://pubmed.ncbi.nlm.nih.gov/24862940 24862940]|[https://pubmed.ncbi.nlm.nih.gov/31243630 31243630]|[https://pubmed.ncbi.nlm.nih.gov/28736232 28736232]|[https://pubmed.ncbi.nlm.nih.gov/22895512 22895512]|[https://pubmed.ncbi.nlm.nih.gov/24578244 24578244]|[https://pubmed.ncbi.nlm.nih.gov/29478902 29478902]|[https://pubmed.ncbi.nlm.nih.gov/23574147 23574147]|[https://pubmed.ncbi.nlm.nih.gov/23768762 23768762]|[https://pubmed.ncbi.nlm.nih.gov/27797400 27797400]|[https://pubmed.ncbi.nlm.nih.gov/29227830 29227830]| [https://pubmed.ncbi.nlm.nih.gov/18773292 18773292]|[https://pubmed.ncbi.nlm.nih.gov/25123923 25123923]|[https://pubmed.ncbi.nlm.nih.gov/22924692 22924692]|[https://pubmed.ncbi.nlm.nih.gov/22665977 22665977]|[https://pubmed.ncbi.nlm.nih.gov/23330736 23330736]|[https://pubmed.ncbi.nlm.nih.gov/31831622 31831622]|[https://pubmed.ncbi.nlm.nih.gov/31916611 31916611]| [https://pubmed.ncbi.nlm.nih.gov/2412924 2412924]|[https://pubmed.ncbi.nlm.nih.gov/16033656 16033656]|[https://pubmed.ncbi.nlm.nih.gov/24866102 24866102]| [https://pubmed.ncbi.nlm.nih.gov/20458727 20458727]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/21149348 21149348] [https://pubmed.ncbi.nlm.nih.gov/21149348 21149348]]|[https://pubmed.ncbi.nlm.nih.gov/26940129 26940129]| [https://pubmed.ncbi.nlm.nih.gov/17008424 17008424]| [https://pubmed.ncbi.nlm.nih.gov/2874662 2874662]|[https://pubmed.ncbi.nlm.nih.gov/23301556 23301556]|[https://pubmed.ncbi.nlm.nih.gov/27836003 27836003]|[https://pubmed.ncbi.nlm.nih.gov/19118716 19118716]|[https://pubmed.ncbi.nlm.nih.gov/24550271 24550271]|[https://pubmed.ncbi.nlm.nih.gov/32988880 32988880]|[https://pubmed.ncbi.nlm.nih.gov/22743677 22743677]|[https://pubmed.ncbi.nlm.nih.gov/20683402 20683402]|[https://pubmed.ncbi.nlm.nih.gov/17062733 17062733]|[https://pubmed.ncbi.nlm.nih.gov/23570331 23570331]|[https://pubmed.ncbi.nlm.nih.gov/30310530 30310530]|[https://pubmed.ncbi.nlm.nih.gov/31545316 31545316]|[https://pubmed.ncbi.nlm.nih.gov/23509763 23509763]|[https://pubmed.ncbi.nlm.nih.gov/24364909 24364909]|[https://pubmed.ncbi.nlm.nih.gov/18273440 18273440]|[https://pubmed.ncbi.nlm.nih.gov/28985528 28985528]|[https://pubmed.ncbi.nlm.nih.gov/22266579 22266579] <br>
  '''definition''' :  <br>
  '''definition''' :  <br>
  '''term_xref''' : GTC:G84263XI|GlycoEpitope:EP0044|CID: 91845478|CHEBI:154843 <br>
  '''term_xref''' : GlycoMotif:GGM.000088|GTC:G37830TX|CID:[https://pubmed.ncbi.nlm.nih.gov/91852258 91852258]|KEGG:G00474|CHEBI:150159|SugarBind_Ligand:48  <br>
  '''synonyms''' :  <br>
  '''synonyms''' :  <br>
  '''function''' :  <br>
  '''function''' :  <br>
  '''disease_associations''' : teratocarcinoma[GlycoEpitope:EP0044] <br>
  '''disease_associations''' : Pyelonephritis[SugarBind_Ligand:48]|Acute cystitis[SugarBind_Ligand:48] <br>
  '''wikipedia''' :  <br>
  '''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453023/ Chapter 47] <br>
  '''essentials_of_glycobiology''' : <br>




===Sulfated LacdiNAc===
===GSD000029===
[[File:G18464VS.png|thumb|G18464VS]]
  '''term (main_entry)''' : Blood group A trisaccharide <br>
  '''term (main_entry)''' : Sulfated LacdiNAc<br>
  '''glycan_dictionary_accession''' : GSD000029 <br>
  '''glycan_dictionary_accession''' : GSD000191<br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00066MO G00066MO] <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G18464VS G18464VS] <br>
  '''term_in_sentence''' : A readily detectable carbohydrate in the urine of two siblings with neuronal ceroid lipofuscinosis was found to be the blood group A trisaccharide.[PMID:[https://pubmed.ncbi.nlm.nih.gov/7249368 7249368]] <br>
  '''term_in_sentence''' : The mRNA expression of the enzymes related to the formation of sulfated LacdiNAc:β(1,4)-N-acetylgalactosaminyltransferases 3 (B4GALNT3) and 4 (B4GALNT4), carbohydrate sulfotransferases 8 (CHST8) and 9 (CHST9); and β(1,4)-galactosyltransferase 1 (B4GALT1) in these cells was confirmed by RT-PCR (Fig. S4).[PMID:31558607]<br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/19582848 19582848]|[https://pubmed.ncbi.nlm.nih.gov/7249368 7249368]|[https://pubmed.ncbi.nlm.nih.gov/8774717 8774717]|[https://pubmed.ncbi.nlm.nih.gov/2749874 2749874]|[https://pubmed.ncbi.nlm.nih.gov/28771597 28771597]|[https://pubmed.ncbi.nlm.nih.gov/30619340 30619340]|[https://pubmed.ncbi.nlm.nih.gov/2122121 2122121]|[https://pubmed.ncbi.nlm.nih.gov/11886841 11886841]|[https://pubmed.ncbi.nlm.nih.gov/2991755 2991755]|[https://pubmed.ncbi.nlm.nih.gov/12588002 12588002]|[https://pubmed.ncbi.nlm.nih.gov/3149698 3149698]|[https://pubmed.ncbi.nlm.nih.gov/7048329 7048329]|[https://pubmed.ncbi.nlm.nih.gov/7015594 7015594]|[https://pubmed.ncbi.nlm.nih.gov/10359132 10359132]|[https://pubmed.ncbi.nlm.nih.gov/8724140 8724140]|[https://pubmed.ncbi.nlm.nih.gov/1418679 1418679]|[https://pubmed.ncbi.nlm.nih.gov/1446307 1446307] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31558607 31558607]|[https://pubmed.ncbi.nlm.nih.gov/27318476 27318476]|[https://pubmed.ncbi.nlm.nih.gov/19756298 19756298]|[https://pubmed.ncbi.nlm.nih.gov/11279168 11279168]|[https://pubmed.ncbi.nlm.nih.gov/26688390 26688390]<br>
  '''definition''' : A branched amino trisaccharide consisting of β-D-galactose having an α-L-fucosyl residue at the 2-position and an N-acetyl-α-D-galactosaminyl residue at the 3-position.[CHEBI:61012] <br>
  '''definition''' : <br>
  '''term_xref''' : GlycoEpitope:EP0255|GTC:G00066MO|CID:[https://pubmed.ncbi.nlm.nih.gov/49852448 49852448]|KEGG:G10638|CHEBI:61012  <br>
  '''term_xref''' : GlycoMotif:GGM.000049<br>
  '''synonyms''' : blood group A trisaccharide|blood group A type 1 trisaccharide <br>
  '''synonyms''' : 4'-O-sulfated LacdiNAc|4'-sulfated LDN|sulfated LDN<br>
  '''function''' :  <br>
  '''function''' :  <br>
  '''disease_associations''' :  <br>
  '''disease_associations''' :  <br>
  '''wikipedia''' :  <br>
  '''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' :
  '''essentials_of_glycobiology''' : <br>




===Sulfatide===
===GSD000030===
  '''term (main_entry)''' : Sulfatide <br>
  '''term (main_entry)''' : Blood group A (Type 1) <br>
  '''glycan_dictionary_accession''' : GSD000162 <br>
  '''glycan_dictionary_accession''' : GSD000030 <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G72548RZ G72548RZ] <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G66163TI G66163TI] <br>
  '''term_in_sentence''' : In a previous study we found that sulfatide was efficient in lowering HIV-1 viral loads in SCID mice engrafted with human fetal liver/thymus tissues (SCID-hu).[PMID:[https://pubmed.ncbi.nlm.nih.gov/23550344 23550344]] <br>
  '''term_in_sentence''' : he basis of blood group A(1) and A(2) phenotypes has been debated for many decades, and still the chemical basis is unresolved. [PMID:[https://pubmed.ncbi.nlm.nih.gov/19121199 19121199]] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/23550344 23550344]|[https://pubmed.ncbi.nlm.nih.gov/18465098 18465098]|[https://pubmed.ncbi.nlm.nih.gov/26542149 26542149]|[https://pubmed.ncbi.nlm.nih.gov/15158666 15158666]|[https://pubmed.ncbi.nlm.nih.gov/10434709 10434709]|[https://pubmed.ncbi.nlm.nih.gov/22619219 22619219]|[https://pubmed.ncbi.nlm.nih.gov/29676479 29676479]|[https://pubmed.ncbi.nlm.nih.gov/30196830 30196830]|[https://pubmed.ncbi.nlm.nih.gov/16143863 16143863]|[https://pubmed.ncbi.nlm.nih.gov/1052451 1052451]|[https://pubmed.ncbi.nlm.nih.gov/30400820 30400820]|[https://pubmed.ncbi.nlm.nih.gov/29887538 29887538]|[https://pubmed.ncbi.nlm.nih.gov/26981544 26981544]|[https://pubmed.ncbi.nlm.nih.gov/17986152 17986152]|[https://pubmed.ncbi.nlm.nih.gov/31739035 31739035]|[https://pubmed.ncbi.nlm.nih.gov/19941861 19941861]|[https://pubmed.ncbi.nlm.nih.gov/24578319 24578319]|[https://pubmed.ncbi.nlm.nih.gov/30531843 30531843]|[https://pubmed.ncbi.nlm.nih.gov/25645724 25645724]|[https://pubmed.ncbi.nlm.nih.gov/31197846 31197846]|[https://pubmed.ncbi.nlm.nih.gov/22821828 22821828]|[https://pubmed.ncbi.nlm.nih.gov/27861899 27861899]|[https://pubmed.ncbi.nlm.nih.gov/31037952 31037952]|[https://pubmed.ncbi.nlm.nih.gov/23593400 23593400]|[https://pubmed.ncbi.nlm.nih.gov/23604989 23604989]|[https://pubmed.ncbi.nlm.nih.gov/17855742 17855742]|[https://pubmed.ncbi.nlm.nih.gov/25966258 25966258]|[https://pubmed.ncbi.nlm.nih.gov/25989600 25989600]|[https://pubmed.ncbi.nlm.nih.gov/9657940 9657940]|[https://pubmed.ncbi.nlm.nih.gov/29497057 29497057]|[https://pubmed.ncbi.nlm.nih.gov/12838515 12838515]|[https://pubmed.ncbi.nlm.nih.gov/25170267 25170267]|[https://pubmed.ncbi.nlm.nih.gov/9878314 9878314]|[https://pubmed.ncbi.nlm.nih.gov/20554435 20554435]|[https://pubmed.ncbi.nlm.nih.gov/1410493 1410493]|[https://pubmed.ncbi.nlm.nih.gov/26585924 26585924]|[https://pubmed.ncbi.nlm.nih.gov/17257892 17257892]|[https://pubmed.ncbi.nlm.nih.gov/17044925 17044925]|[https://pubmed.ncbi.nlm.nih.gov/21089387 21089387]|[https://pubmed.ncbi.nlm.nih.gov/11445552 11445552]|[https://pubmed.ncbi.nlm.nih.gov/22977233 22977233]|[https://pubmed.ncbi.nlm.nih.gov/21437360 21437360]|[https://pubmed.ncbi.nlm.nih.gov/17179664 17179664]|[https://pubmed.ncbi.nlm.nih.gov/6273571 6273571]|[https://pubmed.ncbi.nlm.nih.gov/8370675 8370675] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/10942408 10942408]|[https://pubmed.ncbi.nlm.nih.gov/19121199 19121199] <br>
  '''definition''' : <br>
'''definition''' : An α-D-GalpNAc-(1→3)-[α-L-Fucp-(1→2)]-β-D-Galp-(1→3)-D-GlcpNAc having β-configuration at the reducing end anomeric centre.[CHEBI:62485] <br>
'''term_xref''' : GlycoMotif:GGM.000063|GTC:G72548RZ <br>
'''term_xref''' : GlycoMotif:GGM.000044|GTC:G66163TI|GlycoEpitope:EP0256|CID:[https://pubmed.ncbi.nlm.nih.gov/53262359 53262359]|CHEBI:62485 <br>
'''synonyms''' :  <br>
  '''synonyms''' : Blood group A(1)|blood group A antigen type 1 <br>
  '''function''' :  <br>
  '''function''' :  <br>
  '''disease_associations''' :  <br>
  '''disease_associations''' :  <br>
  '''wikipedia''' :  <br>
  '''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453023/ Chapter 47]<br>
  '''essentials_of_glycobiology''' : <br>

Revision as of 23:58, 9 April 2023

T antigen

G00031MO
term (main_entry) : T antigen 

glycan_dictionary_accession : GSD000163 

glytoucan_accession  : G00031MO 

term_in_sentence : Tn, sTn, and T antigen neo- or over-expression occurs in many types of cancer including gastric, colon, breast, lung, esophageal, prostate, and endometrial cancer.[PMID:27679419] 

publication : 723127|19505650|31527246|28113048|25868857|26731525|22994493|3849428|25589241|[https://pubmed.ncbi.nlm.nih.gov/12709866 12709866 12709866]|26615524|26136575|19671663|18551603|11160729|22261839|30758913|[https://pubmed.ncbi.nlm.nih.gov/25681708 25681708 25681708]|29113555|24998850|1654819|28039910|29206210|32404521|10555041|26517398|2446015|2998768|3026642|18812503|6092664|2153691|8709258|3009889|15109748|[https://pubmed.ncbi.nlm.nih.gov/12709866 12709866 12709866]|31787742|27433780|26017382|24048785|26735515|9224657|26061652|29343574|[https://pubmed.ncbi.nlm.nih.gov/25681708 25681708 25681708]|23805194|26751495|22023388|15381338|8249277|3023660|25866902 

definition : An amino disaccharide composed of D-galactose and N-acetyl-α-D-galactosaminyl residues in β-(1→3) linkage.[CHEBI:61820] 

term_xref : GTC:G00031MO|GlycoEpitope:EP0020|CID:5288347|CHEBI:61820|GlycoMotif:GGM.000009

synonyms : TF antigen 

function : accumulation Lipoprotein(a) or LDL within arterial walls in atherogenesis [GlycoEpitope:EP0020]|cancer progression (increase interaction/communication of the cells)[GlycoEpitope:EP0020]|T antigen expression in RMA lymphoma cells leads to a reduced growth of the tumor[GlycoEpitope:EP0020]|correlation with elevated Golgi pH in cancer cell (breast, colorectal cancer cells)[GlycoEpitope:EP0020]|T antigen on apical surfaces of corneal epithelial cells provide protection against rose bengal penetrance.[GlycoEpitope:EP0020]|reduction of a flexibility of the glycosidic bond and thereby favour certain glycan conformation[GlycoEpitope:EP0020]|T antigen is a target for NK cell-mediated lysis[GlycoEpitope:EP0020]|inverse relationship between T antigen expression and VWF plasma levels[GlycoEpitope:EP0020] 

disease_associations : anaplastic meningioma[GlycoEpitope:EP0020]|breast cancer[GlycoEpitope:EP0020]|colorectal cancer[GlycoEpitope:EP0020]|colon cancer[GlycoEpitope:EP0020]|esophageal cancer|gastric cancer[GlycoEpitope:EP0020]|liver cancer[GlycoEpitope:EP0020]|ovarian cancer[GlycoEpitope:EP0020]|prostate cancer[GlycoEpitope:EP0020]|bladder tumor[GlycoEpitope:EP0020]|invasive pneumococcal infection (hemolytic uremic syndrome, hemolytic anemia)[GlycoEpitope:EP0020] 

wikipedia :  

essentials_of_glycobiology : Chapter 47


Tetraantennary

term (main_entry) : Tetraantennary 

glycan_dictionary_accession : GSD000164 

glytoucan_accession  :  

term_in_sentence : In contrast, myeloma IgE showed a higher abundance of triantennary and tetraantennary glycan structures and a low abundance of species with a bisecting N-acetylglucosamine.[PMID:24308486] 

publication : 24308486|17951374|28880909|9177699|9760189|12322961|20129637|2492275|3402460|2361735|6525453|27730440|2551687|25365149|9751793|29875690|29479898|9134426|30943309|3546284|29888905|30624066|30537828|31110965|29311294|12852965|3015940|1907570|29137999|29359131|29858715|30295034|31829566|8381405|26929217|20662591|30612270|3089784|28186213|3427034|26763099|27354006|24991291|7496138|1940447|11114588|29031301|9448855|3979385|27722599|31126011|28002670|28991403|[https://pubmed.ncbi.nlm.nih.gov/24032650 24032650 24032650]|[https://pubmed.ncbi.nlm.nih.gov/15316281 15316281 15316281]|25154914|22490318|22430811|1463783|18803208|7881173|7697655|7240157|1768292 

definition : Type of N-linked glycan in which four antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The four antennae are initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 2 GlcNAcs to the _6 Man (at the 2 and 6 positions) of the trimannosyl core. Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  [Essentials of Glycobiology:Glossary] 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia : https://www.wikidata.org/wiki/Q27104888 

essentials_of_glycobiology :


Tetraantennary complex-type

term (main_entry) : Tetraantennary complex-type 

glycan_dictionary_accession : GSD000165 

glytoucan_accession  :  

term_in_sentence : A variety of high-mannose structures , as well as bi-, tri-, and tetraantennary complex-type carbohydrate , has been found, in relative amounts of 1-25% of the total oligosaccharides.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1899031 1899031 1899031]] 

publication : [https://pubmed.ncbi.nlm.nih.gov/1899031 1899031 1899031]|8251489|8274017|[https://pubmed.ncbi.nlm.nih.gov/1899031 1899031 1899031]| 6317691|23668542| 6088518|21495009|1457971|1783599|10988252|11425798|7522229|2574992|3730425|10200178|2939068|21584695| 7524670|7682847|2930192|1726466|9881746|11068879|6704968|2302846|[https://pubmed.ncbi.nlm.nih.gov/24032650 24032650 24032650]|[https://pubmed.ncbi.nlm.nih.gov/15316281 15316281 15316281]|11051207|10220588|2813359|2174368|21755550|3571208|1929437|3681300|6581225|3364983|2902877|2297756|1315684|6830758|1998670 

definition : Type of N-linked glycan in which four antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The four antennae are initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 2 GlcNAcs to the _6 Man (at the 2 and 6 positions) of the trimannosyl core. Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  [Essentials of Glycobiology:Glossary]  

term_xref : https://www.sigmaaldrich.com/technical-documents/articles/biology/glycobiology/n-glycans.html

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 10


Tetrasialylated diantennary

term (main_entry) : Tetrasialylated diantennary 

glycan_dictionary_accession : GSD000166 

glytoucan_accession  :  

term_in_sentence : A further preparation, obtained from the most anionic DEAE-cellulose fraction (peak V) or rTf contained several tetrasialylated diantennary glycans whose precise structures remain to be established in future studies.[PMID:1997323] 

publication : 1997323 

definition : A biantennary glycan with two GlcNAc branches linked to the core and the addition of four sialic acid residues. 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :


Tn antigen

G57321FI
term (main_entry) : Tn antigen 

glycan_dictionary_accession : GSD000167 

glytoucan_accession  : G57321FI 

term_in_sentence : Furthermore, we confirmed that LS174T cells (Tn-positive) transfected with wild-type Cosmc, thus expressing no Tn antigen, had down-regulation of H-Ras expression and subsequent inhibition of EMT process.[PMID:30637914] 

publication : 27679419|31938254|30637914|24643043|31225574|21259410|31742337|28514044|33014816|28708980|27432485|33050853|26045765|27542280|24411673|27760846|30115016|1410473|29802864|29669308|29251002|32541028|31019509|1582597|2981150|10842187|29638123|22367369|10778170|1510031|19372570|20641477|16149605|15770530|27856425|23814067|28068458|32134186|8174100|10571017|27453399|1727666|23740330 

definition : Tn anitigen or alpha-galnac or N-Acetylgalactosamine is an N-acetyl-D-galactosamine having alpha-configuration at the anomeric centre. It has a role as an epitope. It derives from an alpha-D-galactosamine.[CHEBI:40356,HMDB0000212] 

term_xref : GTC:G57321FI|GlycoEpitope:EP0021|CID:84265|CHEBI:40356|HMDB0000212|GlycoMotif:GGM.000008 

synonyms :  

function : lymphatic metastasis[GlycoEpitope:EP0021]|tube formation in Drosophila development[GlycoEpitope:EP0021]|modulation of malignant phenotype (gastric carcinoma cell)[GlycoEpitope:EP0021]|correlation with tumor stage, lymphatic invasion and lymph node matastasis[GlycoEpitope:EP0021] 

disease_associations : breast cancer[GlycoEpitope:EP0021]|cervical cancer[GlycoEpitope:EP0021]|colon cancer[GlycoEpitope:EP0021]|colorectal cancer[GlycoEpitope:EP0021]|fibrosarcoma[GlycoEpitope:EP0021]|gastric cancer[GlycoEpitope:EP0021]|liver cancer[GlycoEpitope:EP0021]|ovarian cancer[GlycoEpitope:EP0021]|pancreas cancer[GlycoEpitope:EP0021]|prostate cancer[GlycoEpitope:EP0021]|Tn syndorome[GlycoEpitope:EP0021]|Barrett'sesophagus[GlycoEpitope:EP0021]|Schindler/Kanzaki desease (alpha-N acetylgalactosaminidase deficiency)[GlycoEpitope:EP0021]. 

wikipedia :  

essentials_of_glycobiology :


Triantennary

term (main_entry) : Triantennary 

glycan_dictionary_accession : GSD000168 

glytoucan_accession  :  

term_in_sentence : Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.[PMID:24992960] 

publication : 24992960|27025342|29642865|29456020|26914862|[https://pubmed.ncbi.nlm.nih.gov/26926155 26926155 26926155]|26299345|28981809|18395704|2211710|23461434|18327885|15264862|22954207|9061362|16581187|26537865|3979568|28129130|7679920|8068017|7783116|3857231|20540518|1706936|2430615|8078981|2211711|6767476|3814128|2597120|7451505|8204583|20619452|10460831|1924399|6643471|31809011|30042045|2477056|7882496|2430614|[https://pubmed.ncbi.nlm.nih.gov/2551687 2551687 2551687]|2426141|2065052|28988716|31144994|[https://pubmed.ncbi.nlm.nih.gov/26966183 26966183 26966183]|29809215 

definition : Type of N-linked glycan in which three antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The three antennae can be be initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 1 GlcNAc to the _6 Man (at the 2 position) of the trimannosyl core or 1 on the _3 and 2 on the _6 Man (at the 2 and 6 positions). Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:Glossary] 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :


Triantennary complex

term (main_entry) : Triantennary complex 

glycan_dictionary_accession : GSD000169 

glytoucan_accession  :  

term_in_sentence : Fucosylated biantennary complex-type and small amounts (less than 5%) of triantennary complex-type structures were identified on the glycosylated asparagine residues using sequential exoglycosidase and endoglycosidase digestions combined with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS).[PMID:9118998] 

publication : 9118998|9061362|18395704|3814128|7451505|10460831|[https://pubmed.ncbi.nlm.nih.gov/26926155 26926155 26926155]|[https://pubmed.ncbi.nlm.nih.gov/26966183 26966183 26966183]|16581187|16973123|8204583|29809215|[https://pubmed.ncbi.nlm.nih.gov/11114588 11114588 11114588]|31322324|15044389|16372382|[https://pubmed.ncbi.nlm.nih.gov/8251489 8251489 8251489]|8299583|1555586|7509658|1569060|16261636 

definition : A complex N-glycan that has three branches attached to the non-reducing terminal Man residues of the trimannosyl core.[CHEBI:156252]  Each branch is initiated with a GlcNAc and can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  

term_xref : CHEBI:156252 

synonyms : Triantennary complex-type 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 10


Triantennary N-glycans

term (main_entry) : Triantennary N-glycans 

glycan_dictionary_accession : GSD000170 

glytoucan_accession  :  

term_in_sentence : Increased expression of the high-mannose M6N2 and NeuAc3H3N3M3N2F tri-antennary N-glycans in cholangiocarcinoma.[PMID:29399163] 

publication : 29399163|22325877|18439991|24873509|11454001 

definition : Type of N-linked glycan in which three antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The three antennae can be be initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 1 GlcNAc to the _6 Man (at the 2 position) of the trimannosyl core or 1 on the _3 and 2 on the _6 Man (at the 2 and 6 positions). Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  [Essentials of Glycobiology:Glossary]  

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :


Triantennary sialylated

term (main_entry) : Triantennary sialylated 

glycan_dictionary_accession : GSD000171 

glytoucan_accession  :  

term_in_sentence : LC-ESIMS/MS analysis revealed that both light chain and heavy chain were N-glycosylated mainly by A2S2 but also by triantennary sialylated glycans.[PMID:18642129] 

publication : 18642129|31964828|3979568|27936604|23681398|21538882|7579793|7613477|2223825|3539023|3674882 

definition : A triantennary glycan with three GlcNAc branches linked to the core and the addition of one sialic acid residues. 

term_xref :  

synonyms :  

function : Appears in human serotransferrin.[PMID: 3979568] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology :


Triantennary trisialylated fucosylated

term (main_entry) : Triantennary trisialylated fucosylated 

glycan_dictionary_accession : GSD000172 

glytoucan_accession  :  

term_in_sentence : Diantennary monosialylated glycans and triantennary trisialylated fucosylated and non-fucosylated structures have also been identified.[PMID:17591618] 

publication : 17591618 

definition : A triantennary glycan with three GlcNAc branches linked to the core and the addition of three sialic acid residues and fucose added. 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :


Trifucosyl Lewis b antigen

G74578MX
term (main_entry) : Trifucosyl Lewis b antigen 

glycan_dictionary_accession : GSD000173 

glytoucan_accession  : G74578MX 

term_in_sentence : Extended type-1 chain glycosphingolipid antigens. Isolation and characterization of trifucosyl-Leb antigen (III4V4VI2Fuc3Lc6)[PMID:1735443] 

publication : 1735443 

definition : N-[(2R,3R,4R,5S,6R)-4-[(2R,3R,4S,5S,6R)-4-[(2S,3R,4R,5S,6R)-3-Acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-5-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxy-6-(hydroxymethyl)-5-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]acetamide is an amino sugar.[CHEBI:153783] 

term_xref : GlycoEpitope:EP0092|GTC:G74578MX|CID:91845957|CHEBI:153783 

synonyms : trifucosyl-Leb antigen 

function : cancer-associated antigen[GlycoEpitope: EP0092] 

disease_associations : colonic cancer[GlycoEpitope: EP0092]|endometrial cancer[GlycoEpitope: EP0092]|liver cancer[GlycoEpitope: EP0092]|pancreatic cancer[GlycoEpitope: EP0092]|rectal cancer[GlycoEpitope: EP0092] 

wikipedia :  

essentials_of_glycobiology :


Trifucosyl lewis y

G74917JX
term (main_entry) : Trifucosyl lewis y 

glycan_dictionary_accession : GSD000174 

glytoucan_accession  : G74917JX 

term_in_sentence : The third, major component, common in all eight cases, has been identified as trifucosyl Ley (lactotrifucononaosylceramide, III3FucV3FucVI2FucnLc6, Structure 2 below) based on 1H NMR spectroscopy, methylation analysis, and direct-probe electron-impact mass spectrometry.[PMID:3733752] 

publication : 3733752|2426269

definition : A branched heptasaccharide derivative consisting of two repeating units of β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc (joined by a (1→3)-linkage) with an α-L-fucosyl residue attached at the 2-position of the galactose residue at the non-reducing end.[CHEBI:61332] 

term_xref : GlycoEpitope: EP0094|GTC:G74917JX|CID:50909806|CHEBI:61332  

synonyms : trifucosyl Ley 

function :  

disease_associations : colonic adenocarcinomia[GlycoEpitope: EP0094] 

wikipedia :  

essentials_of_glycobiology :


Trimannosyl core

term (main_entry) : Trimannosyl core 

glycan_dictionary_accession : GSD000175 

glytoucan_accession  :  

term_in_sentence : This glycoengineered H. polymorpha strain produced glycoproteins mainly containing trimannosyl core N-glycan (Man(3)GlcNAc(2)), which is the common core backbone of various human-type N-glycans.[PMID:18320567] 

publication : 18320567|27629418|26514868|26821880|2477227|6213618|31747570|29273674|31064325|1291063|28353332|1421754|29666272|11421342|15648688|28179475|28903882|27189951|9455915|22768188|9254048|8721739|2249985|22933239|25629585|24489949|2981047|11067815|1729985|1710649|16672288|2719668|19003000|23025485|22500028|10409642|1325461|23136055|23085445|21656680|22448293|22132163|1425696|20696712|18056652|15084511|18633282|15814299 

definition : A glycan that constitutes the core structure common to all high-mannose, complex, or hybrid N-glycans. The trimannosyl core composition is Man3 GlcNAc2 and includes a chitobiose at the reducing terminal which is extended by a single b-linked Man residue. The b-linked Man is branched by two additional a-linked Man residues, one at the 3 position and one at the 6 position. 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :


Trisialylated

term (main_entry) : Trisialylated 

glycan_dictionary_accession : GSD000176 

glytoucan_accession  :  

term_in_sentence : Many (82.7%) were found to be tetraantennary N-acetyllactosamine-type (22.8% with one, 3.6% with two and 0.4% with three N-acetyllactosamine repeats) being tetrasialylated (41%), trisialylated (29.6%) and disialylated (12.2%) |HPAE-PAD and FACE analysis suggests that they are triantennary and trisialylated with core fucosylation.[PMID:8477709] 

publication : 6469957|18818422|18332077|21138277|9136890|10782293|19841910|20067809|14751029|8797382|16877748|19131698|20578731|24669823|22426998|27501865|2121479|24663386|32209427|32737218|33245334|26927318|30962676|28370937|30194503|26321095|30463578|31455764|31566965|31266306|29782424|31247951|30487799|2049094|[https://pubmed.ncbi.nlm.nih.gov/1997323 1997323 1997323]|10913832 

definition : A glycan with three sialic acid components. 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :


Trisialylated complex-type oligosaccharide-alditols

term (main_entry) : Trisialylated complex-type oligosaccharide-alditols 

glycan_dictionary_accession : GSD000177 

glytoucan_accession  :  

term_in_sentence : The structures of the two major oligosaccharide-alditols separated by ion-exchange chromatography on a Mono Q column were investigated by means of methylation analysis, glycosidase digestion, and Smith periodate degradation, and they were assigned as typical di- and trisialylated complex-type oligosaccharide-alditols with two and three peripheral chains consisting of Gal-GlcNAc sequences , respectively.[PMID:3571205] 

publication : 3571205 

definition :  

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :


Trisialylated diantennary

term (main_entry) : Trisialylated diantennary 

glycan_dictionary_accession : GSD000178 

glytoucan_accession  :  

term_in_sentence : Determination of glycan primary structures and characterization of a new type of trisialylated diantennary glycan.[PMID:1997323] 

publication : [https://pubmed.ncbi.nlm.nih.gov/1997323 1997323 1997323] 

definition : A diantennary/biantennary glycans with three sialic acid components. 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :


Trisialylated triantennary

term (main_entry) : Trisialylated triantennary 

glycan_dictionary_accession : GSD000179 

glytoucan_accession  :  

term_in_sentence : The N-glycans are of the complex type with the core-fucosylated disialylated biantennary and trisialylated triantennary structures predominating.[PMID:8942648] 

publication : 30194503|27501865|10998266|20578731|[https://pubmed.ncbi.nlm.nih.gov/17591618 17591618 17591618]|14751029|18818422|8942648|8900952 

definition : A triantennry glycan with three sialic acid components. 

term_xref :  

synonyms :  

function :  

disease_associations :  

essentials_of_glycobiology :


VIM-2

G22418PV
term (main_entry) : VIM-2 

glycan_dictionary_accession : GSD000180 

glytoucan_accession  : G22418PV 

term_in_sentence : Anti-SSEA-1 which binds to glycoconjugates with a Gal beta 1-4(fuc alpha 1-3)GlcNAc epitope and VIM-2 which binds to gangliosides with a NeuAc alpha 2-3GlcNAc beta-4(FUC alpha 1-3) GlcNAc beta 1-3Gal-epitope were used to determine the expression of their corresponding carbohydrate antigens in human leukocytes and leukemia cells.[PMID:1690317] 

publication : 27834790|31523406|29978304|29575185|27326514|29029114|32450200|29432937|31906402|28739428|29298123|30976429|29091730|27770796|31330771|31138570|27154587|31542553|30519059|30590504|25880997|27490501|29981456|28559273|28193652|26638216|25897818|26238337|19553129|29644540|26242685|28487556|32622213|30248413|24762211|11451678|33169865|11897589|31479607 

definition : α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-β-D-GlcpNAc-(1→3)-β-D-Galp-(1→4)-[α-L-Fucp-(1→3)]-D-GlcpNAc in which the anomeric configuration of the N-acetyl-D-glucosamine residue at the reducing end is β.[CHEBI:85946] 

term_xref : GTC:G22418PV |GlycoEpitope:EP0019|CID:91825708|CHEBI:85946|GlycoMotif:GGM.000033  

synonyms :  

function : CDw65 have been shown to interact with the ELAM-1 molecule on activated endothelium.[GlycoEpitope:EP0019] 

disease_associations : chronic myelogenous leukemia.[GlycoEpitope:EP0019] 

wikipedia :  

essentials_of_glycobiology :


Terms (by Glycan Dictionary Accessions)

GSD000001

term (main_entry) : 2,6-Branched O-mannose 

glycan_dictionary_accession : GSD000001 

glytoucan_accession  : G06953DR 

term_in_sentence : Collectively, these results strongly suggest that GnT-IX may be a novel beta1,6-N-acetylglucosaminyltransferase that is responsible for the formation of the 2,6-branched structure in the brain O-mannosyl glycan.[PMID:14617637] 

publication : 14617637|10469154 

definition : (2S,4S,5R,6R)-5-Acetamido-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-5-acetamido-6-[[(2R,3S,4S,5S,6S)-5-[(2S,3R,4R,5S,6R)-3-acetamido-5-[(2S,3R,4S,5S,6R)-4-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4,6-trihydroxyoxan-2-yl]methoxy]-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.[CHEBI:157265] 

term_xref : CHEBI:157265|GlycoMotif:GGM.000056|GTC:G06953DR  

synonyms : 5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)-beta-D-galacto-hexopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1→2)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)-beta-D-galacto-hexopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1→6)]-alpha-D-manno-hexopyranose|NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-2)[NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-6)]a-Man 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :


GSD000002

term (main_entry) : 2,6-sialyl-Sulfo-LN 

glycan_dictionary_accession : GSD000002 

glytoucan_accession  : G41145LF 

term_in_sentence : The alpha2-6-sialylated 6-sulfo-LacNAc determinant defined by the antibody was significantly expressed on a majority of normal human peripheral B-lymphocytes as well as follicular B-lymphocytes in peripheral lymph nodes.[PMID:17728258] 

publication : 17728258 

definition :  

term_xref : GlycoMotif:GGM.000026|GTC:G41145LF 

synonyms : 6-sialyl-6-sulfo LN 

function : B-cell interaction with blood vessels and trafficking[PMID: 17728258] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology :


GSD000003

term (main_entry) : 2-Fucosyl-GD1b 

glycan_dictionary_accession : GSD000003 

glytoucan_accession  : G67383AR 

term_in_sentence : They were fucosyl-Gv., fucoSyl-GDlb, and two uni que fucogangliosides having GMl or GOlb bas ic structure containing a substituent with the blood group B determinant. [PMID:[https://pubmed.ncbi.nlm.nih.gov/3654655 3654655 3654655]] 

publication : [https://pubmed.ncbi.nlm.nih.gov/3654655 3654655 3654655] 

definition : (2S,4S,5R,6R)-5-Acetamido-6-[(1S,2R)-2-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-1,3-dihydroxypropyl]-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxyoxane-2-carboxylic acid.[CHEBI:156680] 

term_xref : CHEBI:156680|GlycoMotif:GGM.000103|GTC:G67383AR

synonyms : 6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)-beta-D-galacto-hexopyranosyl-(1→3)-2-acetamido-2-deoxy-beta-D-galacto-hexopyranosyl-(1→4)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→8)-5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)]-beta-D-galacto-hexopyranosyl-(1→4)-D-gluco-hexopyranose|Fuc(a1-2)Gal(b1-3)GalNAc(b1-4)[NeuAc(a2-8)NeuAc(a2-3)]Gal(b1-4)Glc 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :


GSD000004

term (main_entry) : 2-Fucosyl-GM1 

glycan_dictionary_accession : GSD000004 

glytoucan_accession  : G56526JU 

term_in_sentence : These glycolipid products were identified as asialo-Gs.., GM h and fucosyl-Gq, by comparison with authentic glycolipid samples.[PMID:[https://pubmed.ncbi.nlm.nih.gov/3654655 3654655 3654655]] 

publication : [https://pubmed.ncbi.nlm.nih.gov/3654655 3654655 3654655] 

definition : (2S,4S,5R,6R)-5-Acetamido-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.[CHEBI:151476] 

term_xref : KEGG:G12241|CHEBI:151476|CID:91849786|GlycoMotif:GGM.000101|GTC:G56526JU  

synonyms : Fuc(a1-2)Gal(b1-3)GalNAc(b1-4)[NeuAc(a2-3)]Gal(b1-4)Glc|6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)-beta-D-galacto-hexopyranosyl-(1→3)-2-acetamido-2-deoxy-beta-D-galacto-hexopyranosyl-(1→4)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)]-beta-D-galacto-hexopyranosyl-(1→4)-D-gluco-hexopyranose 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :


GSD000005

term (main_entry) : 3-Sialyl-LN (type 2) 

glycan_dictionary_accession : GSD000005 

glytoucan_accession  : G10203DW 

term_in_sentence : Using new crystal structures, we also provide the atomic resolution basis for the differential recognition of 3′ and 6′SiaLacNAc1–4 (with the Galβ1–4 linkage known as Type 2 backbone16; Scheme 1) by TgMIC1-MARR, and make comparisons with the Type 1 chain isomer of 3′SiaLacNAc1–4 (designated 3′SiaLacNAc1–3).[PMID:19593815] 

publication : 19593815|15659615|2414279|8586620|2111348|23747419 

definition : A linear amino trisaccharide consisting of α-neuraminyl, β-D-galactosyl and N-acetyl-D-glucosamine residues linked in a (2→3) and (1→4) sequence.[CHEBI:52472] 

term_xref : GTC:G10203DW|KEGG:G00253|SugarBind_Ligand:109|GlycoEpitope:EP0314|CHEBI:52472|GlycoMotif:GGM.000034 

synonyms : 

function :  

disease_associations : Chronic gastritis[SugarBind_Ligand:109]|Toxoplasmosis[SugarBind_Ligand:109]|Peptic ulcers[SugarBind_Ligand:109]|Gastric cancer[SugarBind_Ligand:109] 

wikipedia :  

essentials_of_glycobiology :


GSD000006

term (main_entry) : 3'-Sulfo-Lewis a 

glycan_dictionary_accession : GSD000006 

glytoucan_accession  : G78706CK 

term_in_sentence : A remodeling system of the 3'-sulfo-Lewis a and 3'-sulfo-Lewis x epitopes.[PMID:[https://pubmed.ncbi.nlm.nih.gov/11504739 11504739 11504739]] 

publication : [https://pubmed.ncbi.nlm.nih.gov/11504739 11504739 11504739]|17499486|17691854|12944557|19394320|7534477|11604107|28025252|9061363|9878545|11918697|24239607|28628803|25339106|21400496|17998215|12626387|11425799|12219077|10955596|9453593 

definition : A branched amino trisaccharide consisting of N-acetylglucosamine having a fucosyl residue attached at the 4-position via an α-linkage and a 3-sulfated galactosyl residue attached at the 3-position via a β-linkage.[CHEBI:65149] 

term_xref : GTC:G78706CK|GlycoEpitope:EP0009|CID:5289352|GlycoMotif:GGM.000030 

synonyms : 3'-Sulfo-Lea|SuLe(a)|3'-sulpho-Le(a)|3-O-sulfo-Le(A)|3'-Sulfo Le^a|3'-Sulfo Lea|3'-Sulfo Lewis a 

function : SO3-3-Gal and the SO3-3-Lea blood group antigen bound to H.pylori.[GlycoEpitope:EP0009] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology :


GSD000007

term (main_entry) : 3'-Sulfo-Lewis x 

glycan_dictionary_accession : GSD000007 

glytoucan_accession  : G12295TB 

term_in_sentence : A remodeling system of the 3'-sulfo-Lewis a and 3'-sulfo-Lewis x epitopes.[PMID:[https://pubmed.ncbi.nlm.nih.gov/11504739 11504739 11504739]] 

publication : [https://pubmed.ncbi.nlm.nih.gov/11504739 11504739 11504739]|20695481|8688428|[https://pubmed.ncbi.nlm.nih.gov/10536036 10536036 10536036]|12770775|11352731|9784103|9022803 

definition : An amino trisaccharide that consists of N-acetyl-β-D-glucosamine having an α-L-fucosyl residue attached at position 3 and a 3-sulfated β-D-galactosyl residue attached at position 4; β-D-Galp3S-(1→4)-[α-L-Fucp-(1→3)]-D-GlcpNAc in which the configuration at the anomeric centre of the reducing-end residue is β. [CHEBI:65171] 

term_xref : GTC:G12295TB|GlycoEpitope:EP0013|CID:5289353|CHEBI:65171|GlycoMotif:GGM.000029  

synonyms : 3'-sulfo-Le(x)|3'-Sulfo Lewis x|3'-sulfo Le^x|3'-sulfo Lex 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :


GSD000008

term (main_entry) : 6,6'-bisSulfo-Lewis x 

glycan_dictionary_accession : GSD000008 

glytoucan_accession  : G00659GQ 

term_in_sentence : Comparison of the reactivity pattern of HEV with the reactivity of the pure 6-sulfo, 6'-sulfo, or 6,6'-bissulfo sialyl Lewis X determinant with hitherto known anti-sialyl Lewis X antibodies strongly suggested 6-sulfo sialyl Lewis X to be the best candidate for the major sulfated sialyl Lewis X determinant on HEV, followed by 6,6'-bissulfo sialyl Lewis X, whereas 6'-sulfo sialyl Lewis X was unlikely. [PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9556613 9556613 9556613] [https://pubmed.ncbi.nlm.nih.gov/9556613 9556613 9556613]]] 

publication : 19756298|[https://pubmed.ncbi.nlm.nih.gov/14593101 14593101 14593101]|15175329|14568956|12163379|11919403|11520459|10728707|10200296|10528213|9712885|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9556613 9556613 9556613] [https://pubmed.ncbi.nlm.nih.gov/9556613 9556613 9556613]]|9456330|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9556613 9556613 9556613] [https://pubmed.ncbi.nlm.nih.gov/9556613 9556613 9556613]]|9257857|9164959|[https://pubmed.ncbi.nlm.nih.gov/9015359 9015359 9015359]|8958810|7560094|7485559|7538131|8161542|7684905 

definition : (2S,4S,5R,6R)-5-Acetamido-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-5-acetamido-6-hydroxy-2-(sulfooxymethyl)-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(sulfooxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.[CHEBI:146095] 

term_xref : GlycoEpitope:EP0016|CHEBI:146095|GlycoMotif:GGM.000028|GTC:G00659GQ  

synonyms : 6,6'-DiSulfo Sialyl Lewis x|6,6-bisSulfo-Lewis x (6,60-bissulfo Lewis x )|6,6'- Disulfo Sialyl Lewis x|6,6'-bisSulfo-Lewis x|6,6'-bissulfo Lex|6,6'-Disulfo Sialyl Lewis x|6,6'-bissulfo Le^x 

function : lymphocyte homing[GlycoEpitope:EP0016] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology :


GSD000009

term (main_entry) : 6-Sialyl-GalNAc 

glycan_dictionary_accession : GSD000009 

glytoucan_accession  : G08371CD 

term_in_sentence : mmunohistochemical distributions of carbohydrate antigens based on the type 2 chain in normal as well as fetal and neoplastic tissues of human gastrointestinal tract were investigated with a monoclonal antibody (MAb) H11 (specific for type 2 chain) alone and in combination with the two MAbs MSG15 (for alpha 2----6 sialylated type 2 chain) and IB9 (for the alpha 2----6 sialylated type 2 chain and glycoproteins having NeuAc alpha 2----6Gal-NAc), and 188C1 (for short- and long-chain Lex antigens) and FH2 (for the long-chain Lex antigen). [PMID: 1618643] 

publication : 1618643|6194157 

definition : An amino disaccharide composed of N-acetylneuraminic acid and 2-(acetylamino)-2-deoxy-D-galactopyranose residues joined by an (α-2→6) glycosidic bond.[CHEBI:146820] 

term_xref : GlycoEpitope:EP0352|KEGG:G00455|KEGG:G10625|CHEBI:146820|CID:11409652|GlycoMotif:GGM.000035|GTC:G08371CD 

synonyms : Sialyl Tn antigen|6-Sialyl-GalNAc|6-Sialyl LN|6-Sialyl LN (type 1)|6-Sialyl LN (type 2) 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :


GSD000010

term (main_entry) : 6-Sulfo LacNac 

glycan_dictionary_accession : GSD000010 

glytoucan_accession  : G13157WZ 

term_in_sentence : In the search for an additional marker to better dissect the two subsets we have explored the marker 6-sulfo LacNAc (slan).[PMID:31572354] 

publication : 31572354|31191513|29977237|29900053|30984181|28732748|26510404|28769928|31154896|27541644|25262889|26155414|28499587|27086951|27315572|26162403|26391152|31730025|12354382|27318477|23879812|25340085|24682513|21377044|21098395|18942710|23559493|23890755|22643330|23460612|23402811|22890025|19589615|32939325|20210806|17616642|22907335|16782032|22188261|21283706|29875315|32413173|19546436|19384158|1429720|30519676 

definition : An oligosaccharide sulfate that is N-acetyllactosamine in which the hydroxy group at position 6 of the N-acetylglucosamine ring has been converted into its hydrogen sulfate derivative.[CHEBI:148005] 

term_xref : GlycoEpitope:EP0141|GTC:G13157WZ|CID:10322152|CHEBI:148005

synonyms : 6-Sulfo LacNAc 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :


GSD000011

G00672PE
term (main_entry) : 6'-Sulfo Sialyl Lewis x 

glycan_dictionary_accession : GSD000011 

glytoucan_accession  : G00672PE 

term_in_sentence : Studies using sulfotransferase-deficient mice showed that 6-sulfo sialyl Lewis X (6-sulfo sLe(x)), a major ligand for L-selectin that is expressed on the high endothelial venules (HEVs), plays critical roles in lymphocyte homing to the peripheral lymph nodes.[PMID:2288521] 

publication : 2288521|26137907|9400621|32744401|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9556613 9556613 9556613] [https://pubmed.ncbi.nlm.nih.gov/9556613 9556613 9556613]]|15972893|[https://pubmed.ncbi.nlm.nih.gov/9015359 9015359 9015359]|22691873|18652681|9722682|10435581|19458105|19359410|15228275|18250165|[https://pubmed.ncbi.nlm.nih.gov/10536036 10536036 10536036]|17944600|10460836|27993973|19149511|19150806|17172261|17142960|27956273|7578028|22260995|24519996|21596021|21982762|21775439|17334369|9710564|[https://pubmed.ncbi.nlm.nih.gov/14593101 14593101 14593101]|16227985|11895802|22750968|15157883|19067429 

definition : A branched amino tetrasaccharide comprised of a trisaccharide chain of N-acetyl-α-neuraminic acid, 6-O-sulfo-β-D-glactose and N-acetyl-β-D-glucosamine residues linked sequentially (2→3) and (1→4), to the GlcNAC residue of which is also linked (1→3) an α-L-fucose residue.[CHEBI:71558] 

term_xref : GlycoMotif:GGM.000025|GTC:G00672PE|CID:70698387|GlycoEpitope:EP0014|CHEBI:71558|SugarBind_Ligand:128  

synonyms : 6'-sulfated sialyl Lewis x-|6'-sulfo-sLe(x)|Su-SaiLex|Su-Slex|6'-Sulfo-sialyl Lewis x 

function : lymphocyte homing[GlycoEpitope:EP0014] 

disease_associations : Influenza[SugarBind_Ligand:128] 

wikipedia :  

essentials_of_glycobiology : Chapter 14


GSD000012

term (main_entry) : 9-O-Acetyl GD3 

glycan_dictionary_accession : GSD000012 

glytoucan_accession  : G74121RX 

term_in_sentence : To determine whether 9-O-acetyl GD3 (acGD3) has a general antiapoptotic potential, the apoptosis-sensitive Jurkat cell line and an apoptosis-sensitive variant of the cell line Molt-4 were preincubated with micromolar concentrations of acGD3 and then treated with inducers of apoptosis.[PMID:16432837] 

publication : 16432837|21507905|17512674|21930212|18194438|20739294|3216430|14724245|31373393|7558412|11273644|17385751|30694652|22894715|12973826|7859075|9749956|9874495|12486096|1989525|25330147|23478187|21807667|8486686|11465673|9511990|29270199|9268945|25045067|21618115|16434401|12493756|2302705|2198284|2685488|9328574|4055789|10096568|1644805|2582447 

definition :  

term_xref : GTC:G74121RX|GlycoEpitope:EP0064|CID:91852520|GlycoMotif:GGM.000093 

synonyms : acGD3|9-O-Acetylated GD3|9-O-Acetyl-GD3|9-O-Ac-GD3|CD60b 

function :  

disease_associations : pancreas cancer[GlycoEpitope:EP0064] 

wikipedia :  

essentials_of_glycobiology :


GSD000013

term (main_entry) : 9-O-Acetyl sialic acid 

glycan_dictionary_accession : GSD000013 

glytoucan_accession  : G47325QT 

term_in_sentence : Levels of 9-O-acetyl sialic acid provide a distinct way to define progenitors and thus facilitate the study of hematopoietic differentiation.[PMID:31411667] 

publication : 31411667|27936566|2509478|10049046|1826463 

definition : N-acetyl-9-O-acetyl-alpha-neuraminic acid is a member of the class of N-acetylneuraminic acids that is alpha-neuraminic acid which has acetylated on N-5 and O-9. It has functional parent alpha-neuraminic acid.[CHEBI:84941] 

term_xref : GTC:G47325QT|GlycoEpitope:EP0065|CID:13991612|CHEBI:84941  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 15


GSD000014

term (main_entry) : Blood group A (Type 2) 

glycan_dictionary_accession : GSD000014 

glytoucan_accession  : G74353FF 

term_in_sentence : One hybridoma antibody (AH16), obtained on immunization with human gastric cancer cell MKN45, was directed to the blood group A determinant carried by both type 1 and type 2 chains. [PMID:6583282] 

publication : 27196314|6583282|8340255|18701592|21901093|2413709|8036794|1615929|3285099 

definition : A branched amino tetrasaccharide comprising N-acetyl-β-D-glucosamine at the reducing end with a N-acetyl-α-D-galactosaminyl-(1→3)-[α-L-fucosyl-(1→2)]-β-D-galactosyl moiety attached at the 4-position.[CHEBI:62486] 

term_xref : GTC:G74353FF|CID:53262376|GlycoEpitope:EP0257|CHEBI:62486|GlycoMotif:GGM.000038 

synonyms : A Type 2|Blood group A type 2 chain

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 14


GSD000016

term (main_entry) : Alpha-gal antigen 

glycan_dictionary_accession : GSD000016 

glytoucan_accession  : G24432YB 

term_in_sentence : Therefore, alpha-gal antigen might be eliminated after a prolonged culture, when using human cells.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31267683 31267683 31267683]] 

publication : [https://pubmed.ncbi.nlm.nih.gov/31267683 31267683 31267683]|29319188|29481481|26140655|30337555|29235434|22909134|28280265|7532618|23390540|22808845|29898796|22262104|[https://pubmed.ncbi.nlm.nih.gov/31267683 31267683 31267683]|25430953|22993330|23578170|21043478|28294277|27696820|15814276|17991149|25577211|30578545|19895316|28068870|18546155|32907757|26485996|9771839|12042247|27567275|12131678|23114154|19184002|29577591|29806570|15638815|21118731 

definition : A glycosylgalactose that consists of β-D-galactose having an α-D-galactosyl residue at the 3-position.[CHEBI:62330] 

term_xref : GTC:G24432YB|GlycoMotif:GGM.000015|CID:52939789|CHEBI:62330  

synonyms : a-Gal antigen 

function : Has role as a carbohydrate allergen, epitope or an antigen.[CHEBI:62330] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 14


GSD000017

term (main_entry) : Alpha-galactosylceramide 

glycan_dictionary_accession : GSD000017 

glytoucan_accession  :  

term_in_sentence : From 24 weeks of age, NZB/NZW F1 mice were injected with alpha-galactosylceramide (α-GalCer) or vehicle once a week for four weeks.[PMID:29844470] 

publication : 29844470|30421497|31575643|30745361|30953000|30556652|29617191|31689579|28872688|30195979|29940370|27004737|27198610|28743554|31649670|31484693|25752588|21383248|25527277|30821985|28947140|31244823|29311431|30803854|29576533|26101952|31213291|22412194|28067024|31199716|27354638|24465013|25445911|28120096|15630427|27803187|21392534|31075434|22683545|26191196|26811064|23935988|28623127|24913977|25434827|23420533|21839133|25314062|27325450|23874157 

definition :  

term_xref :  

synonyms : alpha-GalCer|alpha-GalCers|α-GalCer 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :


GSD000018

term (main_entry) : Asialo-biantennary 

glycan_dictionary_accession : GSD000018 

glytoucan_accession  :  

term_in_sentence : Typical crystallizable fragment (Fc) glycans attached to the CH2 domain in therapeutic monoclonal antibodies (mAbs) are core-fucosylated and asialo-biantennary complex-type glycans, e.g., G2F (full galactosylation), G1aF (terminal galactosylation on the Man α1-6 arm), G1bF (terminal galactosylation on the Man α1-3 arm), and G0F (non-galactosylation).[PMID:30990348] 

publication : 30990348|17645671|20959391|18615430|16945378|[https://pubmed.ncbi.nlm.nih.gov/2065054 2065054 2065054]|3084472|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2386787 2386787 2386787] [https://pubmed.ncbi.nlm.nih.gov/2386787 2386787 2386787]]|22911097|24692304|17013932|7513972|[https://pubmed.ncbi.nlm.nih.gov/6626573 6626573 6626573]|10835250|9684342 

definition :  

term_xref :  

synonyms : asialo diantennary 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :


GSD000019

G21856LC
term (main_entry) : Asialo-GM1 

glycan_dictionary_accession : GSD000019 

glytoucan_accession  : G21856LC 

term_in_sentence : We compared the lateral structure of giant unilamellar vesicles (GUVs) composed of three pseudo binary mixtures of different glycosphingolipid (GSL), i.e. sulfatide, asialo-GM1 or GM1, with POPC.[PMID:29106974] 

publication : 29106974|3418980|26975993|8613364|9288228|26710925|24922516|6839313|1828259|2581667|8210226|25062498|9671150|10377092|6171919|3093429|6652964|3124753|8905612|18788941|1467432|8225593|2083955|6171918|7806377|1802483|7927723|9209156|21174147|2584393|12137200|6175621|2936802|8610366|21490162|1548508|3486908|26453755|7910939|3756909|1639356|3259967|2443562|3112077|2572647|25137483|2168971|6950172 

definition :  

term_xref : GlycoMotif:GGM.000099|GTC:G21856LC|CID:10169040|GlycoEpitope:EP0047|CHEBI:59216  

synonyms : as-GM1|GA-1|Gangliotetraosylceramide|GgO4|Gg4|Asialo-GM1a|ganglio-N-tetraosylceramide 

function :  

disease_associations : Pleuropneumonia[SugarBind_Ligand:2]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:2]|Actinomycosis[SugarBind_Ligand:2]|Lazy leukocyte syndrome[SugarBind_Ligand:2]|Pertussis[SugarBind_Ligand:2]|Cutaneous lesions[SugarBind_Ligand:2]|Melioidosis[SugarBind_Ligand:2]|Candidiasis[SugarBind_Ligand:2]|Taiwan acute respiratory agent[SugarBind_Ligand:2]|Trachoma[SugarBind_Ligand:2]|Cystitis[SugarBind_Ligand:2]|Chronic gastritis[SugarBind_Ligand:2]|Peptic ulcers[SugarBind_Ligand:2]|Gastric cancer[SugarBind_Ligand:2]|Klebsiella pneumonia infection[SugarBind_Ligand:2]|Pneumonia[SugarBind_Ligand:2]|Legionnaires' disease[SugarBind_Ligand:2]|Gonorrhea[SugarBind_Ligand:2]|Gastroenteritis[SugarBind_Ligand:2]|Toxoplasmosis[SugarBind_Ligand:2]|Plague[SugarBind_Ligand:2]|Diarrhea[SugarBind_Ligand:2] 

wikipedia :  

essentials_of_glycobiology :


GSD000020

term (main_entry) : B-GD1B 

glycan_dictionary_accession : GSD000020 

glytoucan_accession  : G72557NR 

term_in_sentence : The Molecular Modelling and 10 ns MD simulation of Botulinum Neuro Toxin/B-GD1A and BoNT/B-GD1B complex revealed that this toxin can interact with GD1A in the single binding mode and with GD1B in two binding modes.[PMID:22929125] 

publication : 27956354|22929125 

definition :  

term_xref : GlycoMotif:GGM.000104|GTC:G72557NR|CID:91847819|KEGG:G01803|CHEBI:153361 

synonyms : B-GD1b 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :


GSD000021

term (main_entry) : B-GM1 

glycan_dictionary_accession : GSD000021 

glytoucan_accession  : G11485ID 

term_in_sentence : The contribution of GM3 and GD3, which accounted for 95% of the ganglioside sialic acid at birth, decreased during the first 3 weeks of life. GM1, fucosyl-GM1, and B-GM1 were not detected at birth. [PMID: 3680254] 

publication : 3680254 

definition : (2S,4S,5R,6R)-5-Acetamido-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-5-hydroxy-4-[(2R,3R,4S,5S,6R)-5-hydroxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of neuraminic acids.[CHEBI:147588] 

term_xref : GlycoMotif:GGM.000102|GTC:G11485ID|CID:91853157|CHEBI:147588|SugarBind_Ligand:181 

synonyms :  

function :  

disease_associations : Cholera[SugarBind_Ligand:181] 

wikipedia :  

essentials_of_glycobiology : Chapter 37


GSD000022

term (main_entry) : Biantennary 

glycan_dictionary_accession : GSD000022 

glytoucan_accession  :  

term_in_sentence : We found an efficient isopropylidenation reaction that selectively protects the terminal Gal-3,4-OH of a biantennary complex-type nonasaccharide isolated from a natural source.[PMID:[https://pubmed.ncbi.nlm.nih.gov/29249147 29249147 29249147]] 

publication : [https://pubmed.ncbi.nlm.nih.gov/29249147 29249147 29249147]|[https://pubmed.ncbi.nlm.nih.gov/24991291 24991291 24991291]|29409839|[https://pubmed.ncbi.nlm.nih.gov/30325416 30325416 30325416]|18083109|[https://pubmed.ncbi.nlm.nih.gov/26926155 26926155 26926155]|16715395|[https://pubmed.ncbi.nlm.nih.gov/12634321 12634321 12634321]|24211369|23115267|31907993|[https://pubmed.ncbi.nlm.nih.gov/23360551 23360551 23360551]|20861009|[https://pubmed.ncbi.nlm.nih.gov/33142198 33142198 33142198]|11442281|[https://pubmed.ncbi.nlm.nih.gov/18687680 18687680 18687680]|15680603|[https://pubmed.ncbi.nlm.nih.gov/31888963 31888963 31888963]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/14686925 14686925 14686925] [https://pubmed.ncbi.nlm.nih.gov/14686925 14686925 14686925]]|[https://pubmed.ncbi.nlm.nih.gov/15819890 15819890 15819890]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/22530754 22530754 22530754] [https://pubmed.ncbi.nlm.nih.gov/22530754 22530754 22530754]]|[https://pubmed.ncbi.nlm.nih.gov/22098756 22098756 22098756]|9346821|19341309|18529007|[https://pubmed.ncbi.nlm.nih.gov/20580347 20580347 20580347]|[https://pubmed.ncbi.nlm.nih.gov/11784152 11784152 11784152]|[https://pubmed.ncbi.nlm.nih.gov/7773775 7773775 7773775]|10913832|[https://pubmed.ncbi.nlm.nih.gov/8547276 8547276 8547276]|10463590|[https://pubmed.ncbi.nlm.nih.gov/9404657 9404657 9404657]|30525457|15316280|8068637|3881425|[https://pubmed.ncbi.nlm.nih.gov/6425277 6425277 6425277]|8576139|[https://pubmed.ncbi.nlm.nih.gov/29956878 29956878 29956878]|1576211|11129583|30421263|8069634|30973186|[https://pubmed.ncbi.nlm.nih.gov/16704415 16704415 16704415]|[https://pubmed.ncbi.nlm.nih.gov/21612260 21612260 21612260]|29806066|29443078 

definition : Type of N-linked glycan in which two antenna are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). Each antenna can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:Glossary] 

term_xref :  

synonyms : diantennary 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 9


GSD000023

term (main_entry) : Biantennary complex 

glycan_dictionary_accession : GSD000023 

glytoucan_accession  :  

term_in_sentence : The crystal structure of Pterocarpus angolensis lectin is determined in its ligand-free state, in complex with the fucosylated biantennary complex type decasaccharide NA2F, and in complex with a series of smaller oligosaccharide constituents of NA2F.[PMID:16704415] 

publication : 16704415|3731182|26747427|[https://pubmed.ncbi.nlm.nih.gov/32597008 32597008 32597008]|6626573|29249147|28597152|25045879|30325416|12634321|31888963|26926155|23360551|33142198|9404657|29956878|[https://pubmed.ncbi.nlm.nih.gov/14686925 14686925 14686925]|18687680|11784152|7773775|[https://pubmed.ncbi.nlm.nih.gov/22530754 22530754 22530754]|20580347|22098756|21612260|6425277|7691595|26780731|16285669|15819890|3924097|30448401|8547276|17049014|29408873 

definition : A complex N-glycan that has two branches attached to the non-reducing terminal Man residues of the trimannosyl core. . Each branch is initiated with a GlcNAc and can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [CHEBI:156251] 

term_xref : CHEBI:156251 

synonyms : diantennary complex type 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :


GSD000024

term (main_entry) : Bisecting GlcNac 

glycan_dictionary_accession : GSD000024 

glytoucan_accession  :  

term_in_sentence : The presence of a bisecting GlcNAc and the occurrence of alpha 2-6-linked Neu5Ac in the most abundant N-glycans, are new features for hCG-beta.[PMID:1374031] 

publication : 1374031|29909448|29274553|32719771|22476631|31375533|26467158|27429195|20816221|26109616|30542567|30144245|25727145|29593568|32612952|9006930|19508951|16000695|[https://pubmed.ncbi.nlm.nih.gov/32597008 32597008 32597008]|19053837|[https://pubmed.ncbi.nlm.nih.gov/22530754 22530754 22530754]|30405631|19940114|32719549|9560299|29655002|10589784|29959030|20661133|9061364|31065629|20395209|29549127|30305426|29632412|24108122|24282611|27821068|[https://pubmed.ncbi.nlm.nih.gov/14686925 14686925 14686925]|10816579|25032906|30025558|9661906|8542600|31585439|29699572|27443163|30315103|23808883|18812317|19776078 

definition : The bisecting GlcNAc is a modification of hybrid or complex N-linked glycans in which a single GlcNAc is added to the 3 position of the b-linked Man found in the trimannosyl core structure. The modification is catalyzed by beta 1,4-N-acetylglucosaminyltransferase III (GlcNAcT-III) or MGAT3 (E.C. 2.4.1.144). The addition of a bisecting GlcNAc on a hybrid or trimmed hybrid glycan prevents the subsequent action of N-glycan branching glycosyltransferases GlcNAcT-IV and GlcNAcT-V, but GlcNAcT3 can add a bisecting GlcNAc to the products of these enzymes. [PMID: 22476631] 

term_xref : SID:163312364|KEGG:G13066

synonyms :  

function : The bisecting GlcNAc of N-glycans regulates cellular signaling and tumor progression through modulating N-glycan/galectin interactions.[PMID: 22476631]Inhibits growth factor signaling and retards mammary tumor progression[PMID: 20395209]Integrin-mediated cell adhesion [PMID: 20816221]Important in fertilization and fetal development, neuritogenesis, immune tolerance, immunoglobulin G (IgG)[PMID: 32719771] 

disease_associations : mammary tumor.[PMID: 20395209] 

wikipedia :  

essentials_of_glycobiology : Chapter 9


GSD000025

term (main_entry) : Bisialo-biantennary 

glycan_dictionary_accession : GSD000025 

glytoucan_accession  :  

term_in_sentence : Using anion-exchange liquid chromatography mapping of the oligosaccharide units cleaved from the proteins by glycopeptidase F, compared with elution positions of standard oligosaccharide structures, coupled with monosaccharide compositional analysis, we find that the human plasma protein contained only bisialo-biantennary complex-type carbohydrate and asialo-biantennary complex carbohydrate, confirming earlier work published by this laboratory. 

publication : [https://pubmed.ncbi.nlm.nih.gov/2386787 2386787 2386787]|2065054 

definition : A binantennary glycan with sialic acid residues as non-reducing terminal residues on both antennae. 

term_xref :  

synonyms : disialo biantennary|disialo diantennary|disialylated biantennary|disialylated diantennary 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :


GSD000026

term (main_entry) : Bisialo-biantennary complex-type 

glycan_dictionary_accession : GSD000026 

glytoucan_accession  :  

term_in_sentence : Using anion-exchange liquid chromatography mapping of the oligosaccharide units cleaved from the proteins by glycopeptidase F , compared with elution positions of standard oligosaccharide structures , coupled with monosaccharide compositional analysis, we find that the human plasma protein contained only bisialo-biantennary complex-type carbohydrate and asialo-biantennary complex carbohydrate , confirming earlier work published by this laboratory.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2386787 2386787 2386787]] 

publication : [https://pubmed.ncbi.nlm.nih.gov/2386787 2386787 2386787]|26966183 

definition : A binantennary glycan with sialic acid residues as non-reducing terminal residues on both antennae.  

term_xref :  

synonyms : Fully sialylated biantennary N-glycan 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 25


GSD000027

term (main_entry) : Blood group A (Type 2) - Lewis y 

glycan_dictionary_accession : GSD000027 

glytoucan_accession  : G54826OZ 

term_in_sentence : Monoclonal antibodies defining blood group A variants with difucosyl type 1 chain (ALeb) and difucosyl type 2 chain (ALey).[PMID:2417620] 

publication : 2417620 

definition : A branched amino pentasaccharide consisting of the linear trisaccharide N-acetyl-α-D-galactosaminyl-(1→3)-β-D-galactosyl-(1→4)-N-acetyl-β-D-glucosamine having α-L-fucosyl residues attached at position 2 of the galactose and position 3 of the glucosamine. Corresponds to a partial structure of blood group A type 2 oligosaccharide.[CHEBI:62990] 

term_xref : GlycoEpitope:EP0261|GTC:G54826OZ|CHEBI:62990|CID:5289011|GlycoMotif:GGM.000039  

synonyms : Blood group A (type 2) (A-Ley)|Blood Group A Type 2 (difucosyl)|Blood group A (type 2) (A-Lewis Y)|A-Ley|A-Le^y 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :


GSD000028

term (main_entry) : Blood group A (Type 4) 

glycan_dictionary_accession : GSD000028 

glytoucan_accession  : G37830TX 

term_in_sentence : Moreover, we have found that αGal, but not αGalNAc, is a weak binder itself for DC-SIGN, which could endow an additional binding mode for the blood group B antigen, but not for blood group A.[PMID:31283166] 

publication : 7800218|7521740|2458640|31283166 

definition :  

term_xref : GlycoMotif:GGM.000088|GTC:G37830TX|CID:91852258|KEGG:G00474|CHEBI:150159|SugarBind_Ligand:48  

synonyms :  

function :  

disease_associations : Pyelonephritis[SugarBind_Ligand:48]|Acute cystitis[SugarBind_Ligand:48] 

wikipedia :  

essentials_of_glycobiology :


GSD000029

term (main_entry) : Blood group A trisaccharide 

glycan_dictionary_accession : GSD000029 

glytoucan_accession  : G00066MO 

term_in_sentence : A readily detectable carbohydrate in the urine of two siblings with neuronal ceroid lipofuscinosis was found to be the blood group A trisaccharide.[PMID:7249368] 

publication : 19582848|7249368|8774717|2749874|28771597|30619340|2122121|11886841|2991755|12588002|3149698|7048329|7015594|10359132|8724140|1418679|1446307 

definition : A branched amino trisaccharide consisting of β-D-galactose having an α-L-fucosyl residue at the 2-position and an N-acetyl-α-D-galactosaminyl residue at the 3-position.[CHEBI:61012] 

term_xref : GlycoEpitope:EP0255|GTC:G00066MO|CID:49852448|KEGG:G10638|CHEBI:61012  

synonyms : blood group A trisaccharide|blood group A type 1 trisaccharide 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :


GSD000030

term (main_entry) : Blood group A (Type 1) 

glycan_dictionary_accession : GSD000030 

glytoucan_accession  : G66163TI 

term_in_sentence : he basis of blood group A(1) and A(2) phenotypes has been debated for many decades, and still the chemical basis is unresolved. [PMID:19121199] 

publication : 10942408|19121199 

definition : An α-D-GalpNAc-(1→3)-[α-L-Fucp-(1→2)]-β-D-Galp-(1→3)-D-GlcpNAc having β-configuration at the reducing end anomeric centre.[CHEBI:62485] 

term_xref : GlycoMotif:GGM.000044|GTC:G66163TI|GlycoEpitope:EP0256|CID:53262359|CHEBI:62485 

synonyms : Blood group A(1)|blood group A antigen type 1 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :
Retrieved from "https://wiki.glygen.org/index.php?title=Testhyperlink123&oldid=2528"